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Chapter
In troduction 1
1In 2002 prostate carcinoma is, after lung and bronchus, the most frequent cause o f cancer-related 
death in men in the United States (1). The probability o f developing prostate cancer from birth to 
death is 17 %  (1 in 6) (1). The mainstay o f treatment for organ-confined disease is either radical 
prostatectomy or curative radiotherapy (2;3). Both are only considered to be options if no seminal 
vesicle invasion, no extracapsular tumor extension and no metastatic disease are present (TNM  stage 
<  T2N0M 0) (4). This thesis reports on local staging and localization o f prostate carcinoma. Local 
staging involves determination o f extracapsular extension and seminal vesicle invasion. Accurate 
local staging is important to prevent unnecessary radical prostatectomy, which is associated with 
complications, such as erectile dysfunction and decline in urinary function (5). Palliative radiothera­
py is often the preferred treatment in case o f spread o f carcinoma beyond the prostate. The Partin 
tables (6), based upon the findings o f digital rectal exam, prostate specific antigen (PSA) and biopsy 
results (Gleason score), are frequently used to estimate the risk at having non-organ confined 
prostate cancer. However when the Partin tables are used alone, this results in an understaging rate 
o f 45% (7); therefore approximately half o f candidates for radical prostatectomy undergo surgery with­
out curative result if Partin tables are used alone. Thus, additional staging methods like magnetic res­
onance (MR) im aging have been and are evaluated to improve staging performance.
Prostate carcinoma is a multifocal disease; in a series o f 160 whole mount sectionned cases 67% 
had more than 1 tumor (8). Therefore the concept o f the index tumor is often used; this is the 
largest tumor present in the prostate. Although a correlation is present between the tum or volume 
and the presence o f extracapsular penetration, sm aller tumors are also clinically relevant as these 
may also show extracapsular penetration (8). However Stamey et al (9) showed that tumors with a 
volume sm aller than 0.5 ml probably are not likely to reach a clinical significant size. For this rea­
son it is important to localize both the index tumor and the sm aller tumors present in the prostate 
in order to stage more accurately. Accurate localization is also important for guidance o f modern 
focally ablative techniques, such as intensity modulated radiotherapy or high intensity focused 
ultrasound. Also, accurate MR localization o f potential prostate cancer may be o f importance in 
biopsy guidance in patients with elevated PSA and repeated negative ultrasound biopsy results. 
Currently, the reliability o f T2-weighted MR im aging protocols in discrim inating prostate carcinoma 
from normal peripheral zone and central gland tissue is limited (10-13). Therefore it is useful to 
increase the accuracy o f MR im aging in detecting prostate cancer in order to improve localization.
This thesis addresses several problems with regard to accuracy in local staging and localization of 
prostate carcinoma using MR imaging.
T h e  o b je c t iv e s  o f  t h is  th e s is  are
To review the current possibilities and limitations o f clinical staging, transrectal ultrasound, MR 
im aging and MR spectroscopy in staging o f prostate carcinoma.
To explain the large variability in staging performance present in the literature using meta-analysis.
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Introduction
To determine in which subgroup o f patients for radical prostatectomy local staging using MR im ag­
ing is considered useful.
To investigate to what extent new MR techniques, like the use o f the integrated endorectal pelvic 
phased array coil, dynamic contrast-enhanced MR im aging and MR spectroscopy, may increase 
local staging performance and localization o f prostate carcinoma.
O u t lin e  o f  t h is  th e s is
In chapter 2 a general review is presented showing the current possibilities and limitations o f stag­
ing prostate carcinoma using clinical methods (= digital rectal examination, PSA and biopsy 
Gleason score), MR im aging and transrectal ultrasound. In chapter 3 the overall local staging per­
formance o f MR im aging and factors influencing local staging performance are evaluated using a 
meta-analysis. In chapter 4 based on literature data, a subgroup o f radical prostatectomy candi­
dates is defined, in whom MR im aging is considered to be useful, using a decision analytic model. 
In chapter 5 anatomical detail and local staging performance o f MR im aging in prostate cancer 
using the pelvic-phased array coil (PPA) and the integrated endorectal-pelvic-phased array coils 
(ER-PPA) are compared in a prospective study o f 82 candidates for radical prostatectomy. The radi­
ological findings were compared with whole mount section histopathology.
A  potential new way to improve localization and local staging performance o f prostate carcinoma 
is by using dynamic contrast-enhanced MR im aging (D CM RI). DCM RI can display characteristic 
enhancement patterns in (prostate) cancer. Solid tumors depend on angiogenesis to grow beyond 
a few cubic millimeters (14). The resulting neovasculature causes increased abnormal vascularity 
and abnormal interstitial space. Both features may be used to differentiate carcinoma from normal 
prostate tissue. Chapter 6 provides a basic introduction in using DCM RI in bladder and prostate 
cancer.
In chapters 7 and 8 typical enhancement characteristics o f prostate carcinoma and normal prostate 
tissue are determined. While evaluating the enhancement patterns, it was observed that the auto­
mated curve fitting method, the least-squares error optimization method, com monly used for para­
metric im aging, often produced unexpectedly "noisy” estimates. Therefore a new curve fit method 
was developed in chapter 7. In chapter 8 the typical dynamic contrast-enhancement curves of 
prostate carcinoma, peripheral zone and the central gland are studied. U sing the concentration-Gd- 
DTPA curves, developed in chapter 7, possible associations between dynamic parameters and 
Gleason score, cancer volume, extracapsular extension, seminal vesicle invasion, PSA and age are 
explored. In chapter 8, false positive enhancement o f the prostate was found caused by chronic 
severe prostatitis. Therefore in chapter 9 a combined DCM RI and 2D proton MR spectroscopic 
im aging was evaluated with the purpose to improve differentiation between chronic prostatitis and 
prostate carcinoma. In chapter 10 the summ ary and conclusions are presented.
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In tro d u ctio n
The prostate continues to be the com m onest site o f cancer; for example, there were 
184 500 new cases in the U SA in 1998, accounting for 29%  o f new cancer cases in 
American men [1]. It has been estimated that 39 200 men in the U SA died from 
prostate cancer in 1998. These estimates make prostate cancer the second cause of 
cancer-related death in men [2,3] and the probability o f developing prostate cancer 
from birth to death is 20% [3]. Treatment selection depends on patient age and 
health, cancer stage and grade, morbidity and mortality o f treatment, together with 
the preference o f the patient and the physician. The mainstay for organ-confined 
disease is either radical surgery or curative radiotherapy [4,5]. These are only con­
sidered to be options if there is no spread to the seminal vesicles (seminal vesicle 
invasion, SVI), extension through the prostatic capsule (extracapsular extension, 
ECE) or metastatic disease (TNM  stage <  T2N0M 0). Therefore, the purpose of 
staging is to detect extraprostatic disease. Clinical staging by DRE and PSA level are 
relatively inaccurate, and im aging techniques such as TR U S and MRI can be used 
to increase the accuracy o f staging. This review deals with the current possibilities 
and limitations o f im aging in the staging o f prostate cancer.
Prostate cancer staging using imaging
C lin ic a l s ta g in g  m eth o d s
Accurate staging o f prostate cancer is important, because treatment decisions are mainly based on 
whether there is ECE or SVI, and whether there is metastatic disease (lymphatic or haematoge- 
nous). The DRE is not an accurate method for diagnosis or staging because there are no gross 
characteristics that are consistently reliable to distinguish benign from malignant nodules [6]. Also, 
the interobserver agreement among urologists for detecting prostate cancer by a DRE is only fair 
[7]. Data accumulated from carefully examined prostatectomy specimens show that a DRE under­
estimates the local extent o f cancer in 40-60%  o f cases [8,9]. PSA is the most accurate marker to 
screen for prostate cancer, but has limited accuracy in staging because there is a substantial over­
lap between PSA levels and pathological stages. Nevertheless, the combination o f serum PSA level 
and other variables such as tum our grade, volume and clinical stage, significantly enhance the 
value o f serum PSA level in predicting the pathological stage [10,11]. The probability o f ECE, SVI 
and nodal involvement can be predicted by using the nom ogram s o f Partin et al. [10] using clinical 
stage, Gleason score and serum PSA.
T R U S
Since its clinical introduction in 1971 by Watanabe [12], TRU S has become the most frequently used 
im aging technique for evaluating the prostate. Its role in assessing prostate volume and guiding 
biopsies is unquestioned. The role o f ultrasonography (US) in detecting and staging o f prostate 
cancer is more controversial.
Ultrasonography can be used to examine the prostate for hypoechoic lesions, as these have an 
increased probability o f being malignant, especially when they occur in the peripheral zone. 
However, not all hypoechoic lesions are malignant, and not all malignant lesions are hypoechoic. 
In staging prostate cancer, any change in the prostatic contour, e.g. bulging or irregularity, adjacent 
to a focal lesion may be a sign o f ECE. Also, invasion o f the tum our into the seminal vesicle may 
be detected on TRU S; it has the advantage o f allowing visualization o f cancer in many cases as a 
hypoechoic lesion in the peripheral zone (PZ) that has a 17-57%  chance o f being malignant 
[13-20]. About 12-30%  o f tumours appear isoechoic and are thus not visible with grey-scale US 
[21]; only a few prostate tumours are hyperechoic. The visibility o f prostate tum ours on US depends 
on the size o f the tumour, its com position and its site in the prostate. Transition zone (TZ) tumours 
are less visible because o f the heterogeneous pattern o f this zone on US. Next to grey-scale appear­
ances, indirect effects such as asymmetry o f the prostate, both in shape and echogenicity, and 
bulging o f the prostatic capsule, may be signs o f the presence o f a malignancy. Because o f the var­
ied appearance o f malignancy in the prostate and the difficulty in detecting diffuse infiltration, 
TRU S alone is not the best method o f screening for prostate cancer. Aarnink et al. [22] showed the 
additional value o f T R U S in combination with DRE and PSA, resulting in a sensitivity o f 75%, a 
specificity o f 85%  and an improved positive predictive value (PPV) o f 68% . TRU S has limited value
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2in tumour staging, with PPVs o f 50-63%  for detecting ECE [23,24]. Therefore, the merit o f TRU S 
lies in guiding biopsies to provide a histopathological diagnosis. It is generally agreed that TRU S 
guidance o f biopsies is better than digital guidance. Biopsies can also be used to improve staging 
if there is suspicion o f ECE or SVI.
An identification o f the histological grade based on biopsy material is limited; the reported agree­
ment between biopsy grade and prostatectomy grade was correct in only 41%  o f cases [25]. By tak­
ing at least six biopsies, the sam pling error can be reduced. U sing this method, 20% o f biopsies 
underestimated the prostatectomy grade; therefore, a m inim um  o f six biopsies and targeted biop­
sies o f hypoechoic areas provides a reasonable estimate o f the overall tum our volume and infor­
mation on the risk o f ECE. The Gleason grading o f the biopsies is also helpful as the higher the 
Gleason score and the greater the number o f cores involved, the higher the probability o f ECE [26]. 
The development o f a malignant tum our can be considered to have three different stages, i.e. 
growth, infiltration o f surrounding tissue and m etastasis. Angiogenesis is required for a tumour to 
transfer from one stage to another [27,28] and it is therefore logical to include information on 
angiogenesis in the clinical staging process. This information has been obtained from histopatho­
logical specim ens by counting the microvessel density (MVD) using blood vessel stains. The MVD 
is higher in malignant tissue than in surrounding healthy tissue [29]. Bostwick et al. [30,31] report­
ed that the combination o f the M VD from the biopsy with the Gleason score and PSA level sign ifi­
cantly improved the detection o f extracapsular involvement. An alternative approach to the count 
o f static blood vessels is to image the dynamic behaviour o f blood flow in prostatic tumours. To 
allow autonom ous growth and infiltration, the tumour needs sufficient oxygen and nutrients to be 
supplied by the surrounding blood vessels. It is therefore assumed that the malignant tumour 
alters its environment and changes the local metabolism. Such changes in local blood supply can 
be studied with Doppler US techniques (Fig. 1A,B).
Doppler studies o f the prostate have improved the PPV for detecting cancer when Doppler findings 
were abnormal [32-35]. However, these reports indicated som e limitations o f Doppler velocity 
im aging o f the prostate for cancer detection. Prostate cancer is not highly vascular [32]; the 
improvement in the PPV is insufficient to determine biopsy policy [33]. Doppler US appears to have 
limited sensitivity for detecting all the sites o f involvement [33] and the overall sensitivity o f Doppler 
US is poor, so that it should always be used in conjunction with TR U S [34]. More recent studies 
have suggested that Doppler US can be used to improve detection o f the higher Gleason grade 
areas within the prostate [36]. Ismail et al. [37] concluded that colour-coded Doppler flow within the 
tumour and overlying capsule correlated with both tumour grade and stage, respectively.
Future developments
As with many im aging techniques, the interpretation o f TRU S images depends on the user’s exper­
tise and there is intra- and interobserver variability. Som e research groups have begun the devel­
opment o f a computer-aided interpretation system to help the observer to identify abnormalities
14
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F ig . 1 (A) Transverse grey scale TRUS image o f the prostate with no suspicious hypoechoic lesions. (B) On 
the contrast-enhanced Doppler image there is enhancement in the T Z  (arrows) (C) 3D reconstruction of 
image B, shows clear enhancement o f the TZ  (circle) indicating possible cancer. (D) Histological confirma­
tion o f cancer in the right TZ. A = anterior, R = right.
[13,38,39]. Initial results did not fulfil the rigorous requirements needed for clinical application. 
However, attempts to use the computer to improve clinical decision-m aking are likely to continue, 
and the combination o f clinical variables and im aging features will be studied in more detail using 
techniques such as neural networks.
The introduction o f microbubble ultrasonographic contrast media to enhance the visibility o f blood 
flow with US provides a new method to study tumour vascularity. The passage o f contrast agent 
through the circulation provides a measure o f tissue function, and changes in local blood flow 
should be detectable by this dynamic investigation. There have been reports o f the use of 
microbubble contrast medium to study the vascular anatomy and dynam ics o f blood flow in dif­
ferent organs [40-42]. These studies indicate that enhanced Doppler im aging has the potential to 
improve the detection o f prostate cancer [38,43,44] and future research will indicate its exact role.
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2M R I
Prostatic MRI is still being developed and is not yet advocated for routine staging. Prostate MRI 
should be performed in centres where at least 25-50 patients per year are examined and the results 
can be compared with histology, preferably o f whole-mount specim ens [45]. Currently, the major 
clinical indication for MRI is detection o f ECE, SVI, nodal and bone marrow m etastasis, which are 
contraindications for radical prostatectomy [46]. Prostatic MRI should be obtained at least 2 weeks 
(preferably 3 weeks) after prostatic biopsy, as haemorrhage decreases staging accuracy [47]. 
Prostatic MRI is performed using coils, which can transmit radiofrequencies and receive MR-sig- 
nals. The advantage o f using coils is the improved spatial resolution. Three types o f coils can be 
used for prostatic MRI.
Initially a body-coil has been used, which is a built-in coil present in most MRI-scanners. More recent­
ly surface coils are used, which are placed on the surface of the patient at the anatomic region o f inter­
est. In prostatic MRI the pelvic phased array coil (ppa-coil) and the endorectal coil (ERC) are used. 
The ppa-coil is positioned above and under the patients’ pelvis, whereas the ERC is inserted into the 
rectum (Fig. 2 AB, 3 AB). It is possible to combine the ERC with the PPA-coil; the integrated ERC-PPA- 
coil [48]. Considering these different techniques, the use o f an ERC is considered to be an improve­
ment on the body or ppa-coils [48-50]. Patients tolerate the ERC well, although the insertion remains 
uncomfortable.
Prostate cancer is usually seen as a low signal intensity lesion in a bright peripheral zone on a T2- 
weighted image (Fig. 2 A,B). The differential diagnosis o f low signal intensity areas includes cancer, 
haemorrhage (mostly resulting from biopsy), prostatitis, effects of hormonal or radiation treatment, 
BPH , scar, calcifications, smooth m uscle hyperplasia and fibrom uscular hyperplasia [51]. 
Haemorrhage can be differentiated from cancer by studying the T1-weighted images. On these, 
haemorrhage is hyperintense whereas cancer remains hypo-intense relative to adjacent normal tissue. 
BPH, smooth muscle hyperplasia and fibromuscular hyperplasia mostly occur in the central zone 
(CZ) and TZ, unlike cancer which mostly occurs in the PZ. Calcifications are common throughout the 
prostate, and can usually be differentiated from cancer based on their distinct oval shape; scars are 
rare. Detection o f cancer in the C Z  and T Z  is generally not possible, because this area is commonly 
involved with BPH, which has signal intensities sim ilar to those from cancer.
Several MRI criteria for ECE have been used; Table 1 summ arises commonly used criteria for ECE with 
specificity, sensitivity and positive predictive values using the endorectal coil. Fig.2 illustrates a fre­
quently used criterion for ECE (bulging o f the prostatic capsule). SVI is detected by an abnormal 
asymmetric low signal intensity within the lumen on T2-weighted images (Fig. 3 A,B) [52]. However, 
amyloid deposits, stones or blood can also cause low signal intensity of the seminal vesicles on T2- 
weighted images [51,53,54]. Ideally, prostatic MRI should have a low percentage o f false-positives for 
ECE and SVI to ensure that few, if any, patients will be deprived o f potentially curative treatment [55]. 
Sensitivity for periprostatic extension is less important because even a low sensitivity is an improve­
ment of clinical staging [55]. MRI is considered cost-effective if performed in a subgroup o f patients 
with a prior probability o f ECE o f >  30% (a PSA level o f > 10 ng/m L or a Gleason grade o f > 7) [56]
16
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Figure 2C
Fig. 2 Prostate MRI (T2-weighted: transverse view) o f the peripheral and central zone before (A) and after (B) 
insertion of the endorectal surface coil. The dark low signal intensity areas (white arrows) in both A and B indi­
cate the prostate carcinoma. The red arrows in A and B point at a site o f extracapsular extension (bulging crite­
rion). A = anterior, R = right. C: Dynamic MRI o f the prostate of A/B shows early enhancement (t = 8 s.) at the 
same site as the low signal intensity area in 2A and 2B. Early extracapsular enhancement is also seen (circle). 
This confirms tumour location and ECE seen with the T2 weighted images and increases the diagnostic relia­
bility o f the findings on the T2-weighted images. A = anterior, R = right.
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2Table 1 Criteria to predict ECE with accuracy, specificity, sensitivity and
positive predictive value (all % ) on endorectal coil MRI imaging. -; no data available
Criteria for capsular 
penetration
Reference Accuracy Specificity Sensitivity Positive predic­
tive value
Asymmetry o f the neurovascular 
bundle
[84] 70 95 38
Obliteration o f the rectoprostatic 
angle
[84] 71 88 50 -
Bulge [59] 72 79 46 28
Overall impression [59] 71 72 68 32
Extracapsular tumour [59] 73 90 15 34
Figure 3A Figure 3B
Fig. 3 Seminal vesicles (T2-weighted, transverse view) before (A) and after (B) after insertion o f the endorec­
tal coil (ERC). In A the low signal intensity region (circle) is suspicious for SVI. After insertion o f the ERC 
this low signal area is no longer seen, because the seminal vesicles are compressed. Histology confirmed 
that there was no SVI, so that the ERC increased diagnostic accuracy. A = anterior, R = right.
18
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It is not yet possible to state the ‘overall’ accuracy’ o f MRI for staging prostate cancer, because 
there is a wide divergence in the literature. For example the accuracy o f assessing ECE with the ERC 
varies widely, at 58-90%  [48,49,57,58]. There may be several possible explanations, like the use of 
different im aging protocols, differences in reader experience, patient selection and the use o f dif­
ferent criteria for ECE (Table 1).
A  limitation o f prostatic MRI on which there is consensus is that it is still not possible to detect 
m icroscopic ECE [23,58,59,60]. The detection o f SVI is generally good using the ERC, with accura­
cies ranging o f 81-96%  [48,49,57,59] (Fig. 3 ).
Apart from its use in staging, MRI is useful to reduce the number o f false-negative prostatic biop­
sies in patients with an increasing PSA level and repeated negative TRUS-guided biopsies. MRI can 
be used to detect prostate cancer and then an MRI-guided biopsy can be taken. U sing MRI as a 
method to detect cancer in a group o f 36 patients with negative biopsies and elevated PSA levels, 
an accuracy o f 78%, a PPV o f 74% and a negative predictive value (NPV) o f 84% were achieved [61]. 
In summary, the role ofM RI in local staging is not yet clearly defined, but it is considered cost-effec­
tive in a select group o f patients. SVI can be detected with high accuracy, which is an advantage in 
com parison with TR U S alone.
Future developments
Recent developments in MRI include contrast-enhanced dynamic MRI and magnetic resonance 
spectroscopy (M RS). During dynamic contrast-enhanced MRI, the patient receives an intravenous 
injection with a gadolinium-based contrast agent. Fast MR images are then acquired to display the 
enhancement pattern o f the prostate. In our department, an image is recorded every 2 s, which 
gives information about tum our vascularity. Solid tumours depend on angiogenesis to grow 
beyond a few cubic millimetres [27] and the resulting neovasculature causes increased and abnor­
mal vascularity which can be detected with dynamic contrast-enhanced MRI. The abnormalities 
seen include [62,63] more vessels, leaky/porous vessels, tortuous vessels, increased pressure 
inside tum our vessels, altered viscosity o f blood inside tumour vessels, uneven distribution o f ves­
sels throughout the tumour, increased interstitial pressure causing com pression o f tumour vessels, 
and development o f arteriovenous shunts. U sing dynamic contrast-enhanced MRI, these features 
help to differentiate tumour tissue from normal tissue. Prostate cancer shows a typical early and 
rapidly accelerating enhancement compared with normal tissue [64-66], which may be useful both 
for detecting the tum our and for assessing ECE and SVI (Fig. 4 ).
Dynamic MRI may also have a potential role in monitoring treatment and in predicting the success 
o f systemic treatment o f prostate cancer [63]. Current problems for dynamic MRI in detecting 
prostate carcinoma involve the variety o f enhancement patterns in prostate carcinoma and overlap 
with abnormal enhancement in BPH (Fig. 5 A) [64].
Image-guided proton M RS (1H-M RS) provides metabolic information about the prostate, which 
may be used for in situ characterization, diagnosis and evaluation o f treatment o f prostate cancer.
19
2Figure 4A Figure 4B
Fig. 4 Seminal vesicles (A: T2-weighted,/B: contrast-enhanced dynamic MRI. Transverse view). On T2- 
weighted images bilateral low signal intensity is seen (circles), making SVI less likely. On contrast-enhanced 
dynamic MRI asymmetric early enhancement o f the seminal vesicles is seen; suspicious for SVI (circle). 
Histology confirmed SVI. A = anterior, R = right.
Figure 5A Figure 5B
Fig. 5 In 5A dynamic MRI indicates possible tumour site (arrow) in the TZ, but early enhancement in the TZ 
is often caused by BPH. BPH was excluded by MRS, which shows increased choline/citrate ratio (curved 
arrow; red area), indicating prostate cancer. A = anterior, R = right.
20
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1H -M RS is comparable to MRI, although the spatial resolution is reduced (voxel sizes down to 
0.24 cm 3 have been reported for the prostate [67]) and the information reflects metabolism rather 
than anatomy. Prostate cancer is characterised by a decreased level o f citrate and an increased level 
o f (phospho)choline [68]. Tumour tissue can be identified by an increased choline/citrate or 
(choline + creatine)/citrate signal ratio, especially in the PZ [67,68]. The metabolite ratios correlate 
with the histological grade in prostate cancer [70]. The addition o f 1H -M RS to (dynamic) MRI can 
improve tum our visualization and assessm ent o f tumour extent (Fig. 5 A/B) [69,71]. Areas of 
prostate cancer management that may potentially benefit from the 1H-M RS information include 
targeting TRUS-guided biopsies in patients with PSA levels indicative o f cancer but negative previ­
ous biopsies, m onitoring o f treatment (watchful waiting) and guiding focal prostate cancer treat­
ment [71].
M e ta sta tic  d ise a se
Curative treatment such as radical prostatectomy is not an option if metastatic lymph nodes or 
haematogeneous metastases are present. Current methods for nodal staging include surgical 
(open) pelvic lymph node dissection (P LN D ), laparoscopic P LN D , C T  and MRI. P LN D  is the most 
invasive and reliable method o f establishing the presence o f metastatic disease in pelvic lymph 
nodes. Laparoscopic P LN D  is less invasive and alm ost as accurate for sam pling lymph nodes 
(90%), but requires more skill and experience. If no lymph node metastases are found, a second 
operation is necessary [72].
C T  and MRI are reported to be the most accurate noninvasive methods o f detecting involved pelvic 
lymph nodes. Invasive methods such as lymphangiography (LAG) can also be used for detecting 
nodal metastasis. Scheidler et al. [73] concluded that all these modalities (CT, two-dimensional MRI 
and LAG) performed similarly in the detection o f lymph node metastasis, with a trend towards 
improved accuracy with MRI. The recommended methods are therefore MRI and CT, because they 
are not invasive. MRI with a three-dimensional technique produced an accuracy o f 90%, a PPV of 
94% and a NPV o f 89%  in the detection o f nodal metastasis in bladder and prostate cancer [74]. 
This is important clinically because high accuracy in detecting nodal metastasis allows MR-guided 
biopsy [75]. If  the biopsy is positive an invasive diagnostic procedure, P LN D , requiring anaesthesia 
can be avoided. Furthermore, three-dimensional MRI can improve guidance for laparoscopic or 
open P LN D . The m ultiplanar reconstructions obtained allow not only nodal size but also nodal 
shape to be evaluated. This is important because the threshold between normal and metastatic 
nodes differs for round and oval nodes (Fig. 6 A ,B). The sm allest lymph node diameter that can be 
detected is 2 mm. Sensitivities and specificities differ depending on the selection o f the threshold 
[74,76,77]. In our department, we use a minimal axial diameter o f 8 mm for round nodes and
10 mm for oval nodes as the upper limit o f normal. Because o f their high cost, C T  and MRI should 
only be used to detect nodal metastases in a selected group o f patients at high risk, as predicted 
by DRE, PSA and biopsy Gleason score [10,74,78].
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2Fig. 6 3D-MRI of lymph nodes: evaluation of size and shape. (A) coronal view o f the obturator fossa and (B) 
sagital view. In the circle an irregular enlarged iliac node is seen (obturator node). S; spine, P; prostate, i; 
Iliac artery, F; femur.
Hem atogenous metastases are most com mon in the axial skeleton. Currently, the mainstay for 
detecting bone metastases is a radionuclide bone scan. However, it is well known that bone scans 
can produce false-negative findings, especially with very aggressive metastases. Also there is a high 
false-positive rate mainly because o f degenerative disease, healing fractures and various metabol­
ic disorders and their com plications (e.g. osteoporosis and osteomalacia). Bone scintigraphy 
seem s to be unnecessary to evaluate newly diagnosed, untreated prostate cancer with no clinical 
signs o f bone pathology and serum PSA levels o f < 10 ng/m L [79]. In patients with an increased 
PSA level (> 10 ng/m L) and in those with locally advanced tumours, bone scans are considered 
worthwhile to detect both asymptomatic and sym ptomatic metastases. MRI is more sensitive for 
bone marrow metastases than are radionuclide bone scans [80] and can therefore be useful to 
assess patients suspected o f having vertebral metastases, and who have equivocal or negative 
bone scintigram s. Because o f its high spatial resolution, compared with bone scintigraphy, MRI 
may also be helpful in guiding needle biopsy procedures. Plain radiographs are the least sensitive 
in evaluating the axial skeleton for metastases. H alf o f the bone mineral content must be altered 
before there is radiographic evidence o f metastases. In summary, MRI has a major role in detect­
ing nodal and bone marrow metastases in prostate cancer in patients at high risk o f metastatic d is­
ease.
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Future developments
An important limitation o f C T  and MRI in the evaluation o f nodal m etastasis is that both methods 
depend on the enlargement o f lymph nodes as the criterion for m etastasis. The problem is that 
metastases may also be present in normal-sized nodes, and because these are not detected by CT 
or MRI, the sensitivity is relatively low (75-78% ) [74,77]. A  solution to this problem may be the use 
o f lymph node-specific MR contrast agents. New MR contrast agents with ultrasmall superpara- 
magnetic iron oxide particles are currently under investigation. In normal lymph nodes with func­
tioning macrophages, the iron oxide particles are phagocytosed and so decrease the signal inten­
sity on MRI (Fig. 7 A ,B). Areas o f metastatic involvement lack m acrophages and do not take up the 
contrast agent, and so do not change in signal on subsequent im ages [81]. Preliminary results sug­
gest improved accuracy in detecting metastases in normal-sized nodes using a lymph node spe­
cific MR contrast agent [82].
Figure 7A Figure 7B
Fig. 7  Coronal (T1-weighted) 3D-MRI o f lymph nodes (circles) before (A) and after (B) administration o f a 
lymph node specific contrast agent. After contrast medium normal nodes show a signal decrease on T1
weighted images. S; spine, P; prostate, i; Iliac artery, F; femur.
D is c u s s io n
The accurate staging o f prostate carcinoma is essential for making treatment decisions. However, 
preoperative clinical staging is inaccurate, and a DRE and PSA level only provide an inexact indica­
tion o f local extent. Adding other variables such as the number o f positive biopsies and biopsy
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2grade improves clinical staging but is not accurate enough to predict tumour stage in the individ­
ual patient. Therefore im aging methods such as TR U S and MRI are needed to increase the accu­
racy o f staging. These im aging methods have variable accuracies, partly because o f the relative inex­
perience o f users in rapidly developing techniques and partly because o f the limits o f image reso­
lution, which will probably remain too low to detect m icroscopic capsular penetration. This is not 
necessarily a problem if m icroscopic capsule extension has limited prognostic significance. For 
example, it has been stated that a tumour extension o f up to 1 cm outside the capsule has no effect 
on prognosis [83]. A  way to increase staging accuracy and to decrease interobserver variability may 
be to combine im aging methods. Currently, TRU S may be supplemented with MRI; in the future, it 
may be possible to fuse dynamic MRI, MRS contrast-enhanced TR U S and colour Doppler US in one 
image, and so achieve better accuracy in localization and staging. Currently the major role o f MRI 
is to detect nodal and bone marrow m etastasis. In addition MRI can be used for local staging (ECE 
and SVI) for which it is at least as good and potentially better than TR U S [23,24]. The advantage of 
MRI is that nodal, bone marrow and local staging can be carried out in one im aging session, lim ­
iting the number o f examinations and the overall cost.
In future research, cost-effectiveness will be an important factor when working with these ‘expen­
sive’ im aging techniques. In this respect, the detection o f advanced disease by im aging, and so pre­
venting an unnecessary radical prostatectomy, should be weighed against the cost o f im aging. It is 
thus important to select appropriate patients for staging with these expensive im aging techniques. 
Finally, the role o f imaging, especially MRI and MRS, is rapidly changing and improving, and there 
is a need for continued research to establish its role.
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A b stra c t
Objective: To determine the influence o f patient-, study design-, and im aging pro­
tocol characteristics on staging performance o f m agnetic resonance im aging in 
prostate cancer.
Materials and Methods: Electronic literature search and review o f bibliographies 
(January 1984-May 2000). Articles selected, included data on sensitivity and speci­
ficity for local staging. Subgroup analyses examined the influence o f age, prostate 
specific antigen, tum or grade, hormonal pre-treatment, stage distribution, publica­
tion year, department o f origin, verification bias, time between biopsy and MR im ag­
ing; consensus reading, study design, consecutive patients, sam ple size, histology 
preparation, im aging planes, fast spin echo, fat suppression, endorectal coil, field- 
strength, resolution, glucagon, contrast agents, MR spectroscopy and dynamic con­
trast-enhanced MRI.
Results: 71 articles and 5 abstracts were included, yielding 146 studies. M issing val­
ues were highly prevalent for patient characteristics and study design. Publication 
year, sample size, histologic gold standard, number o f im aging planes, turbo spin 
echo, endorectal coil and contrast agents influenced staging performance (p<0.05). 
Conclusions: Due to poor reporting it was not possible to fully explain the hetero­
geneity o f performance presented in the literature. O ur results suggest that turbo 
spin echo, endorectal coil and multiple im aging planes improve staging perfor­
mance. Studies with small sam ple sizes may result in higher staging performance.
Meta-analysis o f the prostate MR-imaging literature
In tro d u ctio n
Since 1984, m agnetic resonance (MR) im aging has been available for use as a local staging m odal­
ity for prostate cancer. However, a large variation (heterogeneity) in staging performance remains 
present in the literature (1-4). Various causes may account for heterogeneity in staging perfor­
mance, such as differences in used reference tests, studied patient population, study methodolo­
gy, random error and used thresholds (5).
The purpose o f this meta-analysis was to determine how and in which degree these mentioned 
characteristics influence staging performance o f MR im aging in prostate cancer.
M a te ria ls  a n d  M ethod s
Data sources
Relevant publications were identified in M ED LIN E and EM BASE databases (between January 1984 
and May 2000) with the following Medical Subject Heading terms: ‘Prostatic neoplasms, Magnetic 
resonance imaging, Neoplasm staging, Sensitivity and specificity, Prostat*, Cancer*, MRI*, Magnetic- 
reson*, Neoplas*, Tumour*, Tumor*, Nuclear Magnetic resonance imaging, Stagin* (all subheadings), 
not restricted to any language. To identify additional relevant references, reference lists o f retrieved 
articles were checked manually, and co-authors were consulted. Furthermore, a manual library 
search o f abstract books o f the Radiological Society o f North America (RSN A ), the International 
Society o f Magnetic Resonance in Medicine (ISM RM ) and the European Society o f Magnetic 
Resonance in Medicine (ESM RM B) (1988 to May 2000) was conducted.
Study selection
All retrieved articles were checked by three independent reviewers for the following exclusion crite­
ria (in the used order):
(a) reanalysis / review;
(b) only data on nodal staging;
(c) no comparison with the surgically resected prostate;
(d) no information on specificity or sensitivity (if sensitivity or specificity could be calculated, 
the study was included).
Disagreements between reviewers were resolved in consensus. If  an exclusion criterion was found, 
the study was excluded and the reason was recorded. Only the first found exclusion criterion was 
recorded.
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3Data extraction
For each study sensitivity and specificity o f MR im aging for detection o f extracapsular extension 
(ECE), seminal vesicle invasion (SVI) and detection o f clinical (c) stage cT3 were recorded or cal­
culated. Additionally data were abstracted according to patient group characteristics, methodolog­
ical characteristics and MR im aging protocol characteristics using a standardized form.
Patient group characteristics included group average age, prostate specific antigen (PSA) level, tumor 
grade, hormonal pre-treatment and percentage patients with pathological (p) stage T3 (pT3). 
Methodological characteristics included publication year, department o f origin (radiology, urology, 
other), verification bias (were all MR im aging results verified by a reference standard), time 
between biopsy and MR im aging, consensus reading, prospective or retrospective study design, 
consecutive patients, sam ple size, histology preparation (whole mount opposed to random sec­
tioning and slice thickness).
MR imaging protocol characteristics incorporated the number o f im aging planes, the imaging 
sequence (spin echo versus fast spin echo and the use o f fat suppression), inclusion o f the 
endorectal coil, magnetic field-strength [in Tesla], image resolution (voxel size), use o f glucagon 
and contrast agents. Finally, the effect o f MR spectroscopy and dynamic contrast-enhanced MR 
im aging on staging performance was evaluated.
It was not possible to perform a subgroup analysis on the criteria for ECE, because the names for the 
various criteria for ECE differ considerably in the literature. Also the role of microscopic capsular pen­
etration was not analyzed, because in general no definition is given o f m icroscopic capsular extension.
Trapezoidal area under the RO C curve analysis
For each sensitivity and specificity pair, the Area Under the Receiver operating Curve (AUC) was cal­
culated using the trapezium method (6). An advantage of using the AUC, instead o f sensitivity and 
specificity, is that inter-study variability due to different cut-off points o f primary studies is decreased 
(7). Although the trapezium method underestimates the AUC, it facilitated the comparison between 
studies. A  limitation o f using the trapezium method is that comparisons between A U Cs are only 
meaningful if there is a good likelihood that the sensitivity-specificity lines are parallel (8).
We stratified studies according to possible determinants o f staging performance and we compared 
A U C s to evaluate if statistically significant differences were present.
We first used an univariate analysis to determine which characteristics were significant sources of 
variation. Then we attempted to model the variation between studies by means o f multivariate 
analysis, in which all patient characteristics, methodological characteristics and MR im aging pro­
tocol characteristics (which were significant in the univariate analysis) were sim ultaneously includ­
ed. Unfortunately, this was not possible, because there were no studies, which reported all men­
tioned characteristics (convergence problems). A  best subset analysis was also not possible for the 
sam e reasons. To correct for the variation in the precision o f the A U C s caused by studies using
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smaller and larger numbers o f patients, we performed a weighted (for sam ple size) regression 
analysis (for the characteristic sample size itself, we used an unweighted regression analysis) (9). 
To correct for the dependence between A U C s within the sam e study population, we used a random­
effect model (multilevel model). The student t-test was used to test for differences between sub­
groups. A  p-value o f 0.05 or less was considered statistically significant. Analyses were performed 
with Statistical Analysis System software (SAS 6.12, SAS institute inc., Cary, NC, USA).
Summary R O C  analysis
Characteristics, which caused significant variation in staging performance and low m issing values 
(n <  24 m issing values) in the trapezium subgroup analyses were additionally analysed using sum ­
mary RO C curves. Sum m ary RO C analysis (5) was performed for publication year, consensus read­
ing, prospective vs retrospective study design, sample size, im aging planes, turbo spin echo im ag­
ing, the endorectal coil and contrast agents. Sum m ary RO C curves were constructed only for stud­
ies, which used the per prostate histologic ‘gold standard’. The per prostate histologic gold stan­
dard is used when a study compares MR im aging predictions o f cT2 vs cT3 with pathology regard­
less o f the location o f the tumour extension seen at pathology. For example MR im aging may pre­
dict stage cT3, because ECE is seen on the left side o f the prostate. If the pathological ECE is actu­
ally on the right side, this fact is ignored using the per prostate histologic gold standard and the 
prediction is scored as a correct hit for MR im aging. We used only the per prostate reference stan­
dard to decrease heterogeneity due to different reference standards and consequently to determine 
more accurately other causes o f heterogeneity.
Subgroup analyses using sum m ary R O C curves are accomplished by a transformation o f sensitiv­
ity and specificity into the logit o f the true positive rate and false positive rate. Subsequently, the 
sum and difference o f the logit terms were calculated. The sum and difference o f the logit terms 
were plotted and sim ple linear regression provided a slope and intercept. When the slopes of both 
regression lines o f two subgroups are near zero, a com parison of the intercepts indicates the pres­
ence or absence o f a statistically significant difference between subgroups. Following the guidelines 
(5) for fitting sum m ary RO C curves, we obtained corresponding single-num ber sum m aries. These 
were the points on the sum m ary RO C curve where sensitivity and specificity are equal. A  p-value of 
0.05 or less was considered statistically significant. Analyses were performed with Statistical 
Analysis System (SAS 6.12, SAS institute inc., Cary, NC, USA).
R e su lts
Literature Search
We found 134 articles with the M ED LIN E and EM BASE databases. Articles were excluded for the 
following reasons: review or reanalysis (n=16), nodal staging data instead of local staging (n=8),
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3no histologic reference standard (n=5), previously published article (n=1), not available in library 
(n=3), no data on sensitivity and specificity (n=50). U sing bibliographies o f retrieved articles and 
knowledge o f co-authors, we additionally included 20 articles. Furthermore we retrieved 35 eligible 
abstracts o f which we excluded 30, due to republication as an article (n=18) and due to absent data 
on sensitivity and specificity (n=12). Finally, we included 71 articles and 5 abstracts for further 
analysis, containing 146 studies. A  study was defined as set o f sensitivity and specificity, resulting 
from one diagnostic evaluation. Therefore one article or abstract can contain more than one study; 
for example when one article evaluates the sam e group o f subjects using spin echo im aging and 
turbo spin echo im aging. A  list o f all included articles and abstracts, with relevant characteristics is 
available on request from the authors.
Table 1 Patient group characteristics
Characteristic AUC ECE AUC SVI AUC T3
Age < 64 yrs 0.50 ±0.21 N=35 0.56 ± 0.19 N=20 0.57 ± 0.12 N=17
Age >  64 yrs 0.70 ±0.21 N=7 0.68 ± 0.23 N=7 0.67 ± 0.14 N=7
Missing value 0.59 ± 0.20 
P<0.001
N=50 0.64 ± 0.23 
P=0.01
N=53 0.61 ± 0.13 
P=0.02
N=59
PSA: 5.9-16.1 0.66 ± 0.09 N=8
PSA:16.2-21.3 0.52 ± 0.05 N=5
Missing value NS NS 0.60 ± 0.14 
P<0.01
07=N
%pT3 < 50% 0.43 ± 0.22 N=20
%pT3 _ 50% 0.65 ±0.17 42=N
Missing value 0.57 ±0.2 
P<0.001
N=48
NS NS
N =  num ber o f  studies. N S  =  not significant. A U C =  trapezoidal area under the curve,
E C E =  extracapsular extension, S V I=  seminal vesicle invasion.
Trapezoidal area under the RO C curve analysis
The patient group characteristics, methodological characteristics as well as MR im aging protocol 
characteristics, which resulted in significant different A U C s are sum m arized in tables 1-3. 
Although significant differences were found in A U C s between different patient populations (table 
1) and study-design characteristics (table 2), m issing values were highly prevalent. For example; 
age showed 59 m issing values out o f 83 studies; PSA showed 70 m issing values out o f 83 studies. 
Because o f the high number o f m issing values for these characteristics, these data may be highly 
biased.
Publication year, sample size and reference gold standard yielded limited m issing values. Staging per­
formance was lower in studies using more than 50 subjects (table 2; p<0.001). Staging performance 
was lower in studies using per prostate scoring compared to the per site scoring (table 2; p<0.001).
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Table 2 Methodological characteristics
Characteristic AUC ECE AUC SVI AUC T3
Publication year
1985-1993 0.57 ± 0.25 N=16
1993-2001 0.64 ± 0.21 N=64
NS P=0.04 NS
Verification bias - 0.49 ±0.15 N=14
Verification bias + 0.64 ± 0.08 N=2
Missing values 0.58 ± 0.22 N=76
P=0.03 NS NS
Not in consensus 0.51 ± 0.20 94=N 0.59 ± 0.23 63=N 0.55 ± 0.10 N=49
Consensus 0.68 ±0.13 N=12 0.73 ± 0.20 N=9 0.67 ± 0.10 N=14
Missing value 0.61 ± 0.22 N=31 0.64 ± 0.21 N=35 0.70 ±0.13 N=20
P<0.001 P=0.04 P<0.001
Prospective 0.58 ± 0.24 53=N
Retrospective 0.67 ±0.23 N=22
Missing values 0.65 ± 0.18 32=N
NS P<0.01 NS
Consecutive 0.51 ± 0.24 N=29 0.57 ± 0.20 N=21 0.56 ± 0.12 N=16
Non-consecutive 0.43 ±0.17 N=4 0.84 N=1 0.64 N=1
Missing values 0.60 ±0.19 N=59 0.64 ± 0.23 N=58 0.61 ± 0.14 N=66
P=0.06 P=0.04 P=0.02
Sample size < 51 0.62 ±0.18 55=N 0.66 ±0.14 93=N
Sample size > 50 0.47 ± 0.22 63=N 0.56 ± 0.12 N=43
Missing value 0.68 N=1 0.65 N=1
P<0.001 NS P<0.001
ECE per site 0.47 ± 0.22 N=27 0.52 ± 0.10 N=9
ECE per patient 0.60 ±0.19 N=61 0.62 ±0.13 N=74
Missing value 0.67 ± 0.17 N=4
P<0.001 NS P<0.001
N =  num ber o f  studies. N S  =  not significant. A U C =  trapezoidal area under the curve, 
E C E =  extracapsular extension, S V I=  seminal vesicle invasion.
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3Table 2 Methodological characteristics N= number of studies. NS = not significant. AUC= trapezoidal 
area under the curve, ECE= extracapsular extension, SVI= seminal vesicle invasion.
Characteristic AUC ECE AUC SVI AUC T3
Sample size <  51 0.62 ±0.18
LOLO=N 0.66 ±0.14 N=39
Sample size >  50 0.47 ± 0.22 N=36 0.56 ±0.12 N=43
Missing value 0.68 N=1 0.65 N=1
P<0.001 NS P<0.001
ECE per site 0.47 ± 0.22 72=N 0.52 ±0.10 N=9
ECE per patient 0.60 ±0.19 N=61 0.62 ±0.13 47=N
Missing value 0.67 ± 0.17 N=4
P<0.001 NS P<0.001
Most studies provided enough information about MR im aging protocol characteristics. The num ­
ber o f im aging planes influenced A U C s (table 3; p<0.012). The highest A U C  was achieved using 
two or more im aging planes. Use of turbo spin echo im aging and the endorectal coil resulted in 
significant higher A U C s (p<0.05). Staging performance was also improved using contrast agents 
(P<0.0024). However, the number o f studies was limited (N = 8). Not enough information was pro­
vided on image resolution (table 3; m issing values: 68 out o f 83 studies).
The following characteristics did not have a significant effect on staging performance: hormonal 
pre-treatment, department o f origin, histology preparation, fat suppression, magnetic field 
strength, the use o f glucagon, MR spectroscopy and dynamic contrast-enhanced MR im aging. This 
does not necessarily mean that these features are not sources o f heterogeneity. However, it may 
also be possible that too limited studies reported on these characteristics.
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Table 4 MR imaging protocol characteristics
Characteristic AU C ECE AUC SVI N=16 AUC T3
1 plane 0.50 ±0.21 22IIN 0.43 ±0.19 N=41 0.52 ± 0.10 N=33
>2 planes 0.57 ±0.23 94IIN 0.66 ± 0.22 N=23 0.64 ±0.13 N=26
Missing value 0.62 ±0.14 N=21 0.70 ±0.15 0.68 ±0.12 N=24
P<0.01 P=0.012 P<0.001
Spin echo 0.49 ± 0.24 N=22 0.55 ± 0.12 93IIN
Turbo spin echo 0.69 ±0.19 N=44 0.65 ±0.14 33IIN
Missing value 0.60 ±0.16 N=14 0.66 ± 0.09 N=11
NS P=0.05 P<0.01
-  endorectal coil 0.58 ± 0.23 72IIN 0.54 ±0.11 N=29
+ endorectal coil 0.67 ±0.21 64IIN 0.65 ±0.13 N=41
Missing value 0.51 ± 0.21 N=7 0.60 ±0.12 N=13
NS P=0.01 P=0.01
Voxel: > 3.0 mm3 0.59 ± 0.24 N=13 0.60 ±0.16 N=9
Voxel: < 3.0 mm3 0.74 ± 0.19 N=12 0.76 ± 0.11 N=6
Missing value 0.61 ± 0.22 N=55 0.59 ±0.12 N=68
NS P=0.05 P=0.02
+Contrast agents 0.70 ±0.15 N=8 0.74 ± 0.17 N=7 0.76 ± 0.12 N=7
-  Contrast agents 0.55 ± 0.21 N=80 0.61 ± 0.22 N=71 0.59 ±0.13 47IIN
Missing value 0.70 ± 0.19 N=4 0.85 ± 0.14 N=2 0.58 ± 0.08 N=2
P<0.001 P=0.02 P<0.01
N =  num ber o f  studies. N S  =  not significant. A U C =  trapezoidal area under the curve,
E C E =  extracapsular extension, S V I=  seminal vesicle invasion.
Summary R O C  analysis
After excluding studies using the per site histologic gold standard, we included 50 articles and 5 
abstracts for sum m ary RO C analysis, yielding 87 studies.
The results o f the sum m ary RO C subgroup analyses are sum m arised in Figs. 1-6 and table 4. 
H igher test accuracy is reflected in a summ ary RO C curve by proximity to the left upper corner of 
the plot.
Statistically significant differences in staging performance occurred with differences in sam ple size 
(fig. 2; p<0.05), number o f im aging planes (fig 3; p<0.001), type o f spin echo (SE) im aging (fig. 4; 
p<0.001), use o f the endorectal coil (fig 5; p<0.05) and contrast agents (fig. 6; p<0.001). We did not 
find significant differences in staging performance for publication year (p=0.49), consensus read­
ing (slopes differed significantly from 0; p=0.03), prospective vs retrospective study (p=0.52).
The overall summary RO C curve for studies using per prostate reference standard appears in Fig. 1. 
This curve may be considered to be symmetric because the slope o f the regression line constructed
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Figure 2  Summary ROC curves (detection stage T3) 
for study size. Diamonds indicate studies with less 
than 50 subjects, and squares indicate studies with 50 
or more subjects. Dotted line indicates summary 
ROC curve for studies with 50 or more subjects and 
solid line indicates studies with less than 50 subjects. 
Differences between both summary ROC curves were 
significant (P<0.05).
FPR
Figure 3 Summary ROC curves (detection stage T3) 
for number o f imaging planes. Diamonds indicate 
studies using one imaging plane and squares indicate 
studies using 2 or more imaging planes. The dotted 
line indicates a summary ROC curve for studies using 
one imaging plane and the solid line indicates ROC 
curves for studies using 2 or more imaging planes. 
Differences between both summary ROC curves were 
significant (P<0.001).
FPR
Figure 4  Summary ROC curves (detection stage T3) 
for type o f SE imaging used. Diamonds indicate stud­
ies using SE imaging and squares indicates studies 
using TSE imaging. The solid line indicates summary 
ROC curve for studies using TSE imaging and the 
dotted line indicates summary ROC curve for studies 
using SE imaging. Differences between both summa­
ry ROC curves were significant (P<0.001).
FPR
Figure 5 Summary ROC curves (detection stage T3) 
for coil type. Diamonds indicates studies using no 
endorectal coil, squares indicates studies using the 
endorectal coil. The solid line indicates the summary 
ROC curve for studies using the endorectal coil and 
the dotted line represents the summary ROC curve for 
studies using no endorectal coil. Differences between 
both summary ROC curves were significant (P<0.05)
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Figure 6 Summary ROC curves for use of contrast 
in the detection o f seminal vesicle invasion. The 
diamonds indicates studies using contrast and 
squares indicates studies without contrast. The 
solid line indicates the summmary ROC curve for 
studies using contrast and the dotted line indicates 
the summary ROC curve for studies without con­
trast. Differences between both summary ROC 
curves were significant (P<0.001)
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Table 5 Summary ROC subgroup 
subgroup comparisons.
analysis results. Results o f T  tests for symmetry and
Characteristic Slope Intercept P value P value for differ- No. of
for slope ence in intercept studies
*Total no. o f patients
< 5 0 0.09 2.13 0.61
> 5° -0.27 1.41 0.07 P=0.03
*No. o f imaging planes P=0.03
1 plane -0.27 0.95 0.07
> 2 planes -0.26 2.24 0.24 P<0.001
*Type o f SE  imaging P<0.001
used
SE -0.19 1.06 0.12
TSE 0.09 2.48 0.66 P<0.001
Missing value P<0.001
*Coil used
Endorectal coil -0.004 2.15 0.98
Other -0.24 1.35 0.17 P=0.04
**contrast agents P=0.04
-Contrast agents 0.19 2.77 0.29
+Contrast agents -0.44 2.20 0.30 P<0.001 P<0.001
The follow ing characteristics were tested fo r  the detection o f  ECE, S V I and T3. Only the significant results are shown. *; fo r  staging 
T2 vs T3, ** fo r  detection o f  SVI.
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3by regressing D on S for all studies is not statistically different than zero. For a symmetric RO C curve, 
reporting a single value for test accuracy is both convenient and appropriate, because the odds ratio 
remains the same at any point along such a curve. This number , representing test accuracy , is the 
joint maximum sensitivity and specificity, which is the point at which the summary RO C curve inter­
sects the 45° diagonal line (broken line in Fig. 1) designating equal sensitivity (TPR) and specificity 
(1-FPR). The summary RO C curve for MR im aging in prostate cancer staging (cT2 vs cT3) has a joint 
maximum sensitivity and specificity o f 71%. At a specificity of 80% on this curve, sensitivity was 62%, 
and at a specificity o f 95%, sensitivity was 29%. The summary RO C curve for detection o f seminal 
vesicle invasion has a joint maximum sensitivity and specificity of 82%. At a specificity o f 80% on this 
curve, sensitivity was 85%, and at a specificity of 95%, sensitivity was 27%. The summary RO C curve 
for detection of extracapsular extension has a joint maximum sensitivity and specificity of 64%. At a 
specificity o f 80% on this curve, sensitivity was 64%, and at a specificity o f 95%, sensitivity was 23%.
D is c u s s io n
Meta-analysis is a statistical analysis that com bines or integrates the results o f several independent 
studies considered to be combinable (10). U sing meta-analysis it is possible to explain variations 
in study results. Additionally meta-analysis may be used to highlight important defects in the qual­
ity o f primary studies and to identify areas o f future research (1 1 ;1 2 ).
A  large heterogeneity in local staging performance o f MR im aging in prostate cancer is present in 
the literature. However, it is not fully understood why staging performance varies so much. We 
could not completely explain the heterogeneity in staging performance. This was partly caused by 
large numbers o f m issing values on patient characteristics and study design in the literature, mak­
ing multivariate analysis not possible. Second, we could not evaluate all possible sources o f het­
erogeneity. For example the role o f criteria for capsular penetration, the role o f experience and the 
role o f clinical knowledge could not be investigated.
At present time the most specific criterion for ECE is asymmetry o f the neurovascular bundle (sen­
sitivity: 38%, specificity: 95%) (13). The most sensitive criterion is overall impression (sensitivity: 
68% , specificity:72%) (14). Other reliable criteria are obliteration o f the rectoprostatic angle (13), 
bulge (14) and extracapsular tumour (14). However, in this meta-analysis we could not determine 
the effect o f criteria for ECE on staging performance, due to the following reasons. First, each study 
used different sets o f criteria, which made classifying criteria into groups not possible. For exam­
ple we found more than 20 different criteria for ECE. Furthermore, the used criteria were often poor­
ly defined or not mentioned.
The role o f reading experience could not be analyzed, because most studies did not state a defini­
tion o f experience. However, from the radiological literature it is known that a learning curve is pre­
sent for local staging o f prostate cancer and that MR staging performance improves with experi­
ence (3;13;15-18).
Finally, we tried to determine the effects o f clinical information (age, PSA), before reading the
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images. However, in most studies the available clinical information was not reported. The sub­
stantial influence o f demographic variables like age, PSA and gleason score on staging perfor­
mance has been demonstrated by Getty et al (19). Other investigators (20), have shown that the 
variation in staging performance may be related to the selection o f patients, i.e. the number of 
patients with clinical T1c tumors has increased during the past few years. The prevalence o f patho­
logical stage T3 has decreased as well as the size o f capsular penetration. Further, the frequence of 
patients with only m icroscopic ECE has increased. Due to the high number o f m issing values (table 
1 ) we could not reliably evaluate the role o f patient selection on the staging performance.
Although large numbers o f m issing values were present, we did identify characteristics, contribut­
ing to heterogeneity. Consistent with the meta-analysis by Sonnad et al (21), we found that studies 
with small patient numbers and studies using turbo spin echo achieved higher staging perfor­
mance. Contrary to Sonnad et al. (21) we found that the endorectal coil improved staging staging 
performance and we did not find any effect o f m agnetic field strength on staging performance. 
Additionally, this meta-analysis demonstrated that more than one im aging plane and contrast 
media result in higher staging performance. However, limited studies have been performed on the 
role o f contrast agents (n=8). We did not find MR spectroscopy to be o f significant value in im prov­
ing staging performance. Although there is some data (22) to support the value o f MR spec­
troscopy in staging prostate cancer, too limited number o f studies have been performed in order 
to perform a meta-analyis.
This meta-analysis covers a time period o f 17 years. Due to the fast-moving technology in the field 
o f magnetic resonance im aging, it is not surprising that current studies differ significantly than ear­
lier work. Nevertheless, when evaluating the literature the incremental value o f certain technologic 
improvements on test performance remains unclear. In order to remain as unbiased as possible we 
have included early studies and have analyzed each characteristic separately.
The subgroup analysis using the trapezoidal area under the RO C curve proved that staging perfor­
mance was lower when verification was performed per site o f ECE. Apparently, the type o f gold stan­
dard influences staging performance. Consequently we used only studies, which used one type of 
reference standard (per prostate) in the sum m ary ROC-analysis. We chose the per prostate refer­
ence standard, because the majority o f papers used the per prostate reference standard and 
because this was considered clinically more relevant. However, the per prostate reference standard 
may be less appropriate, because it allows for the following- to call extra-capsular extension on the 
right, have it be on the left at pathology and determine that to be a correct hit for MR imaging.
The maximum joint sensitivity and specificity numbers in this study (71%) for detecting stage cT3 
are sim ilar to the numbers reported by Sonnad et al (21) (74%). A  limitation o f these estimates is 
that due to the heterogeneity in staging performance it is difficult to discuss the average local stag­
ing performance o f MR imaging.
Despite its widespread use, meta-analysis continues to be a controversial technique. The pooling 
o f results from a particular set o f studies may be inappropriate and meta-analyses o f the same 
issue may reach opposite conclusions. However, by integrating the actual evidence, meta-analysis 
allows a more objective appraisal, which can help to resolve uncertainties when the original
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3research, disagrees. Furthermore, contrary to single studies, it is possible using meta-analysis to 
reach the necessary number o f patients to detect or exclude small effects with confidence (23). 
The quality o f included studies is o f obvious importance for meta-analysis. If  the raw material used 
is flawed, then the conclusions o f meta-analytic studies will be equally invalid. However the type of 
scale used to assess trial quality can dramatically influence the interpretation o f meta-analytic stud­
ies (24). Instead o f using quality criteria, we included all studies that met basic entry criteria and 
analyzed relevant study characteristics individually to determine their influence on staging perfor­
mance (11;24;25).
This study presents the use o f two available meta-analytic techniques to analyze local staging per­
formance o f MR im aging; the trapezoidal area under the curve and the summ ary R O C curve. First 
we analyzed all characteristics using the AUC. Only those characteristics, which yielded significant 
differences and low m issing values, were additionally analyzed using the sum m ary R O C curves. The 
advantage of using the trapezoidal area under the curve is that this method facilitates the analysis 
o f large and complicated data sets. However, the accuracy o f this method when only one point is 
present is not proven. The advantage o f sum m ary RO C curves is that the curves may be tested for 
symmetry and therefore it can be determined if  subgroup analysis is appropriate. A  disadvantage 
o f sum m ary RO C curves is that if a large variability is present between subgroups, the goodness of 
fit using summ ary RO C curves will be limited.
In conclusion; it was not possible to fully explain the present heterogeneity in the literature, partly 
due to poor reporting in primary studies and partly because we could not evaluate the role o f clin­
ical information and reader experience. Therefore, the quality o f reporting in future studies should 
be improved. Secondly it is important to consider that those who perform MR im aging in case of 
prostate cancer should determine their own standard o f accuracy by carefully com paring their 
im aging results with histopathologic findings(16;26). Yet, our results suggest that turbo spin echo, 
the endorectal coil and multiple im aging planes improve staging performance. Furthermore we 
found that studies with small sample sizes may result in higher staging performance, which may 
be o f importance in interpreting the literature.
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A b stra c t
Background: Routine Magnetic resonance (MR) im aging for local staging of 
prostate cancer is controversial, due to moderate staging performance. However, 
MR im aging may be beneficial in a subgroup o f patients with clinically localized 
prostate cancer.
Objective: To define the patient group in which local staging o f prostate cancer 
using MR im aging is useful for treatment outcome.
Methods: We used a decision analytic model based on data found in the literature 
to define the patient subgroup, which may benefit from local staging with MR im ag­
ing. We applied the threshold approach to calculate the threshold where direct 
surgery and surgery after MR im aging (surgery-MR im aging threshold) result in 
equal utility. Additionally, we calculated the threshold where direct treatment with 
radiation and radiation after MR im aging (MR imaging-radiotherapy threshold) 
result in equal utility.
Results: We found the surgery-MR im aging threshold was at a probability o f 45 %  of 
having stage >  T3 disease. The MR imaging-radiotherapy threshold was at a prior- 
probability o f 81 %  o f having stage >  T3 disease.
Conclusions: The application o f the threshold approach indicated that MR imaging 
should be limited to patients with an intermediate-high risk o f having stage T3 d is­
ease.
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In prostate cancer, treatment decisions are dependent among others on the local stage o f prostate 
cancer. The purpose o f local staging o f prostate cancer is to determine whether the prostate can­
cer is non-organ-confined (> stage T3) (1). This is important, because then radical prostatectomy 
is not considered curative anymore. Consequently, radiotherapy is often the preferred treatment. 
The partin tables (2) are most com m only used to identify patients with non-organ confined 
prostate cancer. Although the partin tables have improved staging accuracy, the understaging rate 
remains 45%  (3). Therefore, additional staging studies like trans rectal ultrasound (TRU S) and 
magnetic resonance (MR) im aging are used to decrease the understaging rate. In general there is 
not much enthusiasm  among urologist for MR Im aging, mainly because o f the low sensitivity and 
because it adds little to local staging using routinely performed transrectal ultrasound (TRUS) (4). 
However, staging performance o f MR im aging varies widely in the literature. Therefore we have per­
formed a literature meta-analysis (5) o f the staging performance o f MR im aging in prostate cancer. 
We found that sensitivity and specificity o f MR im aging increased significantly according to a high­
er prevalence o f stage T3 in the studied patient population. Consequently, we hypothesize that only 
a subgroup o f surgical candidates, with high risk o f stage T3 should be staged using MR imaging. 
However, it is not clear how high this risk (probability; P) should be. Thus, the aim o f this model­
ing study is to define a subset o f radical prostatectomy candidates, where MR im aging o f the 
prostate is useful.
M ethod s
The threshold concept
We applied a modification o f the threshold concept o f Pauker and Kassirer (6;7). The concept works 
as follows. If  the probability o f a having prostate cancer stage T3 disease is low, the patient is a can­
didate for surgery. If the probability o f having stage T3 disease is high, the patient is a candidate for 
radiotherapy. The estimation o f the probability o f stage T3 disease at which one is indifferent as to 
performing surgery or radiotherapy (toss-up) is called the surgery-radiotherapy threshold. If the 
probability o f having stage T3 disease exceeds this threshold, the better choice is to perform radio­
therapy; when the probability is below this threshold, the better choice is to perform surgery. Using 
a decision tree (Fig. 1) it is possible to evaluate the utility o f each choice.
If MR Im aging is performed the decision tree changes into Fig. 2. Again, the outcome o f each strat­
egy can be calculated and depends on the staging performance o f MR im aging and the prior prob­
ability o f stage T3. If MR im aging is performed, it is possible to derive a "surgery-MR im aging 
threshold”, which is the probability o f disease at which there is no difference between direct surgery 
without MR im aging and performing the MR im aging. Secondly, the "MR imaging-radiotherapy- 
threshold”, which is the probability o f stage T3 at which there is no difference between performing
In troduction
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Figure 1 Decision analytic model with two strategies 
in patients with prostate cancer: Surgery in case of 
stage T2 prostate cancer and radiotherapy in case of 
stage T3 disease. The square indicates a decision 
node. The nodes represented by circles are used if 
subsequent outcomes occur by chance (probability = 
P). The model starts at the left node. At that node the 
patient has clinically localized prostate cancer. If 
surgery is chosen in case o f stage T2, the expected 
utility equals the probability o f stage T2 x expected 
life expectancy x the quality of life with possible impo­
tence. The probability o f stage T3 can be estimated 
with the partin tables. In the same manner the 
expected utility can be calculated for each branch sit­
uation. Finally, the total expected utility for each 
choice can be evaluated. The treatment with the high­
est expected utility is considered the optimal option.
Figure 2  Decision analytic model with three strate­
gies in patients with prostate cancer: Direct surgery in 
case o f low probability of stage T3 disease; MR imag­
ing in case of intermediate risk of stage T3 disease 
and third: direct radiotherapy in case high risk of 
stage T3 disease. The benefits o f the MR strategy 
include: no mortality, morbidity and complications 
due to operation in case o f a true positive T3, increase 
of life expectancy due to operation in case of a true 
positive T2. The costs include a decrease in life- 
expectancy in case o f a false-positive T3, and an 
increase in mortality, morbidity and complications 
due to operation in case of a false-positive T3. The 
outcomes of each strategy depends on the staging 
performance o f MR imaging, and on the prior proba­
bility o f having T3 disease.
MR im aging and direct radiotherapy. The probability o f disease can be estimated from the Partin 
Tables (2). Thresholds for the risks o f T3 disease were calculated using values found in the litera­
ture (table1-3). In table 2, the utility is a value for patients o f being in an ill state o f health. For exam­
ple a patient with impotence resulting from surgery has a lower utility (0,95). Utility values range 
from 0 (= death) to 1 (= perfect state o f health). The usefulness o f treatment may be expressed as 
the (quality-adjusted) life expectancy after treatment. The product o f life expectancy x utility is 
known as the quality-adjusted life years (Q ALY’s). For example, a patient with a life expectancy of
10 years and impotence has a quality-adjusted life expectancy o f 10 x 0,95 =  9,5 years. First, we cal­
culated the surgery-radiotherapy threshold to determine at which probability o f stage T3 disease
48
Patient selection fo r  MR Imaging
Table 1 Staging performance o f MR imaging with accompanying Threshold surgery-MR imaging (TSMR) 
and Threshold MR imaging-radiotherapy threshold (TMRR).
Characteristic Sensitivity (%) Specificity (%) PPV NPV T s m r  
T  MRR
Ref.
Average literature MRI (T2-T3) 64% 72% 65% 74% 45-81% (5)
High specificity MRI* (T2-T3) 64% 86% 78% 69% 34-81% (26-30)
Extracapsular extension** 55% 82% 71% 72% 45-82% (5)
Seminal vesicle invasion** 58% 89% 67% 87% 45-90% (5)
* Only studies using patient populations with N  >  50 and specificity >  80% .** Additionally we give the average (literature) stag­
ing performance fo r  extracapsular extension and seminal vesicle invasion with thresholds.
Table 2  Risk o f surgery, expressed utility
Utility Reference
Mortality due to surgery 0
Impotence 0,95 (31)
Incontinence 0,85 (31)
Life without complications 1
Table 3 Life expectancy,
according to various treatments for a 65-year-old male
Life expectancy (Years) Reference
Successful operation 14,45 (32)
Unsuccessful operation 10,75 (32)
Not operated because o f T3 10,75 (32)
Not operated with T2 12,64 (32)
Successful radiotherapy 13,4 (32)
there is indifference between surgery and radiotherapy. In order to calculate the surgery-MR im ag­
ing threshold and the MR imaging-radiatiotherapy threshold we modified the form ulas from 
Pauker, and Kassirer (7). The derivations for these thresholds can be found in appendix 1 and 2.
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In this paper we describe the development o f MR im aging and its future prospects. Furthermore 
we address the question whether MR im aging may be helpful in making the treatment decision. We 
applied a modification o f the threshold concept o f Pauker and Kassirer (8) to determine the value 
o f MR for patient outcome. They derived two thresholds. A  "testing threshold”, is the probability of 
disease at which there is no difference between the value o f withholding treatment and that o f per­
form ing the test. Secondly, the "test-treatment threshold” is the probability o f disease at which 
there is no difference between the value o f performing the test and that o f adm inistering treatment. 
Because we apply this approach on patients with established prostate cancer we modify these 
thresholds in the "test-surgery threshold” and the "test-radiation threshold”.
To determine the past, current, and future role o f MR im aging and to assess the variables for the 
decision analysis Relevant publications were identified in the M ED LIN E database we executed sys­
tematic M ED LIN E searches(1991-2000) to assess the variables for the decision analysis. The fol­
lowing text words were used: prostate cancer, staging, magn-res-imaging, magnetic-resonance-imaging, 
prostatectomy-mortality, prostatectomy -statistics, numerical-data, randomized-controlled-trials, MRI, 
treatment, effectiveness, efficiency and outcome.
Furthermore, a manual search o f in libraries available conference proceedings o f the Radiological 
Society o f North America (RSNA) was conducted. Unpublished data was not included. Values on 
the staging performance o f MR- im aging were retrieved from (5).
With an excel (m icro so ft® ) file it is easy to perform calculations with different variables.
The current role of MR staging
In the last 15 years there was a rapid evaluation o f the MR im aging o f the prostate. Factors that con­
tributed to the technical improvement were the devellopment o f new (faster) pulse sequences, sur­
face coils like the endorectal coil, the use o f contrast material. As a result scanning time decreased, 
increased resolution due to decreased pixel size (measure o f image elements) and sm aller Field- 
o f View, increased signal-to noise ratio and less motion artefacts (tabel ) and figure (1-5).
R e su lts
The surgery-radiotherapy threshold (without MR imaging) lies at a probability o f 0,66 o f stage T3 
disease (Fig 3, upper bar). If the probability o f stage T3 disease is lower, surgery will be the better 
choice. If the probability is higher than 0,67 radiotherapy is the better choice.
If MR im aging is added to the decision-model, the thresholds change (Fig 3, lower bar).
Using the test variables in tables 1-3; the surgery-MR im aging and MR imaging-radiotherapy thresh­
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old is at a probability o f stage T3 o f 45% and 81%, respectively. In table 1 we have added the thresh­
olds for high specificity (>80%) MR imaging in studies with large patient populations (N >50). When 
using ‘high-specificity’ MR imaging the lower threshold decreases from 45%  to 34%. The upper 
threshold remains similar (81%). The thresholds for extracapsular extension and seminal vesicle inva­
sion (average literature performance) show similar thresholds. Thus, only a selected group of patients 
with intermediate risk (approximately 34-45% and higher) o f extraprostatic disease will benefit from 
MR imaging. In the following examples we demonstrate the use o f the threshold approach.
A patient with biopsy proven prostate cancer with a low risk o f  stage T3 disease
Case description. A  64-year -o ld  man with an elevated prostate specific antigen (PSA) level o f 9,3 
Ng/m l and a biopsy proved clinical stage T1c prostate cancer. Biopsy results demonstrate a 
Gleason 2 + 3 =  5. Patient is a candidate for radical prostatectomy. The partin tables predict that 
this patient has a 71 %  chance o f organ-confined disease. Thus, the patient has 29%  chance o f non­
organ-confined disease. This patient will not benefit from MR im aging, as this probability is lower 
than 45% . Consequently direct surgery is the better choice.
Diagnosis and treatment: Prostate cancer stage T2N0M 0. Patient underwent surgery without MR 
imaging.
A patient with biopsy proven prostate cancer with intermediate risk o f  stage T3 disease
Case description. A  61-year old man with an elevated PSA o f 9 Ng/m l and a biopsy proved prostate can­
cer with a Gleason score o f 3 + 5 =  8. Digital rectal examination shows stage T2a prostate carcinoma. 
Using the partin tables this patient had a (100-23%=77%) high risk o f stage T3. This is a difficult deci­
sion. Actually, the probability of stage T3 is too high for direct surgery. This is a ‘borderline’ situation. 
The risk o f depriving a patient from a potentially life-saving treatment (surgery) is present. In this case 
the use of MR imaging is justified. As can be seen from the lower bar the probability of stage T3 lies 
in the MR im aging interval (45-81%). Therefore MR imaging was performed. Extra capsular extension 
was seen on the endorectal T2 weighted MR image (Fig 4a) and in the contrast enhanced image (Fig 
4b). Additional images o f the lymph nodes showed no signs of metastasis.
D iagnosis and treatment: Prostate cancer stage T3N0M 0. Patient was excluded for surgery and 
scheduled for radiotherapy. In this case the decision not to perform surgery was justified by the use 
o f MR imaging.
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Case description. A  65-year old patient with an elevated PSA o f 14 Ng/m l and clinical staged T2. 
Prostate biopsy shows gleason grade 3 + 3 = 6. According to the partin tables patient has an inter­
mediate-high probability (100-30% =70% ) o f stage T3 disease. This patient will benefit from MR 
imaging.
Diagnosis and treatment: MR im aging demonstrated extracapsular extension and seminal vesicle 
invasion (Fig 5 a,b). Additionally enlarged lymph nodes were seen. This patient was assigned stage 
T3N+M 0. No surgery was performed and patient was scheduled for radiotherapy.
D is c u s s io n
The results o f MR im aging should have consequences for treatment decisions. Therefore, only 
patients with biopsy proved prostate cancer, who are candidates for radical prostatectomy should 
be considered for MR im aging (8). However, Should MR im aging be included in the staging pro­
tocol: The threshold approachonly a selected group o f surgical candidates benefit from local stag­
ing using MR im aging. In case o f a low probability o f stage T3 (<45% ), direct surgery (without MR 
imaging) is the better option. In ‘borderline’ cases, around the surgery-radiotherapy threshold (Fig. 
2, upper bar), MR im aging can be used to justify the decision (not) to perform surgery. The inter­
val where MR im aging is useful lies between 45 and 81%  probability o f stage T3 disease. If the prob­
ability is above this threshold, no MR im aging should be performed and patient should be treated 
with radiotherapy. U sing the partin tables the probability o f stage T3 can be calculated. U sing the 
threshold approach MR im aging will become more efficient and useful. The threshold approach 
has som e sim ilarity with the approach o f d’Am icgo et al (9;10). They advised for radiotherapy in 
case o f high risk for having extra capsular disease and surgery in case o f low risk. U sing a m ulti­
variate analysis they found that MR staging is useful in the group o f patients with intermediate risk 
o f having extra capsular disease to decide for surgery or radiotherapy.
O ur model shows how the range o f prior probability o f stage T3 disease in which testing should be 
performed depends on operation mortality, expected life-years gain in case o f surgery because of 
T2 or radiation and the sensitivity and specificity o f the test. O ur decision analysis model is a valu­
able instrument in the evaluation o f the merits o f MR im aging. The decision analysis was meant to 
evaluate the optimum use o f MR im aging in staging prostate cancer. U sing this method, urologists 
can determine for individual patients if MR im aging is beneficial. However this should be done with 
care, because urologists may overestimate the effects o f surgery (11). U sing the mentioned relative 
sim ple expressions (in the appendix) it is easy to calculate (using a spreadsheet program) thresh­
olds for any diagnostic test in the local practice (if data are known).
Other methods to stage prostate cancer are serum and pathologic markers. PSA correlates well 
with clinical stage, however PSA is mainly of value, when certain high PSA cut-off levels are used 
(12). Furthermore, staging prostate cancer using PSA remains controversial, because there is con­
siderable overlap between PSA in stage T2 and stage T3 disease (13).
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Probability o f stage T3
Figure 3 Bars demonstrating the relationship between the probability o f stage T3 disease and the preferred 
choice of treatment. The probability o f disease (depicted on the horizontal axis) ranges from 0 to 1. In the 
upper bar clinical staging methods are demonstrated (partin tables). If the probability of stage T3 disease is 
lower than 0,67 the preferred choice is direct surgery. However, in case of a probability higher than 0,67 the 
preferred choice is radiotherapy. In the lower bar the situation using MR imaging is displayed. In case o f a 
probability of stage T3 lower then 0,45 patient should have surgery, without further MR Imaging. If the proba­
bility for stage T3 disease lies between 45% and 81%, the preferred option is MR imaging. Finally if the prob­
ability of stage T3 disease is higher than 81%, patient should have radiotherapy, without further MR imaging.
Currently, urologist are in the possession o f highly accurate staging tools, which consist partly of 
serum markers, like %  free PSA (14;15) and PSA transition zone (16;17). In addition, pathological 
markers can be used such as biopsy gleason score, the number o f positive cores(18;19) and the 
length o f tissue cores invaded by cancer (19). It would be interesting to compare the staging per­
formance o f these markers with MR im aging. However, this is not possible, because the patient 
populations in which serum and pathologic markers are used differ from the patient population 
used for MR im aging. Patients are selected on the basis o f PSA, biopsy and digital rectal examina­
tion to be surgical candidates. MR im aging is only performed in surgical candidates. Different 
patient populations lead to large variations in test characteristics (20). A  comparison between the 
various staging methods is only meaningful if the method is evaluated in the sam e population. 
Even if  such a comparison would be possible, MR im aging would only be performed in addition 
(not instead of) to serum -  and pathological markers. Alternative im aging methods such as trans 
rectal ultrasound (TRU S) are also used for staging. U sing the threshold model it is possible to cal­
culate the surgery-TRUS threshold and the TRUS-radiotherapy threshold. However, the ‘average’ 
staging performance is unknown to us. Furthermore the role that TR U S has in the staging process 
is unclear. An advantage o f performing TR U S is that this examination is routinely performed to 
obtain prostate biopsies. However, in direct comparison with TRU S, MR Im aging proved more 
accurate in detecting extra-capsular extension and seminal vesicle invasion (2 1 ).
O ur decision analysis study contains some limitations. Recent papers suggest that the mortality 
rate o f radical prostatectomy decrease (22;23). We did the evaluation only in one age cohort (65
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4Figure 4  Prostate MRI (T2-weigthed: transverse view) o f the peripheral and central zone before (a) and 
after (b) contrast-enhancement. The area o f low signal intensity in a (white arrows) in the left peripheral 
zone represents the tumor site. Extracapsular extension is seen in the left dorsolateral half in a (white open 
arrow). On the contrast-enhanced images (b) enhancement is seen on the tumor site (circle) and outside 
the prostate capsule (white open arrow), indicative o f extracapsular extension. A = anterior, R = right,
u
Fig 5 Seminal vesicles (T2-weighted image) transverse view (a) and coronal view (b). In (a) a (dark) low 
signal intensity area is seen in the seminal vesicles (circle), suspect for seminal vesicle invasion. This was 
confirmed by the coronal view (b) where the tumor invades the seminal vesicles. A = anterior, S=  superior, 
R = right, B = bladder, SV = seminal vesicles, P = prostate.
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years old) and also we did not compare other treatment alternatives such as watchful waiting and 
brachytherapy. We also did not address the cost-effectiveness. Furthermore, we did not perform a 
formal sensitivity analysis, which evaluates the way the threshold changes as a function o f chang­
ing probabilities. Instead we demonstrated that the surgery-MR im aging threshold is lowered, if 
high specificity MR im aging is used. However, the purpose o f our approach was to give broad 
guidelines for selection o f patients for MR im aging and to give insight how a diagnostic test should 
be used. Finally, our guidelines have not been evaluated prospectively. Therefore, prospective stud­
ies should assess the staging performance o f MR im aging in patients with prostate cancer with 
intermediate-high risk o f extraprostatic disease. Nonetheless, we think that a m odeling study 
should be the basis o f such a prospective study (24)
C o n c lu s io n s
Application o f the threshold approach supports previous opinions (10;25) that MR staging in the 
pre-operative work-up is effective in the group o f patients with intermediate-high risk o f having 
stage T3 disease.
A p p e n d ix  1
Calculation o f  the surgery-radiotherapy threshold without MR Imaging.
Expected value (utility) o f the upper surgery and radiotherapy branch (Fig. 1) can be calculated from Tables 
2-3 as follows:
Expected utility in case o f  surgery f o r  stage T2:
P(Stage T2) x (Life expectancy x Utility in case of impotence)=
P(Stage T2) x (14,45 x 0,95).=
= 13,73 x P(Stage T2).
Expected utility in case o f  surgery f o r  stage T3:
P(Stage T3) x (Life expectancy x utility in case o f impotence) = 1-(P stage T2) x (10,75 x 0,95) = 10,21 x 1 -  
(P stage T2).
Expected utility in case o f  radiotherapy f o r  stage T2:
P(Stage T2) x (Life expectancy)= P(Stage T2) x 12,64 
Expected Utility in case o f  radiotherapy f o r  stage T3:
P(Stage T3) x (Life expectancy)= 1-P(Stage T2) x 10,75 
Expected value (EV) o f  surgery = Utility surgery for stage T2 + Utility Surgery for stage T3 
Expected value (EV) o f  radiotherapy  = Utility radiotherapy for stage T2 + Utility radiotherapy for stage T3 
At the indifference point EV surgery = EV Radiotherapy 
P=(10,75 -  (10,75 x 0,95)) /(14,45 x 0,95) -  12,64 + 10,75 -  (10,75 x 0,95)
P=0,33, 1-P= 0,67 (P=probability o f stage T2; 1-P= probability o f stage T3.
At a probability lower than 0,67 for stage T3, surgery is performed.
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Symbol Definition
Ts
PPV
R*rad
Sens
B**rad
Spec
NPV
Lex_surgT2
Lex_radT2
R*test
Test-surgery threshold
Positive predictive value o f MR imaging
Risk o f radiotherapy in patients with stage T2 disease
Risk o f diagnostic test
Sensitivity o f MR imaging
Benefit o f radiotherapy in patients with stage T3 disease
Specificity o f MR imaging
Negative predictive value o f MR imaging
Life expectancy in patients with stage T2 disease after surgery
Life expectancy in patients with stage T2 disease after radiotherapy
A p p e n d ix  2
Calculation o f  the surgery-MR im aging and MR imaging-radiotherapy thresholds.
U sing the sam e data as in appendix 1, the Surgery-MR Im aging threshold and MR imaging- 
Radiotherapy threshold can be calculated (6). Additionally we use information about the staging 
performance o f MR im aging given in Table 1. For an explanation o f the abbreviations Table 4 is 
given.
Surgery-M R imaging threshold =  (1-ppv) x (R*rad) + R*test/(1-ppv) x (R*rad) + sens x B**rad 
M R imaging-Radiotherapy threshold =  (Spec x R*rad) -  R*test/ (Spec x R*rad) + (1-npv) x B**rad 
R*radT2 =  Lex_surgT2 -  Lex_radT2 
The risk for testing is considered zero.
B**rad =  Mortality_ surgery + (1-utility_surgery) x Lex_radT2.
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Purpose: To compare the visibility o f anatomical details and staging performance in 
m agnetic resonance (MR) im aging in prostate carcinoma (PCa) using pelvic phased 
array coil (PPA) with integrated endorectal pelvic phased array (ER-PPA) coil and to 
see if specificity can be improved.
Methods and Materials: MR im aging was performed in a prospective study in 82 
consecutive patients with biopsy proven PCa, prior to radical prostatectomy on a 
1.5T scanner. Axial T2-weighted turbo spin echo im ages o f the prostate were 
obtained using PPA and ER-PPA coils. MR-images were evaluated by one observer 
prospectively and by 2 different observers retrospectively in consensus, with regard 
to visibility o f anatomical details and local staging. Results were compared with 
whole mount section histopathology and receiver operator characteristics (ROC) 
analysis was performed.
Results: Anatomical detail o f the overall prostate was significantly better evaluated 
using the ER-PPA coil (p<0.05). With the experienced reader, local staging accuracy, 
sensitivity and specificity for the PPA coil was respectively 59% (49/82), 54% 
(21/37) and 62%  (28/45), and for the ER-PPA coil 83% (68/82), 65%  (24/37) and 
98%  (44/45). Accuracy and specificity were significantly better with ER-PPA coil 
(p<0.05). The interobserver variability between experienced reader and consensus 
readers showed substantial agreement (kappa =  0.77). Area under the RO C curve 
(Az) was significantly higher for ER-PPA coil (Az=0.74) compared to PPA coil 
(Az=0.57) alone, for the experienced reader.
Conclusion: The use o f an ER-PPA coil results in significant improvement of 
anatomic details, staging accuracy and specificity. When using an ER-PPA coil over­
staging is reduced significantly with equal sensitivity.
Comparison o f  the PPA and the ERC-PPA  coil
Table 1 Reported staging performance of MR imaging of prostate cancer
Author Year n Coil Sequence Accuracy in % Pathology
Rifkin11 1990 230 B SE 77 b
Chelsky 12 1993 47 ER SE 68 b
Kier 13 1993 20 PPA TSE 85 b
Outwater 14 1994 30 ER TSE 79 w
Quinn 15 1994 70 ER TSE 67 w
Tempany 16 1994 213 B / ER TSE 61 / 54 w
Hricak 17 Huch 1994 71 PPA / ER-PPA TSE 68 / 77 w
Boni 18 1995 33 ER TSE 88 w
Brown 19 1995 20 B SE 80 n/a
Bartolozzi 20 1996 73 ER TSE 82 w
Perotti 21 1996 56 ER SE 64 w
Jager 22 1996 34 ER TSE 68 w
Jager 23 1997 57 ER TSE 72 w
Yu 24 1997 77 ER-PPA TSE 77 w
D'am ico 25 1998 49 multicoil-ER TSE 84 w
Rorvik 26 1999 32 ER TSE 58 w
Tsuda 27 1999 79 ER-PPA TSE 79 w
Ogura 28 2001 38 ER TSE 72 w
n =  num ber o f  patients; B  =  body coil; ER  =  endorectal coil; PPA  =  pelvic phased array coil; S E  =  spin echo sequence; T S E  = 
turbo spin echo sequence; b =  biopsy; w =  whole mount sections; n/a =  not available
In tro d u ctio n
Prostate cancer (PCa) is, despite improved therapeutic management, an increasing socioeconom ­
ic problem, due to its increasing incidence, high morbidity and mortality [1]. Curative therapy can 
only be done in cases o f localized prostate cancer, for example, radical retropubic prostatectomy is 
only considered in case o f stage T2b or less [2, 3] based on the TNM  staging system [4]. Accurate 
staging is therefore an important issue for correct management o f PCa.
The role o f m agnetic resonance (MR) im aging in local staging o f PCa is debated extensively in lit­
erature, due to large variation in accuracy [5]. Initially MR im aging was performed using a conven­
tional body coil with subsequent limited anatomical detail due to insufficient spatial resolution [6­
10]. Num erous studies have attempted to improve its local staging accuracy using endorectal (ER) 
coil, pelvic phased-array (PPA) coil, integrated ER-PPA coil, contrast agents and MR im aging 
sequences. However, results are still variable (range 54% - 88% ) (sum marized in table 1 [11-28]). 
The Radiologic Diagnostic Oncology Group (RD O G ) study [16] in 1994, utilizing the conventional 
body coil, and/or fat suppressed sequence with body coil and ER coil, reported an overall accuracy
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5for each technique o f 61%, 64%  and 54%, respectively. Hricak et al (1994) [17] found a staging 
accuracy o f 68%  using the PPA coil, rising to 77% with integrated ER-PPA coils in a study popula­
tion o f 71 patients. In 1998 Husband et al [29] reported superior image quality for PPA coil com ­
pared with the ER coil, mainly due to fewer artifacts. However, other groups have shown improved 
results for the ER coil im aging, with accuracies up to 88%  [18]. Nevertheless, due to various factors 
such as differing levels o f reader experience, different patient populations and lack o f standardized 
criteria for determining extracapsular extension, staging accuracies still show variability, and there­
fore its general acceptance for staging is still debated.
Com bining turbo spin echo (TSE) sequences and integrated ER-PPA coils has the potential to 
improve staging performance further [24, 27]. Thus far, only one prospective study com paring PPA 
and integrated ER-PPA coils for staging has been published [17]. This paper showed increased stag­
ing sensitivity when using the ER-PPA coil compared to the PPA coil. However, other recent papers 
suggest that it is more appropriate to focus on high specificity for extracapsular extension [30, 31], 
in order to reduce overstaging and thus allow a more appropriate selection o f patients for prosta­
tectomy.
The purpose o f this prospective study is to compare the visibility o f anatomical details and staging 
performance in PCa using high resolution TSE  sequences o f PPA coil and integrated ER-PPA coil 
MR im aging and to see if specificity can be improved.
M a te ria ls  a n d  M ethod s
Patient Selection /  Characteristics
From January 1999 to May 2002, 89 consecutive patients with biopsy proven PCa, who were sched­
uled for radical retropubic prostatectomy were included in a prospective study. Exclusion criteria 
were androgen deprivation treatment (n =  5) and positive lymph nodes at surgery (n =  2). The study 
protocol was approved by the local ethical committee and informed consent was obtained from all 
patients.
Subsequently, 82 patients were enrolled in this study. The age ranged from 43 to 74 years old 
(mean, 62.2 years). The mean prostate specific antigen (PSA) level and median Gleason grade were 
13.2 ng/ml (range: 4 to 78 ng/ml) and 6.3 (range: 3 to 9) respectively. The time interval between 
prostate biopsy and MR examination was 2 -  11 weeks (median, 5 weeks). The time interval 
between MR im aging study and surgery was 1 - 7 weeks (median 3 weeks). In six out o f 10 patients 
where SVI at MR im aging was detected, seminal vesicle biopsy was obtained and yielded positive 
results. Subsequently, the planned prostatectomy was cancelled. These patients were only used for 
SVI for our calculations. In the other cases o f positive SVI at MR im aging, no biopsy was obtained 
because o f urologist preferences.
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MR im aging was performed on a 1.5T machine (Siem ens, V ision, Erlangen, Germany) using both 
a PPA and an integrated ER-PPA coil (Medrad, Pittsburgh, US). Peristalsis was suppressed by intra­
m uscular injection o f 1 mg glucagon (G lu ca ge n ® ; Novo Nordisk A/S, Denmark) prior to the exam­
ination. An additional dose o f 1 mg glucagon was given after insertion o f the endorectal coil. 
Patient was placed in the supine position. The scanning protocol consisted o f two parts.
First, T1-weighted sagittal and axial localizing images were obtained. Thereafter an axial T2-weight- 
ed TSE  sequence (3500-4400/132/180~[repetition time (TR) in msec/ echo time (TE) in msec/ flip 
angle (?)], 5-mm section thickness, 0.1-mm intersection gap, 11 slices, 280-mm field o f view (FO V), 
240 x 512 matrix, pixel size 0.55 x 0.55, echo train length o f 15, two signals acquired) was applied. 
The sagital plane was used for positioning the axial planes. The axial planes were positioned per­
pendicular to ventral edge o f the rectum.
Second, the ER coil was inserted and inflated with approximately 80 ml air. T1-Weighted localizing 
images were obtained to check coil position. Axial T2-weighted TSE  images were acquired, with 
identical parameters to the sequence without ER coil. The direction o f the phase encoding and 
read-out gradient was changed from A-P to L-R to decrease ER motion artifacts. In addition, axial 
intermediate-weighted sequence with following parameters was acquired, 200 (TR), 4.4 (TE), 8~ (?) 
and 280-320 mm FO V  for detecting biopsy hematomas.
Pathologic Examination
The pathologic specimens obtained at radical retropubic prostatectomy were in toto fixed overnight 
in 10% neutral buffered formaldehyde and coated with India ink. Seminal vesicles were separated 
from the prostate and examined separately. For optimal correlation we tried to select an angle per­
pendicular to the rectum for MR im aging and whole mount section techniques. Axial whole mount 
step-sections were made at 4-mm intervals in a plane perpendicular to the base-to-apex axis of the 
prostate and posterior margin. After dividing each step-section into three or four parts (for techni­
cal reasons), all sections were routinely embedded in paraffin. All tissue blocks were labeled accord­
ing to location for whole mount reconstruction. Tissue sections o f 4mm were standard prepared 
with a meat-slicer machine and stained with hematoxylin and eosin. The presence and extent of 
cancer were outlined on the glass cover and retraced onto a histology tumor map o f the axial his­
tology sections by one experienced pathologist, who had no knowledge ofim aging results. For each 
tumor lesion, tumor volume, Gleason grade and location were determined and recorded. Final 
pathologic staging was based on the TNM  classification system [4].
M R  Im a g in g
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Readers -  All images were evaluated by one experienced radiologist (I) prospectively, with knowl­
edge o f clinical data (PSA, biopsy Gleason grade and digital rectal examination findings). 
Retrospective MR im aging evaluation was conducted in consensus and in random order by two 
radiologists (II, III) who were aware o f the clinical data but had no knowledge o f findings from the 
experienced reader. The two readers evaluated the images separately. When there was disagree­
ment, the case was discussed by both readers (II, III) and the stage was decided in consensus. 
Anatomical details were assessed retrospectively by two independent readers (I, III). Data were 
entered on a standardized form developed for this study.
The three readers had different levels o f experience in evaluating prostate endorectal MR images. 
Reader I was the most experienced, having more than 10 years experience in genitourinary MR 
im aging. Reader II and III had less than 2 years each o f experience in reading prostate MR exami­
nations.
Anatomical detail -  Anatomical details were assessed using two approaches used by McCauly et al 
[32]. First, side-by-side comparison o f the PPA and the ER-PPA images was obtained for each 
patient. Each reader determined whether the PPA images were better, the ER-PPA images were bet­
ter, or had equal quality. Second, independent numerical rating o f image quality with the ratings of 
the PPA images was performed one week apart from the ratings o f the ER-PPA images. Images 
were evaluated for motion artifact and coil related artifacts, visualization o f the peripheral zone, 
central gland, and anterior margins, and overall image quality, according to a 5-point scale (1 -  
poor, to 5 -  excellent).
Extracapsular extension -  In each prostate half, the presence o f extracapsular extension (ECE) was 
evaluated based on five specific features described in literature as being highly indicative o f ECE. 
These findings are asymmetry o f the neurovascular bundle [9-10], obliteration o f the rectoprostatic 
angle [10], bulge in the contour o f the prostate, overall impression [14], and extracapsular tumor 
[14]. T1-weighted im ages were used to rule out false-positive findings caused by post-biopsy hem­
orrhage, if  a low signal intensity lesion on a T2-weighted image matched a high signal intensity, 
then this area was considered as biopsy haematoma [33].
Seminal vesicle invasion -  The criterion used for seminal vesicle invasion (SVI) was: abnormal asym ­
metric low signal intensity within the lumen on T2-weighted images [14, 17].
The readers expressed their findings o f ECE and SVI on a five-point confidence level scale. A  rating 
o f "1” indicates the criterion ECE or SVI was not present; "2” probably not present; "3” indetermi­
nate/possible; "4” probably present; or "5” definitely present.
Statistical methods
Image quality data from the side-by-side com parison were analyzed with a one sam ple contingency 
table to determine if there was a significant difference between the number o f times the PPA was
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rated superior versus the number o f times the ER-PPA was rated superior. A  two-tailed Student t- 
test for paired data was used to determine significance between PPA and ER-PPA image quality and 
visibility o f anatomical details.
The sensitivity, specificity, positive predictive value, negative predictive value and overall accuracy 
to predict for tum or stage, ECE and SVI were calculated by dichotom izing the readings so that the 
scores o f 1-3 were rated as ECE/SVI absent and 4-5 were rated as present. The comparison of 
results from PPA and ER-PPA coils was performed with the M cNem ar test by using the S P SS  soft­
ware package (version 10.1, Chicago, Il, U .S.A). All p values reported are from two-sided tests, a p 
value o f 0.05 or less was considered to indicate a statistically significant difference.
Based on the Partin tables [34], patients were categorized in two subgroups with low risk (49 
patients, PSA < 10 ng/ml and biopsy Gleason score 2-7 or PSA 10.1-20 ng/ml and biopsy Gleason 
score 2-5) or intermediate/high risk (33 patients, PSA > 10 ng/ml and biopsy Gleason score > 5 or 
PSA > 20 ng/ml) o f having extracapsular disease. Low risk is considered a probability o f less than 
45%  and intermediate-high risk is a probability o f more 45%.
The statistical analysis included evaluation o f interobserver agreement (single experienced reader 
vs consensus limited experienced readers) by using non-weighted kappa statistics. The following 
qualitative terms associated to the strength o f the various kappa values were used: 0 .0-0.2 =  poor 
agreement, 0.21-0.4 =  fair agreement, 0.41-0.6 =  moderate agreement, 0.61-0.8 =  substantial agree­
ment, and 0.81-1.0 =  almost perfect agreement [35].
Receiver operating characteristic (RO C) curves were generated for the probability o f ECE and SVI 
by both technique and reader. The diagnostic performance was then assessed by calculating the 
area under the curve (AUC). The statistical significance differences in the A U C  were determined 
using the Chi squared test.
R e su lts
Surgical Pathologic Findings
Pathologic examination o f the prostatectomy specim ens revealed that 45 (55%) o f 82 patients had 
disease confined to the prostate. Pathologic staging demonstrated stage pT2a in sixteen patients 
and pT2b in 29 patients. The rem aining 37 (45%) patients had extraprostatic disease. Stage pT3a 
(ECE) was found in 24 patients, T3b (SVI) in 10 patients, and T4 (bladder wall invasion) in 3 
patients. A ssessm ent o f ECE was difficult in seven cases because o f surgical incision through the 
capsule and the cancer, and additionally in 9 cases because o f capsular incision. All o f these 
patients were assigned stage pT2. M icroscopic invasion into, but not through, the capsule was 
found in six patients which were also classified as having stage T2 disease [36]. In 8 out o f thirty 
cases, capsular penetration was less than 1 -mm.
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5Anatomical details -  Side-by-side comparison of PPA versus ER-PPA images yielded a statistically 
significant difference (p < 0.05) in benefit for endorectal coil. With ER-PPA coil, image quality was 
judged superior in 54 patients for reader I and in 66 patients for reader III. U sing the independent 
numerical rating scale ER-PPA images were significantly better for both readers (p < 0.05) in 2 out
4 categories: visibility o f prostate anatomy (figure 1) and overall image quality. ER-PPA coil images 
were in 5 cases degraded by near-field endorectal coil profile. A ssessm ent o f interobserver agree­
ment yielded fair to moderate agreement (kappa =  range 0.43 -  0.77).
Local Staging- Staging accuracy was significant higher using ER-PPA coil (p =  0.02; table 2) for the 
experienced reader, with a sim ilar but non-significant trend for the consensus reader. For reader I 
and consensus readers II/III interpretation o f PPA and ER-PPA images demonstrated significant 
improved specificity (p =  .0002) with ER-PPA coils (96% - 98%) (table 2) and equal sensitivity (59% 
- 65% ). At prospective evaluation by the experienced reader o f the PPA images, stage T2 was over­
staged in 16 patients and T3 was understaged in 15 patients. Evaluation using the ER-PPA images 
resulted in 2 false-positive findings, which reduced overstaging significantly (p =  .0002). The inter­
observer variability between single reader and consensus reading image interpretation showed sub­
stantial agreement ( kappa =  0.77).
Extracapsular extension- Accuracy in detection o f ECE (figures 1 and 2) was significant higher using 
ER-PPA coil (p =  .01; table 3) for both readers. Accuracy in detection o f ECE was sim ilar for the read­
ers (80% vs 76%, respectively; p =  .50). The specificity in detection o f ECE was statistically sign ifi­
cantly higher using ER-PPA im ages for both readers (p =  .009; table 3) compared to PPA images. 
Sensitivity for both readers did not demonstrate any statistically significant differences (p =  .54). 
The interobserver variability between single reader and consensus reading image interpretation 
showed substantial agreement (kappa =  .76). The superior performance o f ER-PPA coil is dem on­
strated in figure 3, which sum m arizes the results o f receiver operating characteristic analysis for 
each reader. There was a statistically significantly greater area under the receiver operating charac­
teristics curve (Az) for reader I using ER-PPA (Az =  .74) compared to the PPA coil (Az =  .57; p = 
.031) alone. The area under the receiving operating characteristic curve was not significantly dif­
ferent between experienced reader (Az =  .57 [PPA], A z =  .74 [ER-PPA]) and consensus readers (Az 
=  .61 [PPA], A z =  .70 [ER-PPA]) for both coils (p =  .53)
Seminal Vesicle Invasion- The results for SVI are presented in table 4. Accuracy in detection o f SVI was 
higher for reader I than for consensus readers (98% vs 89%) for the ER-PPA coil. For the experienced 
reader, the overall specificity in detection o f SVI (figure 4) was significantly increased using ER-PPA 
coil (99%, p < .001). The sensitivity in detection of SVI using PPA for experienced and consensus read­
ers was 45%  and using the ER-PPA coil for experienced and consensus readers was 91% and 73%, 
respectively. Interobserver agreement was substantial (kappa =  range 0.67 to 0.72). Because of the 
low number of pathologic positive cases o f seminal vesicle invasion (n =  11), however, RO C analysis 
was not performed.
M R  Im a g in g  F in d in g s
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Table 2  Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Staging Accuracy
Single reader Consensus readers
PPA ER-PPA PPA ER-PPA
Sensitivity 21/37 (57) 24/37 (65) 18/37 (49) 22/37 (59)
Specificity 28/45 (62) 44/45 (98)* 31/45 (69) 43/45 (96)
Positive predictive value 21/38 (55) 24/25 (96) 18/32 (56) 22/24 (92)
Negative predictive value 28/44 (64) 44/57 (77) 31/50 (62) 43/58 (74)
Accuracy 49/82 (60) 68/82 (83)* 49/82 (60) 65/82 (79)
-  Note: Num bers in parentheses are percentages.
* Differentiation between PPA and ER -PPA coils was significant (p<0.05, M cNem ar two-tailed test)
Figure 1C
Figure 1 Stage T3a carcinoma of the prostate in 54-year-old patient. (a) Axial PPA T2-weighted TSE image 
is graded 2 for image quality and 2 for ECE. Peripheral zone, central gland and capsule are not adequately 
visualized. (b) Corresponding axial ER-PPA T2-weighted TSE image shows low-signal-intensity lesions sug­
gestive for PCa (T). Bulging in the right lateral peripheral zone (arrows) indicates ECE. This image is grad­
ed 4 for image quality and 5 for ECE. (c) Whole-mount section at corresponding location shows tumor (T) 
with capsular penetration (arrows).
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Figure 2  Stage T2a carcinoma of the prostate in a 60-year-old-patient. (a) On the axial PPA T2-weighted TSE 
image, the tumor (T) in the right peripheral zone demonstrates bulging (arrows) that resulted in a misdiag­
nosis o f extra capsular extension (score 4). (b) Axial integrated ER-PPA T2-weighted TSE image obtained at 
the same anatomic section as image in a demonstrates a low signal intensity lesion in the left peripheral 
zone (score 2). (c) Whole-mount slice at corresponding level shows that no tumor (T) penetrates the cap­
sule on the right side.
Table 3 Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Accuracy of 
Extracapsular Extension
Single reader Consensus readers
PPA ER-PPA PPA ER-PPA
Sensitivity (%) 15/30 (50) 17/30 (57) 13/30 (43) 14/30 (47)
Specificity (%) 33/46 (72) 44/46 (96)* 33/46 (72) 44/46 (96)*
Positive predictive value (%) 15/28 (54) 17/19 (89) 13/26 (50) 14/16 (88)
Negative predictive value (%) 33/48 (69) 44/57 (77) 33/50 (66) 44/60 (73)
Accuracy (%) 48/76 (63) 61/76 (80)* 46/76 (61) 58/76 (76)*
-  Note: Num bers in parentheses are percentages.
* Differentiation between PPA and ER -PPA coils was significant (p<0.05, M cNem ar two-tailed test)
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Figure 3 Receiver operating characteristic curves for the experienced (I) and consensus readers (II/III) for 
the presence of ECE. Statistically significantly greater area under the curve using ER-PPA coil for the expe­
rienced reader (p = .031) compared to PPA coil. No significant difference was found for the unexperienced 
readers (p = .24).
Subgroup analysis- Table 5 shows for the experienced reader the total number o f patients found to 
have ECE and/or SVI on MR and histopathology stratified by low and intermediate/high risk group 
o f having extra capsular extension. O f  the 49 study patients in the low risk group, 13 (27%) had ECE 
and 1 (2%) had SVI (table 5). Respectively, in 28 (57%) and 42 (86% ) o f 49 (p =  .035) patients the 
presence or absence o f ECE and/or SVI was correctly identified on the preoperative PPA and ER- 
PPA MR im aging (table 5). Specificity in this group increased significantly from 64% to 97% (p = 
.009) for ER-PPA MR im aging. O f  the patients in the intermediate/high risk group (n=33), 17 (52%) 
had ECE and 9 (27%) had SVI, respectively, ECE and/or SVI were identified in 64 for PPA MR, and 
79% for ER-PPA MR im aging, respectively.
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5Table 4  Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Accuracy of 
Seminal Vesicle Invasion
Single reader Consensus readers
PPA ER-PPA PPA ER-PPA
Sensitivity (%) 5/11 (45) 10/11 (91) 5/11 (45) 8/11 (73)
Specificity (%) 57/71 (80) 70/71 (99)* 64/71 (90) 65/71 (92)
Positive predictive value (%) 5/19 (26) 10/11 (91) 5/12 (42) 8/14 (57)
Negative predictive value (%) 57/63 (90) 70/71 (99) 64/70 (91) 65/68 (96)
Accuracy (%) 62/82 (76) 80/82 (98) 69/82 (84) 73/82 (89)
- Note: Num bers in parentheses are percentages.
* Differentiation between PPA and ER -P P A  coils was significant (p<0.05, M cNem ar two-tailed test)
Figure 4  Seminal vesicle invasion in 64-year-old patient.(a) Axial PPA T2-weighted TSE image through seminal 
vesicles shows reduced signal-intensity in left seminal vesicle (arrows). This case was rated as possible seminal 
vesicle involvement (score = 3) (b) On corresponding axial ER-PPA T2-weighted TSE image, this case was rated 
as definitely presence o f seminal vesicle invasion (arrows, score = 5) (c/d) Invasion o f prostatecarcinoma into 
muscle wall of the left seminal vesicle. The inset shows cancer (on the right site) approaching the seminal vesi­
cle glandular epithelium with characteristic golden brown pigment (left corner; arrows). (400x; HE).
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Table 5 Number of Patients found by the experienced reader to have ECE and/or SVI and the 
Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Accuracy o f these cases 
correctly identified on the preoperative PPA and ER-PPA MR imaging.
Low risk (n = 49) Intermediate/high risk (n=33)
ECE n=13 (27)/SVI n=1 (2) ECE n=17 (52)/SVI n = 9 (27)
PPA ER-PPA PPA ER-PPA
Sensitivity 5/13 (38) 7/13 (54) 16/24 (67) 17/24 (71)
Specificity 23/36 (64) 35/36 (97)* 5/9 (56) 9/9 (100)
Positive predictive value 5/18 (28) 7/8 (88) 16/20 (80) 17/17 (100)
Negative predictive value 23/31 (74) 35/41 (85) 5/13 (38) 9/16 (56)
Accuracy 28/49 (57) 42/49 (86)* 21/33 (64) 26/33 (79)
- Note: Num bers in parentheses are percentages.
* Differentation between PPA and ER -P P A  coils was significant (p<0.05, M cNem ar two-tailed test)
D is c u s s io n
Available diagnostic staging modalities, transrectal ultrasound and biopsies are not accurate 
enough for staging [37]. Local staging o f PCa in terms o f patient prognosis and treatment options 
is important for the therapeutic decision making process. More accurate staging is needed for ade­
quate therapy planning. The role o f MR im aging is still under investigation because o f limited avail­
ability, high costs and variability in results [5, 23].
Since Rifkin et al (1990) demonstrated the limited value o f body coil MR im aging in staging PCa, sev­
eral studies have addressed the use o f endorectal and pelvic phased array coils [11-28]. Although 
these developments resulted in improved image resolution, the subsequent staging accuracy of 
prostate MR im aging still is not high enough. Factors responsible for this variation o f results are 
patient population size, use o f an endorectal coil, MR sequences such as TSE  and reader experience 
[31]. Hricak et al [17] combined ER and PPA coils which improved local staging. Jager et al [30] devel­
oped a decision analytic model which supported the opinion that MR staging in preoperative work­
up o f PCa is cost-effective and should be performed with a high specificity. Langlotz et al [31] empha­
sized this need for high specificity in prostate MR im aging to ensure that as few patients as possi­
ble will be unnecessarily turned down o f potentially curative therapy on the basis o f false-positive MR 
im aging results. D’amico (1998) [25] et al advised the use MR im aging in patients with intermediate 
risk only, because in this group the probability o f extraprostatic disease is high enough to warrant 
the use o f MR imaging. This was recently confirmed by Cornud et al. [38], who stated that endorec­
tal MR imaging is indicated in carefully selected patients-specifically, those with three or more pos­
itive biopsy specimens, a palpable tumor, and/or a PSA level greater than 10 ng/ml.
The results o f our study show that ER-PPA overall image quality is better than those obtained with 
PPA coil im aging alone. O ur study also revealed that the visibility o f the prostate anatomy was s ig ­
nificant better with the ER-PPA coil. This is in disagreement with Husband et al [29], who showed 
that PPA coil produces better image quality than ER coil alone, however the current study is com-
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5paring PPA coil with integrated ER-PPA coil, which results in superior quality for combination of 
coils. Another explanation for the better results in our study could be that Husband et al only inves­
tigated a small group o f patients (n =  2 1 ), used different criteria for evaluating anatomical details 
and had a fair to moderate interobserver agreement, which reflects the difficulties in attempting to 
quantify degree o f artifacts.
In the present study, superior results were noted with the use o f ER-PPA coils in visibility o f anatom­
ical details and local staging compared with the PPA coils alone. O ur results o f 83% in the overall 
staging accuracy for differentiation between stage T2 and T3 disease by endorectal coil im aging, fall 
within the range o f published studies (accuracies, 54% to 88% ) but are higher than reported in the 
RD O G  study o f Tempany et al. [16]. The difference between results o f this study and our study may 
be related to differences in techniques and the use o f whole mount sections. Langlotz et al [31], 
reported possible effect o f inconsistent image quality in the RD O G  study due to variations in tech­
nique between institutions. Also, our study included T2-weighted TSE  images and integrated 
endorectal coils, whereas the RD O G  technique consisted o f conventional SE and the use o f an 
endorectal coil without a PPA coil. Rifkin et al (1990) [11] reported a staging accuracy o f 77% using 
a body coil, however biopsy results were used for correlation with MR im aging results. The results 
o f the PPA coil images, however, are inferior to those o f Kier et al. [13]. In part, this may reflect the 
difference in study design. O ur study used whole-mount section pathology slides; the study o f Kier 
et al used biopsies. Also, our sam ple size is three times larger. Studies with small sam ple sizes may 
result in higher staging performance [5]. Huch Boni et al [18] demonstrated the highest staging 
accuracy o f 88% , however with a small sam ple size o f 33 patients. A  possible limitation o f our study 
relates to the order in which PPA and ER-PPA examinations were interpreted. PPA examinations 
were always interpreted before ER-PPA examinations. It is possible therefore that reader was biased 
towards ER-PPA coil. The possibility o f preconceived bias is supported by the observation that the 
experienced reader demonstrated worse results using the PPA coils than the non-experienced con­
sensus readers. The experienced reader would be expected to have better results using both the ER- 
PPA and the PPA coils.
On the other hand, our results concur with Hricak et al [17] who also combined both coil types. For 
overall staging accuracy for differentiation between T2 and T3 disease by endorectal MR imaging, 
our results o f 83% are almost sim ilar compared to Hricak et al. (77%). However, our study used 
TNM  classification for staging like recent studies, whereas Hricak et al used two different staging 
systems (TNM  classification and the Jewitt-Whitmore staging criteria). This resulted in a lower 
staging accuracy o f 60% for TNM  classification and higher accuracy o f 77% (Jewitt-Whitmore), 
respectively. Furthermore, the specificity and positive predictive value in our study are higher com ­
pared to Hricak et al. This can be explained by the fact that our study focused on high specificity 
reading, which resulted in low false positive findings. Thus we have more reliable results.
Finally, our results do not support the conclusion o f the RD O G  study by Tempany et al [16], that 
experienced readers were significantly better than less experienced readers [17, 24]. As our study 
showed, that the accuracy o f interpretation was only slightly better when read by a more experi­
enced reader. RO C analysis demonstrated greater area under the curve for experienced reader com ­
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pared to the less experienced consensus readers, however, this difference was not significant. An 
explanation for this could be that one less experienced reader had already 2 years experience and 
that both unexperienced readers learned prostate MR reading from the experienced reader. A lso the 
less experienced readers performed consensus reading, which is reported to improve performance 
compared to a single reader [5].
In 8 out o f thirty cases, capsular penetration was only less than 1-mm resulting in false negative find­
ings, which shows the limits o f resolution of MR imaging. However, recent reports suggest that m in­
imal capsular penetration of less than 1-mm does not adversely affect surgical cure rate [36, 39].
The use o f MR im aging to detect seminal vesicle invasion is considered to be a useful tool [11, 26]. 
This is in agreement with the results o f this study (accuracy o f 98%, sensitivity o f 91%  and a speci­
ficity o f 99%, respectively). We concur, as 6 (7%) o f our patients, who were initially planned for 
prostatectomy, underwent ultrasound-guided seminal vesicle biopsies preoperatively, all o f which 
were positive. Subsequently the prostatectomy was cancelled. The ability o f MR im aging to diag­
nose seminal vesicle invasion with fairly good sensitivity and specificity is an important advantage 
o f this technique in the local staging o f prostate cancer, because this information can rarely be 
obtained by using transrectal ultrasound [1 1 ].
O ur results suggest that MR staging is accurate in a population at low risk for having extraprosta­
tic disease. In this low risk group ER-PPA MR im aging identified in 7 patients correctly stage T3 d is­
ease with a high specificity (97%), which may be used to save the patient an unnecessary prosta­
tectomy. U sing the results from our study, MR im aging is considered useful at an a priori chance 
between 0.08-0.86 (range low-risk -  high-risk) [30]. In clinical practice this means that in our local 
situation both patients with low risk and patients with an intermediate-high risk o f non-organ con­
fined disease may benefit from treatment selection by MR imaging.
In conclusion, we demonstrated that use o f MR im aging with the integrated ER-PPA coil results in 
a significant improvement o f anatomical, staging accuracy and specificity. This technique may be a 
useful tool even in patients who are at low risk o f extraprostatic disease.
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A b stra c t
Am ong the noninvasive im aging modalities, contrast enhanced magnetic reso­
nance (MR) im aging is the most powerful tool with which to visualize vascularity. 
Com monpathology only shows microvessel density, whereas dynamic MR imaging 
is sensitive to the total endothelial surface area o f perfused vessels. Therefore, 
dynamic MR im aging may be o f additional value in tum or staging and in evaluating 
therapies that affect the perfused microvessel density or surface area, such as 
chemo-, radiation, or anti-angiogenic therapy. In urinary bladder cancer, this tech­
nique results in improved local and nodal staging, in improved separation of 
transurethral granulation tissue and edema from malignant tumor, and in improved 
evaluation o f the effect o f chemotherapy. In prostate cancer, dynamic MR imaging 
may be o f help in problematic cases.This technique can assist in determining sem ­
inal vesicle infiltration, in depicting o f m inimal capsular penetration, and in recog­
nizing tum ors within the transitional zone. Also, based on very rapid enhancement, 
very poorly differentiated tumors can be recognized. Evaluation o f the effects of 
therapy is another prom ising area, however a lot o f research remain to be done. This 
article reviews some basics o f fast enhancement techniques, provides practical 
information, and shows recent developments, in using these fast techniques for 
staging and grading o f bladder and prostate cancer, and for evaluating the effect of 
therapy.
Fast dynamic gadolinium-enhanced M R imaging
In som e tumors, such as in breast cancer, information on tumor angiogenesis is important in pre­
dicting its potential to grow and metastasize (1,2). Several clinical studies have shown that 
increased microvessel density in prostate and bladder cancer is correlated to 
poorer overall survival and/or increased risk for metastasis (3-5). Therefore, direct and indirect 
methods have been developed to analyze the angiogenic capacity. One o f the direct methods of 
assessing tumor vascularity is the determination o f the mean microvessel density (1,6, 7). This 
technique has many drawbacks such as the heterogeneity o f the tumor and the lack o f uniformity 
to identify the number o f pathologic m icrovessels (8,9). Furthermore, the morphological appear­
ance o f the vascular bed does not allow judgm ent on functional aspects (10). In particular d is­
crimination between perfused and nonperfused m icrovessels is o f importance, as nonperfused 
m icrovessels will not contribute to tumor growth or metastatic capacity and will result in decreased 
radiosensitivity.
Am ong the noninvasive im aging modalities, contrastenhanced magnetic resonance (MR) im aging 
is the most powerful tool to visualize vascular enhancement. With this technique, differentiation 
between benign and m alignant tissues is possible to some extent (11). Initially, slow multi-slice 
techniques were used before and after contrast administration and subsequent enhancement. In 
some organs the recognition o f m alignancies was thus improved. Nevertheless, differentiation 
between inflammatory tissue or edema and cancer or between prostatic hypertrophy and cancer 
was disappointing with this technique (13). The use o f fast dynamic techniques has been described 
recently, with prom ising results (14-18).
This article reviews some basics o f fast MR enhancement, provide practical information and will 
show recent developments, in using these fast techniques for staging and grading o f bladder and 
prostate cancer, and for evaluating the effect o f (chemo)therapy.
B a s ic  p r in c ip le s
Gadolinium  (Gd) chelates are extracellular contrast agents. After intravenous bolus injection with 
a power injector in the antecubital vein, this agent is transported through the heart and lungs. 
Although dilution occurs, the contrast agent enters the arterial system as a bolus. During the first­
pass phase o f the contrast agent, the difference in concentration between intraand extravascular 
compartment is at its m aximum, and in this phase fast transportation from the vessels into the tis­
sues will occur. Contrast medium, present in capillaries and the extracellular extravascular space, 
provides increase o f signal intensity on T1-weighted images. This enhancement starts during the 
first-pass, then reaches a plateau phase, and finally decreases. The wash-out is caused by dim inu­
tion o f contrast in the vessels due to renal excretion and tissue uptake. The enhancement process 
can be displayed by a time-signal intensity curve (Fig. 1). The curve is defined by four factors: (i) 
onset of enhancement with respect to an appropriate reference (this is when a structure starts to
In troduction
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Figure 1 Time-signal intensity curve o f artery (red extrapolated curve), prostate cancer (white extrapolated 
curve) and normal peripheral zone of prostate (blue extrapolated curve). At t 5 t0 the artery begins to 
enhance, followed shortly by cancer at t5tC; normal peripheral zone at t 5 tP.
enhance visibly (eg, when the when signal intensity is at an arbitrary level above the noise baseline) 
or is the cross-point of the x-axis and the extrapolated curve; (ii) the fastest slope o f enhancement, ie, 
the maximal enhancement rate during the first pass; (iii) the plateau phase, which occurs usually after 
about 1 minute, when enhancement of the specific tissue is maximum and an equilibrium has 
occurred; and (iv) the wash-out phase o f the contrast medium, when contrast leaves the tissues and 
returns to the vessels, because of diminished concentration o f contrast in the vascular system.
The enhancement rate and onset o f enhancement in a given tissue depend on a complexity o f fac­
tors: the number o f vessels, perfusion (5flow) through the vessels, vascular resistance, vessel wall 
permeability, composition o f the extracellular space, and venous outflow. These factors differ from 
tissue to tissue, and therefore enhancement curves differ (Fig. 1).
Van der Sanden et al (19) have shown that there is a linear correlation between Gd-uptake rates and 
the two-dimensional distribution o f perfused m icrovessels in 9L-gliom as in rat brain. As common 
pathology only shows microvessel density, dynamic MR im aging may
be o f additional value in tum or staging and the evaluation o f therapies, that affect the perfused 
microvessel density or surface area, such as chemo-, radiation, or anti-angiogenic therapy.
With fast dynamic MR im aging bladder and m ost prostate cancers show early enhancement, and 
in som e cases a steeper slope, higher maximal signal intensity, and wash-out, as compared with 
normal tissue. However, differences in enhancement patterns may beminimal or absent, as is seen 
in benign prostatic hypertrophy and prostate cancer. In our clinical experience, differences in 
enhancement between m alignant and other tissues are best seen in the early dynamic, firstpass 
phase (Fig. 1). It is expected, that fast im aging sequences displaying the first pass (at least 1 
im age/2 seconds) will have maximum specificity for characterizing m alignancies and differentia­
tion from benign tissues.
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Figure 2  A: T2-weighted turbo SE image of patient with invasive bladder cancer (circle). Tumor invasion in 
pelvic fat can be seen; however, no invasion o f pelvic side wall is visible. B: T1-weighted gradient echo image 
also shows tumor (circle). C: Same image sequence 60 seconds postcontrast. Tumor shows enhancement; 
however, infiltration in the perivesical fat is much more difficult to see because of higher signal intensity. D: 
Subtracted image from B and C; enhancement is displayed in black. Enhancement is seen in the pelvic side 
wall (arrows), arguing for tumor infiltration.
Gadolinium  contrast agents increase T1-weighted signal intensity, so that a lesion may be difficult 
to depict when fat surrounds it. In order to detect early minimal differences in contrast enhance­
ment, subtraction techniques should be used (Fig. 2). In cases in which motion artifacts are 
unavoidable, and thus subtraction is not possible, the application o f fat-suppression techniques is 
advised.
The onset o f enhancement o f a given tissue can be related to the enhancement o f a large artery in 
the area o f the tumor. This avoids variation caused by differences in circulation time. For determi­
nation o f the onset o f enhancement o f a tumor, measurement o f the startenhancement time o f a 
main artery in the same im aging plane in which the tumor is located is required. The various 
enhancement phases can be displayed as timesignal intensity curves o f operator defined regions
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6Figure 3 Patient with prostate cancer (circle) and minimal capsular penetration invasion. Fusion o f high-res- 
olution T2- weighted turbo SE image and functional information obtained with a fast dynamic first-pass 
sequence (see also Fig. 6) A: Gd concentration is shown (intensity of red correlates with concentration). B: 
Beginning o f enhancement: t0 (the more blue the image, the earlier the enhancement. C: ‘‘time to peak” 
(blue). D: Wash-out (blue). E: Graphic display o f time SI curve showing the parameters o f B, C, and D.
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Figure 4  Patient with superficial bladder cancer (stage T1). A: T1-weighted gradient echo image showing 
tumor (arrows); however, separation o f tumor from bladder wall is not possible. B: Postcontrast image. C: 
Subtracted image, thanks to more enhancement tumor (arrows) can be separated form bladder wall. There 
is no deep muscle invasion.
o f interest (RO I). When adding this functional information to the images on a pixel-by-pixel basis, 
this functional information is more comprehensive to radiologists and clinicians (Fig. 3).
With the currently available MR systems, fast im aging with a speed o f one image every 2 seconds 
can only be performed with moderate resolution at seven levels. This approach restricts the use of 
the dynamic sequences. A  decision must be made between the use o f a fast dynamic sequence with 
a limited number o f slices (7 slices/2 sec) or a higher-resolution multi-slice sequence with limited 
temporal resolution (20 slices/45 sec). These sequences performwell in those tumors that show a 
higher maximal signal intensity at the plateau phase compared with the surrounding structures, 
such as bladder (Fig. 4) cervical, and breast cancer. This is in agreement o f results o f other inves­
tigators (20, 21), who are using slower sequences. These authors focus on the use o f slope, maxi­
mal signal intensity, time to peak, and wash-out. However, if  differences between tissues are very 
small, such as is the case in prostate cancer and benign prostate hypertrophy, fast techniques 
focusing on the early enhancement features (onset o f enhancement) may be advantageous.
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6Image fusion provides a means o f obtaining both a high temporal as well as a high spatial resolution. 
With this technique, the information o f a high-resolution T2-weighted sequence and a low-resolution 
fast dynamic sequence can be integrated. Provided that the patient does not move during these 
sequences, this fusion can be done without a disturbing image shift. Image fusion may improve 
lymph node (Fig. 5) or local staging (Fig. 6).
B la d d e r  can ce r
This section describes clinical experience with dynamic contrast-enhanced MR im aging in bladder 
cancer. Carcinoma o f the urinary bladder is one o f the most com m onm alignant tumors o f the uri­
nary tract in males and females. The depth o f tumor infiltration and the
extent o f metastases (22) largely determine treatment and prognosis. Therefore, precise staging is 
mandatory. As clinical staging is not reliable for deeply infiltrative tumors, more accurate methods 
are needed. Recently, several investigators have described the use o f Gdenhanced MR im aging for 
staging urinary bladder cancer (16,23-26).W ith the use o f IV Gd-contrast, visualization o f small 
tumors improved (16,24-26), and furthermore, an increase in accuracy o f local staging was report­
ed (23,26). The best staging results with enhanced MR im aging were obtained with fast T1-weight- 
ed sequences (27).
Most patients are referred for MR staging after transurethral resection (TUR) with histology-proven 
invasion o f the m uscular layer o f the bladder wall. In these patients, even when Gd-contrast is used, 
differentiation between residual tumor and edema, scar, or granulation tissue remains problemat­
ic (13,26,28-30).
A  previous study showed that the use o f fast dynamic contrast-enhanced MR im aging, with a time 
resolution o f at least 1 image per 2 seconds, may provide a solution to this problem. Urinary blad­
der cancer begins to enhance 6.5 seconds after the beginning o f arterial enhancement. This is 4 
seconds earlier than most other structures, such as postbiopsy tissue, which begins to enhance 
after 13.6 seconds. Therefore, in a series o f 61 patients, based on the beginning o f enhancement, 
improved accuracy (from 79% to 90%, P < 0.02) and specificity (from 33%  to 92%) was obtained 
in differentiating postbiopsy effect from malignancy. Also, overall tumor staging accuracy improved 
significantly from 67% to 84%  (P < 0.01). All lymph node metastases in enlarged nodes (n 5 10) 
showed early enhancement, equal to that o f the primary bladder tumor; however, som e inflam m a­
tory lymph nodes showed early enhancement as well. Nonetheless, in two patients, metastases in 
normal-size lymph nodes were detected with this technique only (31).
In another study in 22 patients with advanced urinary bladder cancer, fast dynamic imaging per­
formed better than unenhanced MR imaging in predicting the results o f chemotherapy. Dynamic 
information about the beginning of enhancement correctly predicted response after two chemother­
apy cycles in 21 o f 22, and in all patientsafter four cycles. In 8 o f 9 cases after two and cycles, and in 
all after four cycles, persisting early enhancement correctly corresponded with nonresponse, whereas 
the unenhanced technique showed initial < 50% tumor size reduction in 3 o f 9 nonresponders (Fig.
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Figure 5 Patient with invasive bladder cancer and lymph node metastasis. A,B: High-resolution T2-weight- 
ed turbo SE images show lymph nodes (circles) and bladder wall thickening. C,D: Early arterial phase 
enhancement, acquired by applying a fast low-resolution multi-slice sequence (7 slices/2 seconds), super­
imposed in red over A and B. C: Lymph nodes (circles) show enhancement and proved to be metastatic. D: 
Lymph node (circle) did not show enhancement and appeared to be nonmetastatic.
7). Thus, after the second chemotherapy cycle, fast dynamic MR imaging may permit one to predict 
whether the patient will respond to chemotherapy. In this way, based on dynamic MR imaging, expen­
sive therapy with many side effects may be eliminated at an early phase (32).
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6Figure 6 Prostate cancer (same as patient depicted in Fig. 4) with minimal capsular invasion. Fusion 
images of high-resolution T2-weighted tSE and low-resolution dynamic images. At t50, no invasion of tumor 
outside the prostate is seen. At t54, however, early enhancement o f cancer tissue outside the capsule can be 
recognized (circle). At 10 seconds (t 5 10) after beginning of arterial enhancement, complete filling in of 
prostate cancer has occurred, indicating high vascularity/perfusion.
P ro sta te  can ce r
MR im aging is considered a reliable technique in im aging prostate cancer (13). However, the tech­
nique also adds little to the traditional information gained by clinical staging completed with infor­
mation obtained from biopsies such as tumor grade and involvement o f seminal vesicles (33-35). 
Furthermore, as prostate cancer is recognized by its low signal intensity on T2- weighted images, 
recognition o f this tumor in the low signal transition zone is not possible. There is a poor correla­
tion between tumor size on conventional MR im aging and pathology, and diffuse tumor spread is 
frequently not recognized. Finally, minim al capsular invasion is also difficult to recognize with con­
ventional MR imaging.
The use o f Gd-enhanced MR im aging to increase the diagnostic information has been described in 
the literature (36-41). The results suggest that postcontrast T1-weighted im ages do not provide 
additional information compared with T2-weighted images, but that it may be useful in evaluating 
seminal vesicle infiltration in equivocal cases (37,41). Brown et al (39) evaluated early phase T1- 
weighted bolus enhanced MR imaging. These workers found that information that was provided by
86
Fast dynamic gadolinium-enhanced MR imaging
n '
i -
n■ /  r
Figure 7 Patient with stage T3b urinary bladder cancer 
and lymph node metastases, without response to 
chemotherapy. A: Prechemotherapy coronal recon­
structed T1- weighted MP-RAGE image show tumor (T) 
left in bladder and enlarged left iliac node (arrow). B: 
Prechemotherapy dynamic subtraction image obtained
5 seconds after beginning o f arterial enhancement. 
Both the tumor (large circle) and node (small circle) 
already show enhancement. Enhancement is displayed 
in black. C: Coronal reconstructed MP-RAGE image 
after 2 MVAC cycles tumor (T) and node (arrow) have 
decreased in size (.50%), arguing for response. D: Time 
image at t 5 5 second; enhancement of both node and 
tumor is still early, before the threshold o f 10 seconds. 
This is an unfavorable sign and reflects nonresponse, 
confirmed by E the MP-RAGE image after 6 MVAC 
cycles. Despite continuation of chemotherapy, both 
tumor (T) and node (arrow) have increased in size. 
Even more enlarged nodes are now present (arrow­
heads).
B
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6T1-weighted im ages during early phase o f contrast enhancement enabled the best delineation of 
tumor within the gland. Jager et al (17) showed that adding a single slice fast dynamic sequence 
with a time resolution o f 1.25 second resulted in better tumor depiction and delineation and 
improved staging results. Jager and colleagues also found that poorly differentiated tumors showed 
the earliest enhancement and highest enhancement rate and wash-out (Fig. 8).
Recently, thanks to new developments, it became possible to use a fast technique with an accept­
able resolution and a speed o f 7 slices every 2 seconds. Initial results show that, with this tech­
nique, the entire prostate can be visualized and that in some patients ventrally located tumors can 
be depicted based on their early enhancement. Furthermore, this dynamic technique was helpful in 
determining seminal vesicle infiltration (Fig. 9) and in detecting minimal capsular penetration (Fig. 
6). Although very poorly differentiated tum ors showed very early enhancement, not all cancers 
could be recognized using this technique. Accurate assessm ent o f tum or volum e remains a prob­
lem. Another important
improvement is provided by the previously mentioned fusion o f high-resolution T2-weighted and 
dynamic images. Optim ism  regarding the value o f dynamic MR im aging o f the prostate is justified. 
This technique may have value particularly in monitoring the effects o f therapy. Validation and fur­
ther development o f dynamic techniques in prostate cancer remain to be done.
C o n clu s io n
With the use o f optimal fast MR sequences with adequate postprocessing techniques, the phases 
o f enhancement o f malignant and benign tissues after injection o f Gadolinium  contrast can be eval­
uated. This results in improved delineation o f bladder and prostate cancer tumors, in improved 
determination o f tumor grade and evaluation o f the effects o f therapy. An im aging study such as 
(fast) dynamic contrast-enhanced MR im aging can noninvasively provide functional information 
about both neovascularization and morphology. Potentially, a combination o f this m orphologic and 
kinetic information can lead to improved evaluation o f cancers and follow-up evaluation o f treat­
ment. Increasing numbers o f studies report on the value o f assessing neovascularity in the prog­
nosis and treatment o f m alignant tumors. Therefore, the use o f these MR techniques during con­
trast injection will become more important. However, the basic understanding o f enhancement 
processes is still incompletely understood. Further combined basic clinical research on the mor­
phological and functional basis o f first-pass enhancement o f prostate and bladder cancer, also in 
respect to therapy response is needed.
Although the clinical effect o f angiogenesis research is limited, a host o f prom ising diagnostic and 
prognostic applications based on the angiogenic phenomenon, as well as a number o f potential 
therapeutic interventions, are on the horizon.
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Figure 8 Fast dynamic Gd-enhanced MR imaging. Patient with small very poorly differentiated stage T2 
prostate cancer in left peripheral zone. a: T2-weighted turboSE image shows small low signal intensity area 
(arrow) without capsular invasion. b: T1-weighted SE image acquired 2 minutes after contrast injection 
shows less enhancement o f prostate cancer compared with normal peripheral zone (arrow). This can be 
explained by rapid wash-out. c-e. Subtracted T1-weighted turboFLASH images acquired 1.25, 2.5, and 5.0 
seconds after beginning o f arterial enhancement show very fast enhancement (arrow) o f prostate cancer. f  
Wash-out image speed o f wash-out is color coded; prostate cancer shows very rapid wash-out. g: Whole- 
mount section pathology section confirmed Gleason sum 10 prostate cancer at this site (circle).
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6Figure g  Patient with prostate cancer and seminal vesicle infiltration on right side only. Fusion mages of 
high-resolution T2-weighted tSE and low-resolution dynamic images. On t 5 0 both left and right medial 
parts of seminal vesicles show low signal intensity, arguing for tumor infiltration. At t 5 6, early enhancement 
of right seminal vesicle only is seen (circle). Enhancement increases even at t 5 8, t 5 10, and t 5 12. Left side 
shows no enhancement.
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A b stra c t
Quantitative analysis o f contrast-enhanced dynamic MR images has potential for 
diagnosing prostate cancer. Contemporary fast acquisition techniques can give suf­
ficiently high temporal resolution to sam ple the fast dynamics observed in the 
prostate. Data reduction for parametric visualization requires automatic curve fit­
ting to a pharmacokinetic model, which to date has been performed using least- 
squares error m inim ization methods. We observed that these methods often pro­
duce unexpectedly noisy estimates,
especially for the typically fast, intermediate parameters time-to-peak and start-of- 
enhancement, resulting in inaccurate pharmacokinetic parameter estimates. We 
developed a new curve fit method that focuses on the most probable slope. A  set of
10 patients annotated using histopathology was used to compare the conventional 
and new methods. The results show that our new method is significantly more accu­
rate, especially in the relatively less-enhancing periferal zone. We conclude that esti­
mation accuracy depends on the curve fit method, which is especially important 
when evaluating the periferal zone o f the prostate.
Accurate estimation of dynamic M RI parameters
A contemporary review of the literature on the clinical efficacy o f available contrast-enhanced MRI 
techniques for prostate diagnosis shows a difference between the U.S. and European approaches. 
U.S. researchers reported generally disappointing results (1-3). European researchers continued to 
apply the latest technology (stronger gradients and improved pulse sequences resulting in higher 
spatial and temporal resolution) with increasingly positive results (4 -9 ). Recent developments allow 
fast, multislice contrast-enhanced MRI at an acceptable spatial resolution that shows prom ising 
results for the prostate (10,11). Robust estimation and visualization o f contrast dynamic parameters 
is o f paramount importance, and in this work we focus on improving the accuracy and robustness 
o f fast, multislice, contrast-enhanced T|-weighted parametric im aging o f the prostate.
Steady-state postcontrast enhancement is already an indicator o f a suspect lesion in the breast (e.g., 
Ref. 12). However, in the prostate nearly all voxels tend to enhance; thus more thorough analysis of 
the curves is required. Focal differences in prostatic contrast enhancement patterns are generally 
thought to be due to differences in tissue physiology due to, e.g., neovascularization (13), although 
the causes of pathophysical changes in microvessel density are still debated (14,15). The type o f dif­
ferences that can be observed depend strongly on the type o f acquisition technique (16). Most tech­
niques can visualize differences in peak tracer concentration. With increasing time resolution, 
dynamic phenomena are better visualized. We use a high temporal resolution (7-slice volume every
2 sec) sequence to enable accurate visualization o f differences in start-of enhancement, and time- 
to-peak, which contain additional information that may help in analyzing prostate MRI (4,6,9). 
Having chosen an MRI acquisition technique, the next problem is to find relevant differences in 
enhancement patterns. Merely looking at enhancing images is not an optimal manner of using all the 
information contained within the enhancement patterns o f the voxels in the prostate. A  generally 
accepted approach is to fit a parameterized model for each voxel, or for the average o f a set o f tissue- 
homogeneous voxels. The model should also account for variations in enhancement due to differ­
ences in focal proton density and coil profile (17,18). To be most useful, parameters should be com ­
parable between investigators and be related to biological phenomena, which practically implies try­
ing to adhere to a pharmacokinetic model (19). We implemented a method using the pharmacoki­
netic models and applied the proper corrections, but found unsatisfactory results for the typically fast 
dynamic contrast enhancement related parameters start-of-enhancement, and time-to-peak, which 
will adversely affect the estimation o f the other parameters.
Fitting a model to an enhancement pattern is generally solved by using an approach from the opti­
mization sciences (20). We observed that this classical approach, especially for the fast dynamic 
parameters start-of-enhancement and time-to-peak, leads to noisy variations in the observed esti­
mates and am biguous situations that could not be directly related to visual observation o f the 
curves, especially for the start-of-enhancement and time-to-peak parameters. Observation o f the fit 
results, however, showed that improvements should be possible. We have developed and are cur­
rently using an enhanced, robust fit method. In this work we explain the method, which we already 
tested with simulated data (21), and evaluate it with ample clinical data.
In troduction
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7Figure 1 The five-parameter fast contrast-enhanced Tpweighted MRI signal-enhancement curve model.The 
resulting intermediate parameters are converted into calibrated pharmacokinetic parameters before actual use.
C u rv e  f i t  m eth o d s
We developed a tool to visualize the kinetic parameters from dynamic contrast-enhanced Tpweight- 
ed MRI. For each voxel, the tool estimates calibrated dynamic parameters (17,18) which are stored 
in parametric images. The tool offers various visualization techniques to enable inspection o f the 
parametric images. The curve parameter estimation is a two-step process. First, the signal- 
enhancement curve is fitted to a five-parameter signal enhancement model. Second, these inter­
mediate parameters are converted and calibrated. We choose this approach for three reasons: First, 
it results in a more accurate estimate o f the static level than the often-used first sam ple o f the 
curve, resulting in a more accurate dynamic tracer concentration estimate. Second, the nonlinear 
transformation o f signal-enhancement to tracer concentration renders a curve that has level-depen­
dent noise. This means that an irrelevant fluctuation level in one curve part may be a relevant slope 
in another, which is a much more difficult assumption than a constant signal noise model. Third, 
it is faster by reducing the number o f calculations in the calibration steps.
The five-parameter (x) ^-w eighted signal enhancement model f(t , x )  is shown in Fig. 1. A  curve is 
assum ed to start with a constant signal level S0 (static). Then, at time t 5 t0 (start-of-enhancement) 
an exponential curve starts with a time constant t (time-to-peak) that reaches level sm (plateau). At 
t 5 t0 1 2t a wash-in or wash-out component w is added, which leads to:
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(1) ƒ(*  3 )
So
f(t0, ~t) +  (sm -  s0)exp 
f(t0 +  2t, 1) +  (sm -  s0)
t ^ t  o ,
, ((t -  í 0) / t )  t0 <  t <  t0 +  2 t ,
i  >  t0  +  2 t
+  w(t-t0-2 t )
It is further assumed that the sampled N-point contrast enhancement curve s[t;j is a realization of 
the theoretical model (Eq. [1]) and a stochastic noise component:
Least-Squares Optimization Curve-Fit Method
The com m only used (17,20) least-squares optimization method tries to find a set o f parameters
where X env is a parameter set that can be constrained using prior knowledge about the expected 
parameters. In this study the Nelder-Mead simplex ( s im )  optimization method (23) was used, with 
the parameter search space restricted to "feasible” solutions (e.g., t0 > 0).
The parametric images start-of-enhancement and time-to-peak o f the prostate obtained with the 
simmethod often show large fluctuations resulting in many contrasting details. Evaluation o f the 
s im  method leads to the following observations: First, significant changes in the model parameters 
start-of-enhancement and time-to-peak often hardly affects the least-squares error. Consequently, 
sim-method parameter estimates in visually identical curves from within the normal periferal zone 
still showed large variations. Second, the s im  method is sensitive to unrelated signal fluctuations 
distant from the start-of-enhancement curve area and to deviations o f the curve shape from theo­
ry (actual start is often not as sharp as depicted in Fig. 1).
x 0p t such that the model curve f ( t ,  x 0pt) (Eq. [1]) best fits the measured curve s[t] (Eq. [2]) in a least 
squares sense:
(3)
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7Figure 2  Example operation of the mss method. 
Top curve (s[t(]) is a simulated curve (static = 0, 
start-of-enhancement = 10, time-to-peak = 10, 
plateau = 20, as = 1). Bottom three curves (s^t;], 
s’4[t|], s’8[t|]) are derivatives at a different scales. 
The dashed line is the upper level below which 99% 
of the estimated derivatives would lie if there were 
no positive slope. Notice the decrease at coarser 
resolutions. Starting at the coarsest scale, a signifi­
cant maximum is found, indicated by the arrow. 
The method then proceeds to the next scale to try 
to find a significant maximum near the previous 
maximum. A second arrow indicates such a maxi­
mum. The highest resolution does not contain a 
significant maximum, and the method stops.
Most Probable, Steepest Slope Curve-Fit Method
To improve the accuracy and robustness o f the estimated start-of-enhancement and time-to-peak 
we developed a new method that focuses on accurate estimation o f the “slope-part” o f the curve. 
In an analytical, noiseless situation (Eq. [1]), the slope can be shown to start at the location o f the 
maximum o f the analytical derivative:
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4) io,theory = 3Tg m a x { f ( t ,  £)}
where ‘ denotes the derivative and * stands for “estimate.” For the MR-acquired signal (noisy, sam­
pled, and discretized (Eq. [2]) the derivative s’[t;] needs to be estimated. The slope of a least-squares 
fitted line in an m-point window in the measured curve is a smooth estimate of the derivative:
(5) è ' M  =  a rg  m in  i ^  (s fó J  -  a - ( t k -  t¡)b )2
T h e
parameter m can be regarded as a scale parameter, and larger values of m will result in smoother 
estimates of the derivative. See Fig. 2 for an example signal intensity curve and estimates of the 
derivative at three scales.
The steepest slope of all possible m-point windows (or equivalently, at all scales) can easily be 
shown to overestimate the slope; even worse, this is prone to finding a slope at the wrong location. 
A better method is to choose the most probable, steepest slope (mss). The estimated slope (Eq. 
[5]) can be regarded as a stochastic variable with standard deviation:
(6) (m 3 _  m )d i
which is independent of the actual curve and can be calculated when an estimate of the background 
noise level a s is available (24). Table 1 shows some example noise levels in windows of varying size. 
Eq. [6] allows slopes at different scales to be compared. The mss method starts by finding a statis­
tically significant maximum slope starting at level m = M:
(7) SM,max = m ax {sM [iJ} > 3 ( 7 ^ )
Proceed to the level m = M/2 and look for a significantly larger maximum near the location of the 
previous maximum
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7Table 1 Normalized Standard Deviation of Slope Estimates Using 
Different Window Sizes (m)
m 2 4 8 16 32
Q5'm(L°) 1.41 0.45 0.11 0.05 0.02
As an example, for an enhancement curve with Q = 10 a two-point slope below 
14.4 (10 * 1.41) has a 95% chance of occurring even without any slope being pre­
sent.
Figure 3 Histogram of variables plateau and time-to-peak (tau) for 
comparing all the curves or periferal zone only.
(8) m ax{sM - iM }  + 2 * 0 ^  ,(<0
where n is the neighborhood defined as seven samples centered about the previous maximum 
{/max - 3 . . . imax + 3}, or the whole level if a previous maximum was not found. If at two succes­
sive scales no adequate slope can be found, the method stops and returns the last found slope. 
Otherwise, the method iterates to the next higher resolution. (See Fig. 2 for an example).
The curve parameters are estimated using the found slope as follows. The start of the slope is at 
to slope and the width of the window is ms¡ope. The static line is estimated by taking the average with­
in the region 0 < t¡ < toslope, and results in the parameter so. The plateau
line is estimated with a least-squares straight-line fit within the region to slope + 2 * m s¡ope < t¡ < tN. 
If this line has a significant slope, that is the estimate of the parameter w and sm is estimated by 
the value in the first part of the plateau line. If no significant slope is found, then w = 0 and sm is 
the average value of the plateau line. The parameters start-of-enhancement and time-to-peak are 
estimated from the intercepts of the most probable slope line with the static and plateau lines.
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The study population consisted of 10 patients with biopsy-proven prostate cancer, who had an MR 
scan and underwent radical prostatectomy. The mean patient age was 63 years (range 55-72). MR 
images were acquired using a Siemens Magnetom SP system (Siemens, Erlangen, Germany) at 
1.5T using integrated endorectal- pelvic phased-array coils (Medrad, Pittsburg, Pa) (25). 
Precontrast, 72-weighted fast spin-echo studies and a seven-slice proton density study (TR 5 200 
msec, TE 5 4.4 msec, a 5 8°) were acquired. Subsequently, an intravenous bolus injection (0.5 mM,
2 ml/sec) of gadopentetate dimeglumine (Gd-DTPA) with a MedRad Powerlnjector was adminis­
tered. Simultaneously, a sequence of 44 image volumes of seven slices 71-weighted FLASH (TR 5 
50 msec, TE 5 4.4 msec, a 5 60°, time interval 5 2.05 sec) were acquired (160 3 256, FOV 40 cm, 
slice thickness 5-7 mm). The contrast injection timing is such that, on average, the iliac artery 
starts to enhance in the third or fourth volume.
Using histology tumor maps of whole-mount sections of the resected prostate, voxels matching 
tumor, benign prostatic hyperplasia (BPH ), normal periferal zone (PZ), and artery locations were 
annotated (by M.E. and H.J.). Biopsy-related hematoma sites (high 71w signal) were avoided. The 
labeled coordinates were stored in a database. A total of 442 curves from these voxels were col­
lected, of which 159 were in the periferal zone.
R esu lts
The accuracy of the two curve-fit methods is compared by assessing the difference in variability of 
the estimated parameters in the PZ group, because PZ curves will be shown to have a low plateau 
level and/or a long time-to-peak relative to the other curves. For such
curves, under simulated conditions, we have already shown that the accuracy of both estimation 
methods differs most (21). Furthermore, PZ appears to be sufficiently homogeneous with respect 
to pharmacokinetic parameters to reveal accuracy differences due to the estimation method. 
Statistical results and plots were calculated using R (26).
Histograms of estimated plateau and time-to-peak are shown in Fig. 3 for the whole dataset and 
for PZ only. The histograms indicate that PZ generally has a lower plateau level and a longer time- 
to-peak. It is thus expected that the strongest differences in accuracy will occur in the PZ.
To visualize the difference between the PZ and fast, strong-enhancing curves, scatterplots were con­
structed, one for each parameter, plotting the estimate of one method vs. the other. If the two meth­
ods were equal, all observations would be on the main diagonal. These plots have been made for two 
groups: the PZ and a set with large plateau and short time-to-peak, as shown in Fig. 4. As expected, 
the PZ shows the largest differences between the two estimation methods. Similar to the simulations, 
the differences are most obvious for start-of-enhancement (t0), time-to-peak (tau) and wash. 
Concentrating on the PZ curves, a qualitative comparison of accuracy can now be done by con­
structing scatterplots of parameter combinations of the same method. The size of the point cloud
Patient study
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7Figure 4 Pairwise comparison of both estimates for each curve. The mss-estimated parameter is on the x- 
axis, and the sim estimate is on the y-axis. The top row of figures are periferal zone curves and the bottom 
row are strong and fast-enhancing (plateau . 250 and time-to-peak , 8) curves. In each column a different 
parameter is plotted.
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Figure 5. Comparing scatterplots of curve parameters estimated in the periferal zone for the sim (bottom row) 
and mss (top row) method. Each column has a different combination of parameters.
Table 2 Snedecor F-Tests of the Hypothesis That the Accuracy of mss
Method is Higher Than the sim Method For Each Variable in the PZ Group
Variable Static Start-of-enhancement Time-to-peak Plateau Wash
P-value 0,55 <2.2e-16 0.006 ss9m(1.0) <2.2e-16
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Figure 6 Comparison of the sim (left column) and mss (right column) method in an example prostate study 
with a diagnosed tumor visible in the left side of the periferal zone. From top to bottom the following para­
meters are displayed: start-of-enhancement (t0), time-to-peak(tau), positive and negative wash.
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7is a visualization of the (co)variance in the observations in the PZ group. To remove any interpa­
tient variation, each variable was normalized by subtracting the mean value for each patient. Figure
5 shows the resulting scatterplots comparing both methods. It is clear that the mss method has 
smaller scatterclouds, and thus lower (co)variance in all three variables shown. To quantify this 
hypothesis, a Snedecor F-test was applied. The results are shown in Table 2. The F-test results show 
that the variables start-of-enhancement, time-to-peak and wash, but also plateau, are estimated 
with significantly lower variance by the mss method with a P  value < 0.01.
The difference in estimation accuracy can also be observed from the parametric images. Example 
parametric images of the same image slice were produced by both the sim and mss methods, and are 
shown in Fig. 6. The tumor area in the left side of the prostate has early, fast enhancement combined 
with negative wash, most clearly visualized by the mss method. Notice that the wash images esti­
mated by the mss method clearly reveal patterns that are not visible in the sim-estimated images.
A practical result is that curve-fitting nearly 500,000 curves in the 44 image volumes with the mss 
method took 45 sec while the optimization method required 1800 sec on a Pentium-III 450-MHz 
machine.
D iscussion
The mss method is significantly more accurate than the simplex, optimization method for the para­
meters startof-enhancement, time-to-peak and wash and even plateau in the PZ of the prostate. 
These results confirm earlier observations under simulated conditions (21). Furthermore, the mss 
method is 40 times faster, and thus we believe it is the method of choice for analyzing fast contrast- 
enhancement curves.
There are three reasons why the mss method outperforms the sim method. First, the optimization 
method tries to minimize the least-square error between the actual curve and the fitted model. This 
works best if a small deviation of the parameters from this optimum results in a large increase of 
the error. Small variations in start-of-enhancement and time-to-peak parameters, however, result in 
only small variations of the least- squares fit error. Second (and closely related to the first reason) 
is the ambiguity that arises for curves with significant wash-in. For the sim method this often leads 
to finding substantially longer time-to-peak values mistakenly interpreting the wash-in as the tail of 
an exponential with longer time-to-peak; accordingly, no wash is found in these curves with the sim 
method. Third, the optimization method fits a curve globally, and any fluctuations distant from the 
steep slope will affect its estimate.
As explained in the Curve Fit Methods section, the estimated parameters described in this work are 
the result of an intermediate parameter reduction step in our software analysis tool. These para­
meters are subsequently transformed into actual pre- and postcontrast T| estimates (using the pro­
ton density image and MR acquisition parameters), which in turn leads to an estimated concen­
tration of gadolinium (18) and pharmacokinetic parameters. We indicated that this is a more robust 
approach even for the optimization procedure; however, one may argue that it does not allow for a
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proper pharmacokinetic model. Directly fitting an accurate pharmacokinetic model, including all 
corrections, would require the use of an optimization method, which we have shown in this study 
to be less accurate. Moreover, due to the increasingly nonlinear relation between the pharmacoki­
netic parameters and the "raw” signal curve, the accuracy will decrease even more, which is a well- 
described phenomenon in optimization theory.
Another source of parameter fluctuations are interpatient variations. Although we use a power 
injector to keep variations minimal, patient-related variations may still introduce fluctuations that
affect the diagnostic power of a parameter. In this study we were interested in the variance and not in 
the absolute value of a parameter; thus we could remove these variations by subtracting the mean for 
each patient. In practice, a possible correction is to use the so-called arterial input function (AIF), 
which is also a necessary requirement for accurately estimating pharmacokinetic parameters (19). A 
single-slice MR sequence synchronized to the heart rate such that sampling occurred during low-flow 
conditions has been shown to give good results (27). We have tried several protocols to measure the 
A IF with our (unsynchronized) multislice sequence, but always observed large fluctuations in A IF esti­
mates, very likely due to flow-related artifacts. The use of a low-flow reference tissue may help, for 
example, muscle (28). Our signal intensity curve model contains the parameter wash, which quanti­
fies an increase or decrease in the later part of the curve. In the breast, wash-out has already been 
established as an indicator of malignancy (29,30), and we are also observing wash-out signs in 
prostate tumors. Unfortunately, it is not directly incorporated into current pharmacokinetic models, 
and future research will be done to include it in realistic physiological models.
In conclusion, we have demonstrated a new method with improved accuracy compared to con­
ventional methods that estimate pharmacokinetic parameters with contrast-enhanced T1-weighted 
images, which will improve the diagnostic accuracy of fast contrast-enhanced dynamic MRI of the 
prostate.
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A b stract
Purpose: To evaluate which parameters of dynamic magnetic resonance (MR) imag­
ing and T2-relaxation rate result in optimal discrimination of prostatic carcinoma 
(PCa) from peripheral zone (PZ) and from central gland (CG) tissue and to corre­
late these parameters with tumor stage, Gleason score, patient age and tumor 
markers, such as prostate specific antigen (PSA).
Materials and methods: Thirty-six PCa patients underwent MR imaging at 1.5T 
using an endorectal-pelvic-phased array coil and subsequent prostatectomy. A T2- 
weighted turbo spin-echo, an proton intermediate density-weighted and a fast T1- 
weighted gradient-echo sequence (7 slices/ 2.03 sec.) during bolus injection of 0.1 
mmol Gd-DTPA/kg b.w. were acquired. Time-c[Gd-DTPA] curves were obtained of 
PCa, PZ and CG using whole mount sections to guide placement of regions of inter­
est. Onset time, time to peak, peak-enhancement (Pe), relative peak-enhancement 
(APe), wash-out and T2-relaxation rates were calculated. Multivariate ROC-analysis 
was performed with and without APe.
Results: Multivariate ROC analysis showed that APe was best at enabling the dis­
crimination of PCa in PZ and CG (Az=0.93 and 0.822). Multivariate analysis without 
APe showed that Pe in the PZ and wash-out in the CG showed the highest Az 
(Az=0.9 and 0.81). Pearson correlation coefficients between dynamic parameters or 
T2-relaxation-times in carcinoma and tumor stage, Gleason score, patient age and 
tumor markers ranged between 0.02-0.44.
Conclusion: The optimal parameter for PCa discrimination in PZ and CG was APe. 
In case APe is not used, Pe was optimal in the PZ and wash-out in the CG. Poor - 
moderate correlation was present between dynamic parameters or T2-relaxation 
rate in carcinoma and tumor stage, Gleason score, patient age, tumor volume and 
PSA.
Discrimination o f peripheral zone and central gland prostate cancer
In troduction
The reliability of T2-weighted imaging protocols in discriminating prostate carcinoma tissue from 
normal peripheral zone (PZ) and central gland (CG) tissue is limited (1-4). Potential advantages of 
improved malignant tissue discrimination in the prostate as in other tumors include better local 
staging performance, increased accuracy of biopsy, improved focussing of irradiation using inten­
sity modulated radiotherapy, improved follow-up of therapy response and earlier detection of car­
cinoma recurrence. An additional potential advantage might be guidance of other modern focally 
ablative techniques, like cryosurgical ablation (CSAP), high intensity-focussed ultrasound (H IFU ), 
and radiofrequency intersitial tumor ablation (RITA) (5). Imaging protocols that include conven­
tional contrast-enhanced T1-weighted (6-9) and dynamic contrast-enhanced images (10,11) result 
in slight improvement of carcinoma detection and staging performance, compared to T2-weighted 
imaging protocols alone (12). Thus, the purpose of our study was to evaluate which parameters of 
dynamic magnetic resonance (MR) imaging and T2-relaxation rate result in optimal discrimination 
of prostatic carcinoma from PZ and from CG tissue and to correlate these parameters with tumor 
stage, Gleason score, patient age and tumor markers.
M a te ria ls  and  M ethods
Patients
This was a prospective single-institution cross-sectional study. The study population consisted of 
58 consecutive patients with biopsy proven prostate carcinoma, who underwent dynamic contrast- 
enhanced MR imaging complementary to the routine staging MR examination of the prostate in 
the period between June 1, 1997 and July 1, 2000. Patients were included in this study only if they 
were candidates for radical retropubic prostatectomy.
This study received institutional approval of the local ethical committee, and informed consent was 
obtained from all patients prior to MR imaging. After MR imaging all patients underwent radical 
retropubic prostatectomy. Patients who received neo-adjuvant hormonal treatment before surgery 
were excluded from this study. The mean age of the 58 patients was 62.3 years old (range, 71-46 
years). The PSA was 12.9 ng/ml (range, 1.8 -60 ng/ml). All patients had clinical stage < T2N0M0.
Imaging studies
MR imaging was performed on a 1.5 T Siemens Magnetom Vision system (Siemens medical systems, 
Erlangen, Germany) using the integrated endorectal-pelvic-phased array coil (MRInnervu; M edrad®, 
Pittsburgh, Pa.). The endorectal coil was inserted with the patient in the lateral decubitus position and 
was inflated with 50 - 100 cc. of air. Peristalsis was suppressed by means of intramuscular adminis­
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8tration of 1mg glucagon (Glucagen®; Novo Nordisk A/S, Denmark). First, a sagittal and axial T1- 
weighted localizing image was obtained to confirm coil positioning and to select locations for the axial 
images. Axial, sagittal and coronal T2-weighted FSE images (4000-4400/132 [repetition time 
msec./echo time msec.], echo train lengths of 15, two acquisitions, 180° flip angle, 11 slices) were 
acquired. All examinations were performed using a 4- or 5- mm section thickness with a 0.5-mm gap, 
265-280 mm field of view, and a 180-240 x 512 matrix (voxel sizes; 2.1-4.3 mm3). The phase-encoding 
gradient was left-right in order to decrease motion artifacts over the prostate. Subsequently we 
acquired 7 axial slices covering the prostate from apex to base and the seminal vesicles using a fast 
low angle shot (FLASH)-2D sequence intermediate weighted sequence [200/4.4 [repetition time 
msec./echo time msec.], 8°-flip angle, 160 x 256 matrix, 280-320 mm field of view, 5-7-mm section 
thickness, 0.5-0.7-mm gap (voxel sizes; 9.5 - 17.5 mm3). Thereafter an IV bolus injection of 0.1 mmol 
gadopentetate dimeglumine (Gd-DTPA) / kg b.w. (Magnevist®; Schering, Berlin, Germany) was 
administered using a power injector (Medrad Spectris MR injection system, Medrad, Pittsburgh, Pa) 
with an injection speed of 2.5 ml/ sec, followed by a 20-ml normal saline flush. We used a short bolus 
injection of 2.5 ml/ sec. instead of a long bolus injection because this will result in less noise-related 
error in the estimate of the various dynamic parameters (13).
During the contrast-administration a T1-weighted FLASH-2D sequence [50/4.4] [repetition time 
msec./echo time msec.], 60°-flip angle, 160 x 256 matrix, 280-320 mm field of view, 5-7-mm section 
thickness (voxel sizes; 9.5-17.5 mm3), 0.5-0.7-mm gap, time resolution: 7 slices per 2.03 sec. dur­
ing 90-120 sec. was applied at the same slice position as the intermediate weighted sequence. The 
dynamic image acquisition started at the same time as the contrast administration. Therefore; pre­
contrast no acquisitions and post contrast 45 acquisitions / 90 sec.
All images were transferred to an independent work station (Ultrasparc 2, Sun Microsystems, 
Mountain View). Software was used to analyze and display contrast enhanced dynamic MR imag­
ing datasets (14). Concentration Gd-DTPA - time curves were calculated by computer using inter­
mediate weighted images as a calibration method (16).
The advantage of using concentration-Gd-DTPA [Gd-DTPA] (15) curves instead of signal intensity 
curves is that variations in enhancement due to differences in focal intermediate weighted density 
and coil profile are corrected (16). Our method estimates the actual concentration Gd-DTPA in a 
voxel up to a scaling constant (c). This constant is the same for all patients measured on the same 
MR machine and includes factors such as T1 and T2 relaxivity, effective voxel dimensions, receiver 
gain, image scaling factors TR, TE, flip angle, calibration, and other manufacturer specific con­
stants. After calibration a model yielding 4 parameters, - onset time, time to peak, Pe and wash­
out - was fitted to the [Gd-DTPA]-time curves (14). The resulting parametric images were color- 
coded and integrated with T2-weighted images. T2 relaxation time (ms) of a voxel was estimated 
by inserting the interpolated estimated T1, interpolated intermediate weighted and the acquisition 
parameters into the MR signal function of the used T2 weighted Turbo FLASH sequence.
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Pathologic examination
The pathologic examiners (C.H.K. or G.V.L.) were blinded to the imaging results. Prostatectomy 
specimens were fixed overnight in a solution of 10% neutral buffered formalin. Whole mount sec­
tions were made at 4-mm intervals perpendicular to the dorsal side of the prostate, corresponding 
to slice orientations on MR imaging. After separating the step-sections into right and left halves, 
all sections were routinely embedded in paraffin. Tissue sections of 4 pm thickness were stained 
with hematoxylin and eosin. Regions representing carcinoma were outlined on the glass cover slips 
and retraced onto a schematic overview of all prostate slices, extending from base to the apex of 
the prostate.
From these overviews, topographic relationships between multifocal tumors were evaluated. 
Multifocality of carcinoma was defined as a minimum spatial distance of 4 mm between any two 
malignant foci in any direction. The volumes of all independent carcinomas were calculated by 
C.H.K. or G.V.L as the sum of surface areas for a given carcinoma multiplied by the slice thickness. 
Volumes were expressed in cubic centimeters (cm3). All carcinomas were evaluated for extension 
into the adjacent zone (i.e. peripheral zone or central gland) by one of the authors (M.R.E.) by ret­
rospective evaluation of the histology tumor maps.
Image analysis
Whole mount section histology tumor maps were then used to localize carcinoma and normal tis­
sue on fused T2-weighted parametric images. Only carcinomas > 0.5 cm3 were included for analy­
sis, because we considered malignant lesions <0.5 cm3 to be beyond the limits of reliable correla­
tion between MR imaging and histopathology. Additionally patients were excluded in case of severe 
motion artifacts and/or biopsy hemorrhage artifacts. In case a patient was excluded, due to biopsy 
artifacts the interval between biopsy and MR imaging was recorded. On the fused T2-weighted and 
parametric images (onset time of enhancement, time to peak, Pe and wash-out) voxels were cho­
sen by one author (M.R.E.) for carcinoma and normal PZ or normal CG (depending on the location 
of the malignancy), in such a way that only those voxels that showed highest / maximum individ­
ual values for each parameter were selected. Thus the malignant neoplasm is characterized by a 
limited variable set of voxels. On average 10 voxels (range 4-32) were selected both in carcinoma 
and normal PZ or normal CG tissue.
The CG corresponds primarily to the transition zone enlarged with benign prostate hyperplasia 
(BPH ), although there will be portions of the periurethral zone and central zone involved (17). The 
transition zone is the site of origin of BPH  and therefore often comprises a much larger portion of 
the gland in older men (18).
The entire normal PZ or CG was sampled to get the highest/maximum value for the various dynam­
ic parameters. However it was sometimes difficult to find areas without cancer, because tumors were 
often markedly irregular and often demonstrated fingerlike projections with ill-defined margins
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8spread across the whole prostate gland. In these cases an extensive and meticulous correlation 
between the MR image and histopathology was performed in order to define cancer-‘free’ areas.
In the calculation of the onset time, the beginning of enhancement in the nearest large vessel (Ext. 
iliac art.) was taken in account. Therefore, the onset time is defined as the difference in time (sec.) 
between the beginning of enhancement in this vessel and the beginning of enhancement in the tis­
sue of interest.
In order to decrease interpatient variability we normalized the Pe by using normal PZ or CG tissue 
as a reference tissue. In this manner we introduced the relative Pe (APe), which is the Pe in the car­
cinoma minus the average Pe in accompanying PZ or CG tissue. If the entire PZ orCG is infiltrated 
with carcinoma it is not possible to normalize the Pe using normal PZ or CG tissue. In such a case 
APe cannot be used. Therefore we analyzed our data with and without the use of APe.
The wash-out was calculated using linear regression of the curve in the post-peak area.
Statistics
Differences in onset time, time to peak, Pe, APe, wash-out and T2-relaxation rates between prosta­
tic carcinoma and normal PZ or CG were assessed with the two-tailed paired student t-test, with a 
p-value of 0.05 required for significance. Area under the receiver operating characteristics (ROC) 
curve (Az) was calculated to assess, which parameter was optimal for cancer discrimination in the 
PZ or CG. To assess interpatient variation of dynamic parameters the mean values (± SD) per car­
cinoma site and corresponding normal tissues (PZ or CG) were calculated and plotted in graphs. 
Next histology was reviewed to explain possible interpatient variations.
To determine the additional discriminative value of each parameter, a step-wise logistic regression 
analysis (multivariate analysis) of the Az was used. The multivariate analysis was performed as a 
backward stepping procedure, with a p-value of more than 0.05 required for exclusion. First the 
multivariate analysis was performed using all dynamic and T2-relaxation parameters. Next we per­
formed multivariate analysis without APe.
The correlation between dynamic parameters and T2- relaxation time in carcinoma with Gleason 
score, tumor volume, PSA, ECE, SVI and patient age were assessed using the pearson correlation 
coefficient (r). Additional multivariate regression analysis was performed to explore possible associ­
ations between Gleason score, tumor volume, PSA, ECE, SVI, patient age, dynamic parameters and 
T2-relaxation rate. Next, ROC analysis was performed to determine the performance of dynamic para­
meters and T2-relaxation to predict Gleason score, cancer volume, PSA, SVI, ECE and age.
In the ROC analysis parameters were included which demonstrated significant correlation in the 
multivariate regression analysis and excluding parameters which were not known a priori (i.e. 
before radical prostatectomy).
All statistical analyses were performed using Rockit 0.9B (C. Metz, PhD; Department of Radiology, 
University of Chicago, Ill), SAS/STAT software (SAS Institute Inc.) and Excel (Microsoft Windows 
9 5 ® ).
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R esu lts
Patients
We started with 58 consecutive patients. 22 patients were excluded, due to severe motion artifacts 
(n=6); carcinomas with volumes < 0.5 cm3 (n=11); and biopsy hemorrhage artifacts (n=5), result­
ing in 36 patients included for analysis. The average time between the biopsy and MR imaging for 
the patients excluded because of post-biopsy artifacts was 26 days (range 22-29 days).
The average age of these 36 patients was 61.3 years old (range, 49-72 years). The average PSA was 
10.6 ng/ml (range, 4.5-38.0 ng/ml, from 3 patients no PSA-data was available). Sextant-biopsies 
preceded MR imaging by an average of 23 days (range, 5-67 days). All patients underwent radical 
retropubic prostatectomy within three weeks after MR imaging. In the 36 patients 55 separate 
malignant neoplasms were found, 32 carcinomas in the PZ and 23 in the CG. The median Gleason 
score per carcinoma was 7 (range; 3-9). Out of the 32 carcinomas in the peripheral zone, 16 carci­
nomas demonstrated extension into the central gland and of the 23 central gland carcinomas, 12 
carcinomas extended into the peripheral zone.
Dynam ic and T2-relaxtion time parameters in prostate carcinoma,
P Z  and C G  tissues
319 voxels were measured in 32 malignancies in the PZ and compared with 319 voxels in 32 normal 
PZ sites. Carcinoma located in the PZ showed earlier onset of enhancement and shorter time to peak 
compared to normal PZ-tissue (p< 0.001; table 1). Pe and APe were increased in carcinoma com­
pared to normal PZ (p< 0.001). On average, carcinoma demonstrated wash-out, whereas normal PZ 
tissue did not show wash-out (p< 0.001). T2 relaxation time was lower in malignant neoplasms 
compared to normal PZ (p< 0.001). APe (Az=0.93) and Pe (Az=0.89) demonstrated the highest Az 
in the PZ (table 1). APe and Pe increased the Az compared to T2-weighted images significantly from
0.64 towards 0.93 and 0.89 respectively (p< 0.001). Multivariate analysis showed that APe would be 
the parameter with the highest yield in discriminatory performance (Az=0.94 ±95% C.I. [0.91-0.97]). 
If onset time, time to peak, T2 relaxation time and washout were added, discriminatory performance 
increased from Az=0.94 towards Az=0.96 (95% C.I. [0.94-0.97]). If Pe were used instead of APe, then 
multivariate analysis showed that the highest gain in discriminatory performance would be accom­
plished using Pe (Az=0.90 (95% C.I. [0.87-0.93]). The addition of onset time, time to peak, T2-relax- 
ation rate and wash-out to Pe increased Az from 0.90 towards 0.94 (95% C.I. [0.91-0.97]). O f the 32 
carcinomas located in the PZ, 31 malignant lesions demonstrated higher APe compared to PZ-tis- 
sue (Fig. 1A). In one patient (arrowhead in Fig 1A) a lower APe was demonstrated in carcinoma than 
in PZ-tissue. In this patient a severe coexistent chronic active prostatitis was described present by 
histopathology throughout the whole gland. Although we used the PZ as a reference tissue, there 
were still variations in APe between various carcinomas (Fig 1A).
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8Table i  Mean values (±SD) for onset time, time to peak, Pe, APe, wash-out and T2 relaxation time for car­
cinomas in the PZ and CG. In addition the discriminative performance of each parameter is presented as 
the area under the ROC-curve (=Az).
Parameter Carcinoma normal PZ Az [95% C.I] Carcinoma normal CG Az [95% C.I]
Onset time (sec.) 7.8 ±2.3* 10.5 ± 3.3 0.76[0.71-0.81] 7.6 ± 2.4** 9.9 ± 3.4 0.70[0.63-0.77]
Time to peak (sec.) 6.2 ± 1.8* 6.9 ±2.4 0.60[0.55-0.65] 5.9 ± 1.8** 6.6 ±1.9 0.60[0.53-0.67]
Pe cx (mmol GdDTPA/kg) 2223 ± 932* 1015 ± 487 0.89[0.86-0.92] 2397 ± 944** 1497 ±672 0.79[0.74-0.84]
APe cx(mmol GdDTPA/kg) 1208 ± 752* 0 ±286 0.93[0.90-0.95] 900 ± 926** 0 ±398 0.83[0.78-0.86]
Wash-out cx 
(mmol GdDTPA/sec.)
-0.2 ± 0.78* 0.47 ± 0.51 0.82[0.78-0.86] -0.2 ± 0.5** 0.3 ± 0.4 0.82[0.80-0.84]
T2 (ms) 151 ±89* 331 ± 527 0.64[0.60-0.68] 156 ±183*** 134 ±60 0.51[0.46-0.57]
Positive wash means wash-in and negative wash refers to wash-out. 
*=significant difference between carcinoma and PZ (p< 0.001). 
**=signifcant difference between carcinoma and CG (p< 0.001). 
***=no significant difference between carcinoma and CG (p=0.10). 
c= a scaling factor (see materials and methods).
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Figure iA  Mean APe (± SD) of carcinoma (black diamonds) located in the PZ compared with normal PZ- 
tissue (white squares). Each carcinoma site is represented as a separate case. In the PZ we found 32 sep­
arate carcinoma sites. Carcinoma demonstrates higher APe than PZ. One malignant lesion (arrowhead) 
demonstrates a lower APe than PZ. In this patient a severe coexistent chronic active prostatitis was 
described present throughout the whole gland. Interpatient variation is present. For example malignant 
lesions 2 vs 32 (black arrows). The c on the y-axis is a scaling factor (see materials and methods).
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In the CG 204 voxels were measured in 23 carcinomas and compared with 204 voxels located in 23 
CG sites of normal tissue. As occurred in the PZ, carcinoma enhanced earlier, with a faster time to 
peak, a higher Pe and APe and with wash-out, compared to CG tissue (p<0.001) (table 1). Contrary 
to the PZ, no significant differences in T2 relaxation times between cancer and CG-tissue (p=0.1) were 
seen. In the CG APe (Az=0.83), Pe(Az=0.79) and wash-out (Az=0.82) showed similar discriminatory 
performance (table 1). APe, Pe and wash-out increased Az from 0.51 (T2-relaxation rate) towards
0.83, 0.79, 0.82 respectively (table 1: p< 0.001). Multivariate analysis showed that in the CG, APe 
would be the parameter, with the highest yield in discriminatory performance (Az=0.82 ±95% 
C.I.[0.77-0.87]). If wash-out, time to peak and onset time were added, discriminatory performance 
increased from Az=0.82 towards Az=0.89 (95% C.I. [0.85-0.93]). If Pe were used instead of APe, then 
multivariate analysis showed that the highest gain in discriminatory performance would be accom­
plished using wash-out (Az=0.81 (95% C.I. [0.76-0.86]). Addition of Pe, time to peak and onset time 
increased discriminatory performance from Az = 0.81 towards 0.87 (95% C.I. [0.82-0.92]). In Fig. 1B 
the measurements of APe in carcinomas located in the CG are shown. In 21 carcinomas APe was 
higher compared to CG. However, in malignant lesions 5 and 12 (black arrows in Fig. 1B) a lower APe 
in carcinoma was seen compared to CG-tissue. No difference in histology was noted between the CG 
of patients compared to others. O f the 23 malignancies in the CG; 16 demonstrated wash-out, as 
opposed to normal CG-tissue. Wash-out showed 1 false positive enhancement in the patient with car­
cinoma 12 (Fig 1C; black arrow). Histopathology revealed no difference between this prostate and the 
prostates of other patients.
Poor-moderate correlation (0.02-0.44) was seen between dynamic parameters or T2-relaxation- 
times in malignant prostatic neoplasms and Gleason score, tumor volume, PSA, ECE, SVI and 
patient age in both the PZ and CG (tables 2a, b). The highest correlations were seen in the CG 
between Pe and PSA (r=0.44) and between Pe and extracapsular extension (r=0.44). Multivariate 
regression analysis demonstrated that Gleason score, PSA, patient age, cancer volume, SVI and 
ECE were significantly (P<0.05) correlated with each other and with the dynamic and T2-relaxation 
parameters. Addition of dynamic and T2 relaxation parameters in the prediction of Gleason score, 
cancer volume, ECE and SVI resulted in an AUC increase of respectively 0.05. 0.07, 0.07 and 0.07. 
For age and PSA it was not possible to perform multivariate regression analysis without the addi­
tion of dynamic and T2 relaxation parameters, because there were no variables available. Addition 
of dynamic / T2 relaxation parameters resulted in an AUC of 0.66 for PSA and 0.56 for age.
D iscussion
Dynamic enhancement in prostate carcinoma tissue differs from normal PZ and CG tissue. It is a 
reasonable assumption that dynamic contrast enhancement in prostatic carcinoma might be dif­
ferent than adjacent tissue, among others due to the increased microvessel density (MVD) of 
prostate carcinoma (19, 20). This assumption is supported by a study, which investigated the cor­
relation between microvessel density and enhancement patterns in contrast-enhanced ultrasound
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Figure iB  Mean APe (± SD) of carcinoma (black diamonds) located in the CG compared with normal CG- 
tissue (white squares). Each carcinoma site is represented as a separate case. In the CG we found 23 sepa­
rate carcinoma sites.
In general carcinoma demonstrates higher APe compared to CG tissue. However, in malignant neoplasms
5 and 12 (black arrows) a lower APe was demonstrated than in CG tissue. No histologic differences in his­
tology were noted between the prostate glands of these patients (site 5 and 12) and those of other patients. 
The c on the y-axis is a scaling factor (see materials and methods).
(30). This study showed a significant correlation between pixel intensity in PCa after contrast 
administration and MVD. These differences were quantified and used to discriminate prostate car­
cinoma from normal tissue in both PZ and CG. Both in the PZ and CG APe was the optimal para­
meter. Combination with other dynamic parameters (onset time, time to peak, peak-enhancement 
and wash-out) did not yield a significant gain in discriminatory performance. W e surmise that this 
is because the other dynamic parameters are highly correlated with APe and thus of little addition­
al value.
APe cannot be used if carcinoma has spread throughout the prostate, because it is not possible to 
use normal prostate tissue as a reference tissue for normalization. In these cases Pe can be used as 
the parameter in the PZ and wash-out in the CG. Pe performs less well in the CG compared to the PZ 
because the difference in Pe between carcinoma and CG is smaller. This is caused by the higher Pe of 
normal CG tissue. As a discriminating parameter, T2-relaxation rate performed poor in both the PZ 
and CG. Individual dynamic parameters (except time to peak) showed higher discriminatory perfor­
mance compared with T2-relaxation rate.
The difference in results between Padhani et al (21) and the current study is that we found a sig-
118
Discrimination o f  peripheral zone and central gland prostate cancer
♦ Carcinoma □ Central gland
Figure 1C Mean wash-out (± SD) (of carcinoma (black diamonds) located in the CG compared with nor­
mal CG-tissue (white squares). Each carcinoma site is represented as a separate case. In the CG we found 
23 separate carcinoma sites. In general carcinomas demonstrated wash-out, as opposed to CG-tissue. False 
positive wash-out was seen in malignant lesion 12 (black arrow). No histologic differences were noted 
between the prostate gland of this patient and other patients. The c on the y-axis is a scaling factor (see 
materials and methods).
nificant difference between onset time of enhancement in prostate cancer and PZ or CG. According 
to our data the difference between the start of enhancement in carcinoma and PZ or CG is respec­
tively 2.7 and 2.3 sec (table 1). Probably the 9-10 sec. temporal resolution used by Padhani et al was 
too low to detect these relatively small differences in onset time. Also Padhani et al. did not use 
whole mount section histology as a reference standard.
Similar as in our results Turnbull et al. (22) described significant differences between carcinoma 
and (fibromuscular) benign prostate hyperplasia (BPH ) in the amplitude of the initial upslope 
(comparable to time to peak). However, this study did not demonstrate differences using wash-out. 
Thus far no reports have been published on the discriminative performance of APe and Pe. W ash­
out has already been described as a useful dynamic feature (23) (24) in breast carcinoma lesion 
characterization. Multivariate regression and ROC analysis demonstrated that use of dynamic para­
meters / T2 relaxation time resulted in a marginal increase in the prediction of the Gleason score, 
cancer volume, PSA, ECE, SVI and age.
The poor-moderate correlation between Gleason score, tumor volume, serum PSA, ECE, SVI patient 
age and dynamic or T2-relaxation parameters in carcinoma are in agreement with Padhani et al (21). 
Gossmann et al (25) demonstrated that when using macromolecular contrast media, dynamic MR
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8imaging can provide some differentiation in histopathologic prostatic tumor grades but in xenografts. 
In the same study a comparison was made between macromolecular and small-molecular contrast 
media. In accordance with our study considerable overlap was found between the endothelial tran- 
fer coefficient (a measure for permeability) values for low and high grade tumor types using small- 
molecular contrast media, although in that study (25) a temporal resolution of 30 seconds was 
used. We demonstrate that using a temporal resolution of 2.03 seconds a similar poor-moderate 
correlation between Gleason score and dynamic enhancement in prostatic carcinoma. Although a 
poor-moderate correlation was present between Gleason and dynamic enhancement this may par­
tially explain the differences present in the APe between the carcinomas. A coincidental finding was 
a false positive enhancement in 1 case in the PZ using APe in concomitant severe prostatitis. The 
typical enhancement, caused by prostatitis, has been previously described in contrast-enhanced 
helical computed tomography (26).
Table 2A Pearson correlation coefficient between dynamic parameters, T2-relaxation rates and clinical 
parameters in PZ carcinomas. 319 observations were available, except for PSA; 281 comparisons.
Gleason score Volume PSA ECE SVI Age
Onset time 0.21 0.14 -0.07 0.21 -0.04 -0.17
Time to peak 0.22 0.02 0.08 0.09 0.07 0.09
Pe -0.34 0.02 -0.05 0.07 -0.13 -0.02
APe -0.16 0.07 -0.03 0.05 -0.06 0.10
Wash-out 0.12 0.13 -0.17 0.26 0.18 -0.01
T2-relaxation rate -0.08 -0.07 -0.21 -0.06 -0.12 -0.14
Table 2B Pearson correlation coefficient between dynamic parameters, T2-relaxation rates and clinical 
parameters in CG carcinomas. 204 observations were available, except for PSA 193 observations.
Gleason score Volume PSA ECE SVI Age
Onset time 0.11 -0.16 -0.24 -0.03 -0.01 -0.07
Time to peak 0.00 0.09 0.03 0.14 0.11 0.05
Pe 0.29 -0.06 0.44 0.44 0.34 0.36
APe 0.16 -0.13 0.40 0.40 0.29 0.46
Wash-out -0.22 -0.04 -0.20 -0.25 -0.18 -0.02
T2-relaxation rate 0.05 -0.10 -0.09 -0.09 -0.08 -0.08
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Limitations
A limitation of this study is that, due to selective sampling of voxels in the most enhancing part of 
the carcinoma, enhancement characteristics of other parts of the carcinoma were not evaluated. 
However, if an average region of interest would have been used to include the entire carcinoma, 
then the heterogeneity of carcinoma enhancement would be ignored. Also, when using an unse- 
lective sampling protocol the area under ROC-curve for the various dynamic and T2-parameters 
may be different. As the purpose of this study was to compare which dynamic and T2-relaxation rate 
parameters show the highest performance in carcinoma discrimination, we sampled the voxel val­
ues for each dynamic and T2 parameter in the carcinoma, PZ and CG in the same manner. 
Therefore the various parameters can be compared reliably with each other. Finally, in a similar 
study where prostate carcinoma enhancement was measured a comparable selective sampling 
method has been used (25).
In the current study prostatic carcinomas smaller than 0.5 ml were excluded. Therefore our results 
may be biased towards a higher discriminative performance, because larger carcinomas may be 
easier to discriminate. However, only prostate cancers of 0.5 cm3 or larger are considered clinical­
ly significant (27).
We used a parametric description of time-[Gd-DTPA] curves, while Tofts et al. (28) propose to also 
fit these curves to a physiological model. Yet, the required arterial input function (AIF) is difficult 
to estimate accurately. Difficulties we encountered were strong flow and saturation artifacts, noise, 
and interpatient variability due to differences in vasculature (e.g. anatomy and / or atherosclero­
sis). If a step shaped A IF is assumed, then according to Tofts et al. (28), our time to peak is direct­
ly related to the rate constant between the extravascular extracellular space and the blood plasma 
volume (permeability surface area) and Pe is related to the volume of the extracellular space.
A further constraint may be that the scaling factor in our [Gd-DTPA] measurements does not allow 
comparison with other studies. The fact is that robust calibration to obtain accurate absolute val­
ues is difficult. Developing a method that allows operating under clinical conditions using clinical 
MR machines and has reproducible machine independence requires quite some research, which is 
outside the scope of this study.
A limitation of dynamic MR imaging in the prostate remains the susceptibility to motion and biop­
sy artifacts (29), as can be seen by the fact that over one third of our patient population (22/58) 
could not have their images interpreted at all due to due to severe motion artifacts and/or post­
biopsy artifacts.
A major limitation in the use of the parameter APe is that it can never be used in a prospective man­
ner, as one never knows a priori where the carcinoma is located. Therefore it will not be possible to 
‘normalize’ the peak-enhancement by using normal PZ tissue. In clinical practice the Pe and wash­
out will be the most optimal dynamic parameters.
The purpose of this study was to find new dynamic parameters, which can be used in the interpreta­
tion of prostate M RI’s. Using our proposed parameters APe, Pe and wash-out an efficient dynamic 
MR imaging reading protocol for prostate cancer can be developed. However, future studies should
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8validate the discriminatory performance of the studied dynamic parameters in a prospective study, 
where enhancement is compared with whole mount section histopathology as gold standard.
In conclusion, the optimal parameter for prostate carcinoma discrimination in the PZ and CZ is the 
relative Pe. If it is not possible to use APe, Pe is the optimal parameter in the PZ and wash-out in 
the CG. APe, Pe and wash-out all improve prostate carcinoma discrimination in comparison with 
T2-weighted images. Poor-moderate correlation is present between dynamic parameters or T2- 
relaxation rate in prostate carcinoma and tumor stage, histological grade, patient age, tumor vol­
ume and serum PSA.
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A b stract
Purpose: To determine whether combined dynamic contrast-enhanced magnetic 
resonance (MR) imaging and 2D proton MR spectroscopic imaging allows differ­
entiation between chronic prostatitis and prostate carcinoma (PCa).
Materials and methods: Thirteen patients with a clinical diagnosis of chronic pro­
statitis were studied with an MR protocol, including T2 -weighted MRI, dynamic con­
trast enhanced MRI (DCM RI) and 2D 1H MR spectroscopic imaging (M RSI). 
Patients were treated for six weeks with the antibiotic ciprofloxacin and underwent 
the same MR protocol before and after treatment. The prostatitis data were com­
pared with similarly acquired data from patients with histologically confirmed 
prostate cancer (n=36).
Results: The peak Gd-DTPA contrast enhancement in chronic prostatitis and in 
prostate cancer are both significantly elevated with respect to normal prostate 
peripheral zone (PZ). MRSI showed a mean citrate-to-choline ratio of 5.7 ±  2.5 in 
the prostate PZ with prostatitis, which is similar to the ratio in normal PZ. By con­
trast, in PCa the citrate/choline ratio was significantly lower (p<0.001) at 1.4 ±  1.3. 
Antibiotic treatment of prostatitis did not markedly affect the tissue uptake of Gd- 
DTPA. The citrate/choline ratio in the PZ decreased slightly (p<0.01) after antibi­
otics, but remained significantly higher (p<0.001) than in PCa.
Conclusion: Neither dynamic contrast enhanced MRI nor 1H MR spectroscopy 
could offer a specific diagnosis of chronic prostatitis by itself. When conventional 
MRI and DCMRI cannot distinguish between PCA or prostatitis, an additional MR 
spectroscopy exam may help to exclude PCa in the PZ.
Differentiation o f chronic prostatitis from prostate cancer
Benign prostate diseases such as benign prostatic hyperplasia (BPH ) and chronic prostatitis are 
frequently encountered in urological practice and their clinical symptoms may be very similar to 
those of PCa. Particularly chronic prostatitis is difficult to diagnose and frequently confounds the 
diagnosis of prostate cancer. Patients with chronic prostatitis generally present with a wide variety 
of urological pain complaints and the exact cause is usually unknown (1). According to the National 
Institutes of Health definition, the chronic prostatitis/chronic pelvic pain syndrome (type III), rep­
resenting more than 90% of symptomatic patients, may be of inflammatory or non-inflammatory 
origin (2,3). Even modern medical imaging techniques like transrectal ultrasonography (TRUS), 
computed tomography (CT) and conventional magnetic resonance imaging (M RI) have limited 
capacity to differentiate malignancies from benign diseases, including chronic prostatitis (4,5). 
Histopathology of (TRUS-guided) prostate biopsies continues to be the diagnostic gold standard. 
However, as malignant tumors and benign lesions are often multifocal and heterogeneous, they 
may be easily missed during biopsy. When physical complaints continue after a negative biopsy 
result, often repeat biopsies are taken, which is associated with additional patient discomfort and 
increased risk of sepsis. Therefore, it is of critical importance to improve the accuracy of localiza­
tion of prostate cancer and of its differentiation from chronic prostatitis. This improved diagnostic 
accuracy may obviate the need for repeat biopsies.
MR imaging is a powerful imaging modality giving excellent anatomic detail of the prostate gland. 
The use of MR imaging for staging prostate cancer has gained importance with the introduction of 
endorectal coils (4,6,7), since cancer stage may have significant impact on therapy selection. 
Prostate cancer may be identified on conventional T2 -weighted MR imaging as an area of low sig­
nal intensity compared to normal PZ. However, conventional MR imaging cannot reliably distin­
guish cancer from other causes of reduced T2 -weighted signal intensity, such as chronic prostati­
tis, scars and atrophy, nor can it localize malignancies in the central gland. More advanced MR 
techniques, such as dynamic contrast-enhanced MR imaging (DCM RI) and MR spectroscopy, can 
probe particular functional aspects of malignant tumors and thus potentially improve the accuracy 
of tumor detection (8-12). DCMRI has been proposed as a sensitive tool to evaluate the tumor vas­
cular characteristics. Localized 1H MR spectroscopy can detect potentially important biochemical 
markers in the human prostate in vivo, notably citrate and choline, thereby giving a unique insight 
into tumor metabolism (8,13). 1H MR spectroscopy studies of the human prostate in vivo have 
reported significantly reduced levels of citrate and elevated choline levels in prostate cancer as 
compared to healthy PZ and BPH  (8,9,13,14).
Histologically, chronic prostatitis may appear as a massive infiltration of leukocytes, which sur­
rounds and may compress the glandular ducts (15,16). To our knowledge, it is not known if chron­
ic prostatitis affects the MRS-observed citrate and choline levels in the prostate. Also it is yet 
unclear in how far the microcirculation in chronic prostatitis is disturbed, leading to altered con­
trast enhancement characteristics. Marked differences in the contrast-uptake pattern and/or meta­
bolic profile would significantly contribute to a better differentiation between chronic prostatitis,
Introduction
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9healthy PZ and prostate cancer. Therefore, the purpose of this study was to evaluate the potential 
of DCMRI and MRSI for discriminating prostatitis from prostate cancer in the PZ.
Experim en ta l m ethods
Patient group
Patients (n=13) were selected by an experienced urologist on the basis of clinical symptoms and 
history of chronic prostatitis. This study was approved by the local ethics committee and informed 
consent was obtained from all patients. Ten out of thirteen patients consented to have sextant biop­
sies taken under transrectal ultrasound guidance, which were examined by routine histopathology. 
All thirteen patients received an oral treatment with the antibiotic ciprofloxacin (500 mg, twice a day) 
for a period of six weeks. The prostatitis patients underwent a baseline MR examination, that is 
before treatment with antibiotics and at least 3 weeks after biopsy. After therapy all patients under­
went an identical follow-up MR examination, as will be described below.
MR data from prostatitis patients were compared retrospectively with data from a group of con­
firmed prostate cancer patients. Thirty-six cancer patients (mean age of 61.3 years old, range 49-72 
years, mean PSA of 10.6 ng/ml, range 4.5-38.0 ng/ml) had undergone a combined MR imaging and 
dynamic contrast enhanced MRI protocol (17), while 14 PCa patients also had an additional MRSI 
exam. DCMRI and MRSI scan parameters for the cancer and prostatitis patients were identical. 
Subsequent histopathology of whole-mount sections after radical prostatectomy could positively 
identify and localize prostate cancer in these patients. Contrast uptake and metabolite ratios were 
evaluated in regions that were confirmed by histopathology to be normal PZ or cancer.
Magnetic Resonance
All MR measurements were performed at 1.5 T on a Siemens M AGNETOM  Vision system 
(Siemens Medical Systems, Erlangen, Germany). The body coil was used for RF excitation, and an 
inflatable endorectal coil (MRInnervu; M edrad® , Pittsburgh, Pa.) integrated with a pelvic phased- 
array coil was used for data acquisition. Multislice, axial T2 -weighted turbo spin-echo (TSE) images 
(TR=4400ms, TE=132ms, F0V=280, matrix = 180x512, 11-13 slices, slice thickness = 5 mm) of the 
entire prostate gland were recorded.
On this series of images, an experienced reader (M.R.E.) then localized suspicious hypointense 
areas within the PZ representing the potential lesion site(s). The corresponding section was then 
selected to perform additional 2D MR spectroscopic imaging, as described below. In the absence 
of visible lesions on the T2 -weighted images, an axial section through the prostate midgland was 
chosen for subsequent MRSI investigation.
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Single-slice 2D proton MR spectroscopic imaging was performed with PRESS volume pre-selection 
(TE = 120ms; TR = 1200ms). First, a radiologist selected the appropriate transversal TSE image 
with the slice position to be used for MRSI. Then, a rectangular volume-of- interest (VOI) lying with­
in the prostate gland was outlined on this TSE, excluding as much as possible any tissue from out­
side the prostate. Magnetic field homogeneity over this VOI was then optimized using an auto­
matic, localized 3D shim procedure.
For MRSI a 10-mm thin slab was chosen, which was oriented parallel with the TSE images and per­
pendicular to the rectal wall. The MRSI sequence contained 16x16 phase-encoding steps and a 
field-of-view of 128 mm, providing a nominal voxel size of 0.64 cm3. Three averages were taken to 
improve the signal-to-noise ratio, resulting in a measurement time of 15 minutes. Water and lipid 
signals were effectively suppressed using dual-band frequency-selective 180° pulses surrounded by 
dephasing gradients (18,19).
Routinely, an additional non-water suppressed MRSI of the same plane was recorded with a single 
acquisition, but otherwise identical parameters, which allowed for automatic zero-order phasing 
and eddy-current correction of the metabolite spectra (20).
Dynam ic contrast-enhanced MRI
Dynamic contrast-enhanced MRI was performed after the MRSI exam in order to avoid potential 
spectral line-broadening by the presence of the paramagnetic contrast agent.
Patients were administered an intravenous bolus injection (15 ml; 0.5 M; 2.5 ml/s) of gadopente- 
tate dimeglumine (Gd-DTPA, Magnevist®; Schering, Berlin, Germany) using a power injector 
(Medrad Spectris MR injection system, Medrad, Pittsburgh, Pa), followed by a 20-ml flush of normal 
saline. During infusion of the contrast agent, multislice dynamic contrast-enhanced images of the 
entire prostate gland were recorded with a ^-weighted fast low angle shot (FLASH) sequence (TR/TE 
= 50/4.4 ms, flip angle = 60o; 7 slices, slice thickness = 7 mm, matrix = 160x256, FOV = 280 mm). 
Forty-five images were recorded during a period of 90 s to monitor the contrast agent uptake. To allow 
calculation of the relative gadolinium concentrations (see below), pre-contrast multi-slice proton den­
sity (PD) weighted MR images were also recorded using a similar FLASH sequence (TR/TE: 200/4.4 
ms; flip angle: 8o; FOV: 280 mm). Both series included the exact slice position used for MRSI, allow­
ing an accurate registration of the images and a pair-wise comparison of the two MR techniques.
Postprocessing of dynamic MRI data
The Gd-uptake was analyzed using a simple two-compartment model and a step-function arterial 
input was assumed, i.e. the contrast bolus arrival was instantaneous and constant. A pixel-by-pixel
M R  Spectroscopic Im aging
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9analysis of the uptake kinetics of the contrast agent was performed using home-built software (21) 
implemented on an independent workstation (Ultrasparc 2, Sun Microsystems, Mountain View, 
California). Signal enhancement curves were first modeled by a four-parameter curve-fitting 
method (21). The ^-weighted MR images were calibrated by the matching pre-contrast proton 
density images, giving an enhancement term which is proportional to the Gd-DTPA concentration 
(22). Curve-fitting of the Gd uptake (21) yielded values for the (1) onset time of enhancement, t0 ,
(2) peak enhancement, (3) time to peak enhancement, ttp, and (4) wash-out. The corresponding 
parametric images were automatically co-registered with the anatomical T2 -weighted MR images. 
An experienced reader (M.R.E.) then selected a set of pixels in the suspicious most enhancing 
region, i.e. with the highest peak enhancement, and another set of pixels in a control region, i.e. a 
minimally enhancing region in the normal appearing PZ. About 5-10 pixels were selected for each 
region and the corresponding parameters were averaged. In order to decrease inter-patient vari­
ability, the relative peak enhancement was calculated, which is the peak enhancement in the lesion 
site normalized by the average peak enhancement in the accompanying normal appearing PZ.
Postprocessing of MR spectroscopic imaging data
Prior to Fourier transformation in the two spatial dimensions, a Hamming filter with a filter ratio 
of 50% was applied. Time-domain data from individual MRSI voxels were transferred to the MRUI 
software package (23) on a Sun workstation (Ultra 10, Sun Microsystems, Mountain View, 
California). First, an eddy current correction was applied using the non-watersuppressed MRSI 
dataset (20). Next, residual water and lipid resonances were removed by applying an HLSVD  filter 
(24). Spectra from individual MRSI voxels were then analyzed in the time domain, using the 
AM ARES algorithm (25). Metabolite resonances were modeled by a Gaussian function and prior 
knowledge of the resonance frequencies and of the citrate multiplet structure (26) was imposed. 
Thus, signal amplitudes for citrate, creatine and choline were obtained. The ratio of citrate to 
choline was corrected for partial saturation of the citrate and choline amplitudes using previously 
published T  values (27).
Statistics
All data are expressed as mean values ± standard deviation (s.d.). Differences between prostatitis, 
prostate cancer, normal PZ with respect to the mean contrast uptake parameters or mean cit­
rate/choline ratios were assessed by a one-way analysis of variance followed by Tukey’s Multiple 
Comparison Test. A paired t-test was used to determine therapeutic response.
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R esu lts
The patients recruited for this study had clinical symptoms suggesting chronic prostatitis. All 
patients had normal PSA levels (<4 ng/mL), except for one patient with a PSA of 10 ng/mL. In six 
out of ten patients who received sextant biopsies, subsequent histopathology confirmed the pres­
ence of inflammatory infiltrates with increased numbers of leukocytes, while the remaining biop­
sies did not show inflammation. All biopsies were found negative for prostate cancer.
T2 -weighted Turbo Spin Echo MR imaging showed suspicious areas of low signal intensity in the 
PZ in most but not all prostatitis patients. The section with the most pronounced low-signal-inten- 
sity lesion was then examined in more detail using MR spectroscopic imaging and dynamic con­
trast-enhanced MRI. Figures 1 and 2 show, respectively, illustrative examples for prostatitis patients 
and tumor patients.
Figure 1 shows a case of a 50-year old patient with a PSA of 0.42 who had been diagnosed with 
chronic prostatitis/chronic pelvic pain syndrome. The pre-treatment axial T2 -weighted MRI demon­
strated hypointense regions, both left and right laterally in the prostate PZ. Figure 1b shows dis­
tinct regions of elevated peak enhancement that correspond with regions with lower T2 -weighted 
signal intensity (Fig 1a). The average peak enhancement in the strongly enhancing area (Fig. 1b) 
was 1363 ±  112 a.u., as compared to 839 ±  231 a.u. in a control region in the PZ. A.u. is defined 
as arbitrary units and is closely related to the concentration Gd-DTPA as described in chapter 8 of 
this thesis (17).
Figure 1d shows localized 1H spectra from MRSI of a pre-selected volume-of-interest (Fig. 1c), with 
distinct high signal of citrate throughout the prostate and lower signals for creatine and choline. In 
the region that shows a reduced T2 signal intensity and elevated peak contrast enhancement, the 
citrate/choline ratio was 7.5 after correction for partial saturation.
For comparison, Figure 2 shows similar MR data from a 62-year old patient with a PSA of 27 ng/ml 
who had a tumor in the left prostate PZ. Histopathology of whole-mount sections after radical 
prostatectomy confirmed that this was a poorly differentiated tumor (Gleason sum score of 9). The 
T2 -weighted MR images display a large lesion of low signal intensity on the left side. The peak 
enhancement after applying Gd-DTPA is also markedly elevated on the left side of the prostate, as 
compared to the healthy right PZ. 1H 2D-PRESS MRSI in this tumor patient (Fig. 2) shows that in 
the left prostate PZ the citrate signal is markedly reduced, while the choline signal is somewhat ele­
vated (citrate/choline ratio between 0.35 and 1.13). In the tumor region also signals from creatine 
(3.05 ppm) and spermine (3.1 ppm) are somewhat reduced. By contrast, in the normal appearing 
right PZ, high citrate levels are observed, as well as moderate levels of choline, creatine and sper­
mine (citrate/choline ratio between 2.28 and 4.89). Thus, 1H MR spectra from chronic prostatitis 
revealed high levels of citrate relative to choline, which is comparable to what is found in healthy 
prostate tissue or benign prostatic hyperplasia, but markedly different from relative citrate levels in 
prostate tumors (8,9,13,14).
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Figure i  Contrast-enhanced MRI and 'h  MR spectroscopic imaging of the prostate of a 50-year old patient 
(PSA = 0.42 ng/ml) with chronic prostatitis/chronic pelvic pain syndrome, before treatment (a-d) and six weeks 
after treatment with ciprofloxacin (e-g). a) Pre-treatment axial T2 -weighted turbo spin-echo MR image of the 
prostate, where arrows indicate the low signal intensity regions. b) Pre-treatment map of the peak gadolinium 
enhancement, overlaid on the corresponding T2 -weighted image, showing regions with elevated contrast 
uptake in the left and right lateral areas of the peripheral zone (ovals). c) The pre-selected rectangular volume- 
of-interest (VOI) and spectral grid for MRSI with 0.64 cm3 voxels, overlaid on the same anatomical image. d) 
The individual 1H MR spectra (ppm range: 1-4 ppm) from the indicated VOI, showing pronounced signal for 
citrate at 2.6 ppm and moderate signals of creatine (3.05 ppm) and choline (3.2 ppm) throughout the gland. 
e) Post-treatment T2 -weighted MR image ofthe prostate shows similar low SI areas (arrows). f) Post-treatment 
overlay map of the peak Gd-DTPA enhancement shows strongly enhancing regions similar to the pre-treatment 
images (ovals). g) The pre-selected PRESS volume-of-interest (VOI) and MRSI grid overlaid on the same T2 - 
weighted image. h) Post-treatment 1H MRSI spectral map of the prostate. Note that the upper left spectrum 
is somewhat contaminated by lipids from outside the prostate.
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Figure 2 Contrast-enhanced MRI and spectroscopic imaging of the prostate of a 62-year old patient with a 
PSA of 27 ng/ml and cancer (Gleason sum score of 9) in the left prostate peripheral zone. a) Map of the peak 
Gd-DTPA contrast enhancement, overlaid on the corresponding axial T2 -weighted turbo spin-echo MR image 
of the prostate, showing elevated peak enhancement in the left peripheral zone and central gland (oval). b) 
Overlay of the VOI and MRSI matrix on the T2 -weighted MR image, which shows a large region of low signal 
intensity in the left prostate periphal zone and part of the central gland. c) corresponding 1H MRSI spectral 
map (ppm range of individual spectra: 1-4 ppm), showing markedly reduced citrate signal in the designated 
tumor area and high citrate/choline ratio in the unaffected right peripheral zone.
Pre-therapy dynamic M RI and M RSI
Table I summarizes the modeling parameters for contrast uptake in chronic prostatitis. Peak con­
trast enhancement was significantly higher than in the control region in the normal appearing 
prostate PZ. The time-of-onset, time-to-peak and washout parameters were not significantly differ­
ent from those found in normal appearing PZ. The average peak enhancement in the prostate PZ 
in prostatitis patients pre-therapy was 1598 ± 744 a.u. and in the control regions 993 ± 375. In the
36 patients with histologically proven prostate cancer, the average peak enhancement in tumor 
areas was also significantly elevated (17), namely 2223 ± 932 a.u. compared to 1015 ± 487 a.u. in
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9Table 1 Modeling parameters for gadopentetate dimeglumine uptake in the prostate 
peripheral zone with chronic prostatitis, before and after treatment with ciprofloxacin
pre-therapy post-therapy
parameter most enhancing control Gleason score Gleason score
onset time (s) 9.2 ± 3.3 11.0 ± 4.8 11.5 ± 5.1 11.2 ± 3.2
time-to-peak (s) 7.0 ± 1.1 6.9 ±0.8 7.2 ± 1.2 6.8 ± 0.6
peak enh. (a.u.) 1598 ± 744 * 993 ±375 1800 ± 887 * 1053 ±427
wash (s-1) 0.03 ± 0.51 0.25 ± 0.18 0.18 ± 0.38 0.35 ± 0.20
relative peak enh. 1.57 ± 0.44 1.70 ± 0.41
Note. — Numbers are the means ± standard deviation for n=13 patients. 
* Significant difference from control value (p<0.001).
the normal appearing PZ (Figure 3a). The mean elevation of peak enhancement in chronic prosta­
titis was not significantly different from that in cancer, indicating that cancer diagnosis using con­
trast MRI may be seriously compromised by the presence of prostatitis.
Pre-therapy MRSI in 13 patients diagnosed with chronic prostatitis resulted in 175 localized 1H MR 
spectra originating from voxels within the prostate gland of 0.64 cm3 nominal volume. The pre-ther­
apy MRSI scan could not be performed in one patient, because of technical difficulties. 114 out of 175 
spectra (65%) were used for further quantitative analysis, of which 47 originated from the PZ, 43 from 
the central gland and 24 from the peri-urethral area. The remaining spectra were discarded from the 
analysis, because of poor S/N of both metabolite and corresponding water spectra, lipid contamina­
tion, baseline distortions, voxels that were (partly) outside the prostate gland, or because no corre­
sponding pre and post-therapy voxels were available. MRSI voxels were classified into prostate PZ, 
peri-urethral zone or central gland voxels and for each voxel, the average pre- and post-treatment cit­
rate/choline ratios were determined. This was because citrate levels are known to vary with prostate 
anatomy, with significantly lower levels of citrate being observed in the prostate central gland and peri­
urethral zone as compared to normal PZ (8,28). This is possibly related to the reduced density of glan­
dular cells in the former anatomical regions. 1H MR spectra obtained from the prostate PZ of chron­
ic prostatitis patients displayed high levels of citrate relative to choline, with a mean citrate/choline 
ratio of 5.7 ± 2.5, as shown in Figure 3b. For comparison, in the group of prostate cancer patients, 
the mean citrate/choline ratio in cancer areas was 1.4 ±1.3. This is significantly lower (p<0.001) than 
citrate/choline ratios found in chronic prostatitis (Figure 3b) and also lower (p<0.001) than in the nor­
mal appearing PZ (citrate/choline ratio of 4.2 ± 2.1). Figure 4a indicates that there was considerable 
inter-patient variability in the pre-therapy Gd-enhancements. The mean peak enhancement in the 
most enhancing region in prostatitis patients was 1598 ±  745 a.u. with peak values ranging from 483
a.u. to 2720 a.u.. In order to take the inter-individual systemic variability into account, e.g. variable 
heart rates and blood pressures, the data were normalized to the average peak enhancement in a con­
trol region in the normal appearing PZ (Figure 4c). This simple normalization procedure considerably 
decreased the variability in peak enhancement in the individual prostatitis patients. The average nor­
malized peak enhancement was 1.57 ±  0.44 (range 0.92-2.62).
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Figure 3 a) Peak enhancement in chronic prostatitis and prostate cancer are both significantly elevated 
(p<0.001) with respect to normal peripheral zone. b) The mean citrate/choline ratios in chronic prostatitis is 
not significantly different from normal peripheral zone, while citrate/choline in prostate cancer is reduced 
(p<0.001) with respect to normal peripheral zone. Note that the contrast enhancement in prostatitis patients 
was analyzed only in the prostate peripheral zone.
Post-therapy dynamic MRI and M RSI
Prostatitis patients were treated for six weeks with the antibiotic ciprofloxacin orally. The anatomical 
location from which the detailed pre-treatment MRSI and dynamic MRI analysis was made was 
retraced by comparing the high-resolution pre- and post-treatment TSE images. The pre- and post­
treatment contrast enhanced images consistently showed elevated peak enhancement in the same 
region of the prostate.
Figure 1e-h shows the post-treatment data for the aforementioned patient with chronic prostatitis. 
Treatment with antibiotics did not noticeably affect the low signal intensity lesion on T2 -weighted 
MRI (Fig. 1e), while also a strongly enhancing lesion remained visible on the peak Gd-DTPA 
enhancement map (Fig 1f). Moreover, the post-treatment 1H MRSI showed very similar spectra 
with a high citrate/choline ratio (Fig. 1h), as compared to the pre-treatment MRSI (Fig. 1d).
The average modeling parameters defining the contrast uptake post-therapy are given in Table I. 
Similar to the pre-therapy analysis, regions with elevated peak enhancement were observed in the 
prostate PZ, while other dynamic parameters, such as onset time, time-to-peak and washout were 
not significantly different from those in a control region. In chronic prostatitis, both the region of 
highest peak contrast enhancement (Fig. 1) and the magnitude of this enhancement (Figure 4c) 
were quite reproducible after treatment. No overall trend towards stronger or weaker peak enhance­
ment with therapy could be observed.
Similarly, the ratio of citrate to choline detected by MRSI did not markedly change with therapy 
(Figures 1 and 5). Interestingly, the average citrate/choline ratio in the PZ appeared to be slightly 
but significantly reduced (p<0.01) after therapy, i.e. from 5.7 ±  2.5 pre-therapy to 4.3 ±  2.3 post­
therapy. The post-therapy citrate/choline ratio was unchanged in the peri-urethral and central zones 
(Fig. 5a). Importantly, the majority of MR spectra continued to show a high citrate/choline ratio 
after therapy.
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Figure 4 Variability in peak enhancement among 13 different chronic prostatitis patients. Shaded bars rep­
resent the peak enhancement in the most enhancing area in the peripheral zone. White bars represent the 
peak enhancement in a control region in the peripheral zone. a) pre-therapy and b) after six weeks antibi­
otics therapy, c) Relative peak enhancement in chronic prostatitis pre-therapy (black bars) and post-thera­
py (white bars).
4000
3000
0
B
10 
I  8TS
£ 6 a
£  4 «ri u
2
0
pre-therapy
post-therapy
Figure 5 Effect of antibiotics treatment for chronic 
prostatitis on the MRS-observed citrate/choline 
ratio in different anatomical zones of the prostate,
i.e. in normal peripheral zone (PZ), peri-urethral 
zone (PU) and central gland (CG). The mean cit­
rate/choline ratios pre-therapy are plotted as black 
bars and the post-therapy citrate/choline ratios are 
white bars. ** denotes a significantly different cit­
rate/choline ratio pre- and post-therapy in the PZ 
(p=0.0075).
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For individual MRSI voxels the change in citrate/choline ratio with therapy was quite variable (data 
not shown), but overall, therapy did not significantly affect the citrate/choline ratio.
D iscussion
Generally, neither transrectal ultrasonography nor conventional MRI is able to differentiate between 
chronic prostatitis and prostate cancer (29,30). Accurate staging of PCa with conventional MR 
imaging techniques may therefore be seriously compromised by the presence of chronic prostati­
tis. To our knowledge, chronic prostatitis has not yet been studied with more advanced MR tech­
niques such as dynamic contrast enhanced MR imaging and MR spectroscopy. The present study 
has demonstrated that the chronic prostatitis/chronic pelvic pain syndrome is associated with an 
elevated Gd-DTPA peak contrast enhancement compared to normal PZ, while the levels of major 
prostate metabolites, i.e. citrate and choline, remain essentially unchanged. The elevation of peak 
enhancement in prostatitis is slightly less than that observed in PCa, but significantly higher than 
in healthy PZ. This implies that the strong contrast enhancement associated with chronic prostati­
tis may lead to a false positive diagnosis of cancer. However, the MRS-observed citrate/choline ratio 
was significantly higher in chronic prostatitis than in PCa, which clearly distinguishes between the 
two prostate pathologies. This observation is consistent with earlier in vivo M RS studies reporting 
significant differences in the citrate/choline ratio, (choline+creatine)/choline ratio or absolute cit­
rate levels between cancer and healthy prostate PZ (8,9,13). These findings underline the potential 
of using absolute or relative levels of the MRS-detected metabolites, citrate and choline, as mark­
ers for prostate malignancy.
The absence of reduced citrate/choline ratios in chronic prostatitis, as observed in this study, was 
somewhat unexpected. Moreover, in prostatitis patients the pre-therapeutic citrate/choline ratio 
was even somewhat higher than in the normal appearing PZ. Citrate is normally produced by the 
prostate glandular epithelial cells and secreted into the glandular lumen to high concentrations, 
which are thought to contribute mostly to the M RS observed citrate signal. Thus, the MR-observed 
citrate may be related to glandular density or the volume fraction of luminal space. This is under­
lined by the slightly different citrate concentrations being observed in e.g. the PZ, peri-urethral zone 
and central gland (13). It was anticipated that in chronic prostatitis the glandular density in the PZ 
might be lower and the luminal space might become compressed by the accumulation of mononu­
clear cell infiltrates (leukocytes, monocytes, plasma cells) in the stromal connective tissue around 
acini and ducts (15,16). Then the lower volume fraction of luminal space would cause a reduction 
of citrate levels similar to that found in tumors, but this was not observed. One explanation for this 
may be a partial volume effect. That is, microscopic inflammatory foci might be small with respect 
the MRSI nominal voxel size 0.64 cm3 and/or might not affect the volume of prostate lumen. Such 
small infiltrates may be expected to affect blood supply in a much larger region surrounding the 
inflamed foci, which may account for the elevated contrast enhancement.
Immuno-histochemistry studies have shown that in PCa the microvessel density (MVD) is increased, 
and that MVD is a good predictor of PCa pathologic stage and correlates positively with poorer over­
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9all survival and/or risk of metastasis (31,32). Dynamic contrast enhanced MRI is a powerful tool to 
study tumor vascularity, because of its ability to non-invasively study functional aspects of tissue 
microcirculation. In contrast to the histopathological MVD analysis, DCMRI is sensitive to the total 
endothelial surface area of perfused vessels (33). In this study, the peak contrast enhancement in 
chronic prostatitis was found to be elevated, with respect to normal appearing PZ, while other mod­
eling parameters were not significantly different (Table I). Physiologically, the strong contrast uptake 
in chronic prostatitis may be attributed to a larger interstitial volume (‘leakage space’) and an increase 
in capillary permeability and/or surface area (PS product) (34).
Several studies have shown that the enhancement characteristics of prostate cancer and healthy 
prostate tissue are markedly different. A preliminary study by Jager et al. showed that poorly differen­
tiated prostate cancer was characterized by an earlier onset and faster contrast enhancement as com­
pared to surrounding tissue (10). Padhani et al. detected significant differences between prostate can­
cer and PZ in terms of both qualitative signal-time parameters (rate of enhancement, maximum 
enhancement and washout score) and pharmacokinetic modelling parameters (permeability surface 
area product, tissue leakage space and maximum Gd concentration) (11). However, generally no dif­
ferences in enhancement parameters between central gland (including BPH ) and tumors were found 
(11). Turnbull et al. were able to demonstrate differences in the amplitude of the initial contrast ups- 
lope and contrast exchange rate between tumor and fibromuscular BPH  and for the contrast 
exchange rate between tumor and fibroglandular BPH (12). Unfortunately, there is limited knowledge 
of MR contrast enhancement in chronic prostatitis. Early studies (4,35) failed to detect significant dif­
ferences between pre- and post contrast MR images in prostatitis, whereas prostate cancer did show 
minimal enhancement. More recently, contrast-enhanced helical computed tomography has shown a 
typical strong enhancement pattern caused by prostatitis (36). Also color Doppler ultrasonography 
has shown increased blood flow to the prostatic capsule and parenchyma (37) in the chronic prosta­
titis/pelvic pain syndrome, which is in line with results of the present study.
The present study shows for the first time the application of dynamic contrast enhanced MRI in a 
group of chronic prostatitis patients. The current results indicate that the peak Gd-DTPA contrast 
enhancement is significantly elevated in chronic prostatitis as compared to healthy PZ, but that 
peak contrast enhancement in prostatitis and PCa are not significantly different. It should be noted 
that the the contrast enhancement of chronic prostatitis has only been analyzed in the prostate PZ 
and not in the central gland. Detection of inflammatory lesions within the central gland may be 
challenging, because it would be obscured by the strong enhancement pattern often displayed by 
benign prostate hyperplasia.
The inter-individual variability in contrast uptake, may be attributed to individual differences in the 
arterial input, caused for example by differences in heart rate. In this study, the inter-individual vari­
ability was considerably reduced by normalizing the most enhancing area to a minimally enhanc­
ing region in the PZ. Also care was taken during the follow-up examination to reproduce the exact 
slice position of the pre-treatment scan, by visual inspection of the high-resolution anatomical 
images of both sessions. The present study could not detect a physiological or metabolic response 
to treatment with antibiotics. In individual patients small but significant changes in the peak con­
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trast enhancement were observed after antibiotic therapy, but these changes were not consistent. 
Furthermore, the changes in citrate/choline and peak enhancement after therapy did not correlate 
with the patients physical well-being after therapy. Only half of the prostatitis patients reported 
relief of their pain complaints following treatment with antibiotics. No follow-up biopsies were 
taken and, unfortunately, there was no other objective post-treatment assay to decide on the effi­
cacy of the antibiotic treatment.
Both MRSI and dynamic contrast MRI have recently shown potential for monitoring the response 
to various forms of cancer therapy. Kurhanewicz and co-workers (38,39) observed significant reduc­
tion in the citrate/(creatine+choline) ratio measured by 3D 1H MRSI with duration of hormonal 
ablation therapy. Padhani et al. used dynamic contrast enhanced MRI to monitor the effect of hor­
mone treatment for prostate cancer and noted a significant decrease in vascular permeability (40). 
A limitation of this study is that the imaging findings could not be directly corroborated by 
histopathology. As prostatitis may be focal and is not readily detected by ultrasonography, TRUS- 
guided biopsies may easily miss the inflammatory regions. Moreover, chronic prostatitis can be of 
bacterial or non-bacterial origin and its pathology remains poorly understood, so that even histol­
ogy may not always be conclusive. This is confirmed by a recent study of 97 chronic prostatitis 
patients receiving biopsies, which showed that only 5%  showed signs of moderate to severe inflam­
mation on histopathology (41). In the present study, this number was less dramatic, as in 6 out of
10 biopsied patients the inflammatory infiltrations were found. Due to the fact that we have no his­
tology, we cannot be sure that the control regions selected for dynamic contrast enhanced MRI are 
free from prostatitis. However, from the study on prostate cancer (17) we know that similar regions 
in the PZ, without PCa and without prostatitis demonstrate similar low enhancement.
A second limitation is that the studied patient cohorts (PCa patients vs patients with prostatitis) 
which are compared do not match in terms of age and gland volume. However, from a recent study 
by Engelbrecht et al. (17) it was concluded that a poor correlation was present between dynamic 
parameters and age in the PZ. Furthermore the major difference in gland volume between both age 
groups is likely to be the result of benign prostate hypertrophy, which is primarily located in the 
central gland, whereas our regions of interest for DCMRI were situated in the PZ.
The major progress of this study is that we were able to obtain combined vascular and metabolic 
information on chronic prostatitis. Unfortunately, currently neither imaging technique can offer a spe­
cific diagnosis of prostatitis. However, this study has shown the potential for improved accuracy for 
cancer detection using a combination of dynamic contrast enhanced MRI, at high temporal and spa­
tial resolution, and 1H MR spectroscopic imaging, which intrinsically has limited spatial resolution. 
The implication is that if in the PZ both anatomical and contrast MRI show signs suspicious of can­
cer, which is not corroborated by sextant biopsy and histology, an additional 1H MR spectroscopic 
imaging examination may differentiate cancer from prostatitis in the peripheral zone.
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This thesis reports on the local staging performance and localization of MR imaging in prostate 
carcinoma. Both a literature review and our own results are presented. Additionally this thesis 
describes potential new ways to improve local staging performance and localization with MR imag­
ing. In chapter 2 various staging methods, including digital rectal examination, serum PSA, histo­
logical Gleason score, transrectal ultrasound and MR imaging were discussed based on a literature 
review. Prostate carcinoma can be detected on T2-weighted MR images as a low signal intensity 
area in a bright normal peripheral zone. However, the differential diagnosis of low signal intensity 
areas include however not only carcinoma, but also post biopsy-hemorrhage, prostatitis, benign 
prostate hyperplasia, effects of hormonal or radiation treatment, scars, calcifications, smooth mus­
cle hyperplasia and fibromuscular hyperplasia (1). Detection of carcinoma in the central gland is 
even more difficult, because this area is often subject to benign prostatic hyperplasia, which has 
signal intensities similar to those of carcinoma. The most reliable imaging criteria for the detection 
of extracapsular extension of prostate carcinoma are asymmetry of the neurovascular bundle, oblit­
eration of the rectoprostatic angle, bulging, overall impression and extracapsular tumor (2;3). 
Seminal vesicle invasion can be detected by asymmetric low signal intensity of the seminal vesicles 
on T2-weighted images (4). It was not possible to provide an accurate overall literature review, as 
most studies used different imaging protocols, different patient populations and different study 
designs. Therefore, a systematic meta-analysis was performed.
In chapter 3 the results of this meta-analysis of studies evaluating the local staging performance of 
MR imaging in prostate cancer were described. Using Medline and Embase databases 134 articles 
were found. An additional 35 abstracts were found using abstract books. The following exclusion 
criteria were used: review/reanalysis, only data on nodal staging, inadequate gold standard, no 
information on sensitivity/specificity could be calculated. Finally 71 articles and 5 abstracts were 
included for further analysis. A large variation (heterogeneity) in local staging performance was 
found. A maximum joint sensitivity and specificity (a measure of literature overall test-accuracy) of 
71% was found, which is in accordance with a similar meta-analysis by Sonnad et al (5), who found 
74%. A limitation of this estimation is that due to the large heterogeneity of local staging perfor­
mance in the literature it is difficult to extrapolate these numbers to a given local clinical situation. 
Therefore, the statement made by Jager et al. in 1997 (6) : "those who perform MR imaging in cases 
of prostate cancer should determine their own standard of accuracy by carefully comparing their 
imaging results with histopathologic findings” is an appropriate one. This meta-analysis did not 
succeed in fully explaining the heterogeneity present in the literature, partly due to poor reporting 
in primary studies and partly because it was not possible to evaluate the role of clinical information 
and reader experience. However, factors were identified which may contribute to the heterogeneity 
in local staging. Imaging protocol factors, which may improve local staging performance, are: the 
use of turbo spin echo sequences, the use of the endorectal coil and by imaging in multiple planes. 
Furthermore, studies with more than 50 patients yield a lower staging accuracy than studies with 
larger sample sizes, which suggests the presence of publication bias in the literature; that is stud-
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ies with small numbers of patients and disappointing results are less likely to be submitted or 
accepted by journals. Finally, contrast media may result in higher staging accuracy, although limit­
ed studies (n=8) have been performed. Using the data from the meta-analysis described in chap­
ter 3; a subgroup of radical prostatectomy candidates was defined in chapter 4 in whom local stag­
ing using MR imaging is useful using a threshold approach (7;8). Prostate carcinoma patients were 
divided into 3 groups: a group where immediate radical prostatectomy, without MR imaging, is 
considered the treatment of choice, a group where prior MR imaging is considered useful and 
where treatment selection (in our model either prostatectomy or palliative radiotherapy) depends 
on the outcome of the MR imaging results and finally a group where (palliative) radiotherapy with­
out MR imaging is considered appropriate. At a given literature sensitivity and specificity of MR 
imaging in detection of stage T3 of 64% and 72% we have identified these 3 groups by their risk of 
having T3 disease based on partin tables (9). At an a priori probability of stage T3 disease of 0-0.45 
prostatectomy without MR imaging is appropriate, at an a priori chance of 0.45-0.81 MR imaging 
guided treatment selection is most useful and at an a priori chance of more than 0.81 palliative 
radiotherapy is the treatment of choice without MRI. In chapter 5 it was found that the use of an 
ER-PPA coil resulted in a significant improvement of anatomic details in the prostate and this trans­
lated into greater local staging accuracy and specificity. When using an ER-PPA coil overstaging is 
reduced significantly without affecting sensitivity. The sensitivity and specificity, using the ER-PPA 
coil, for differentiation of stage T2 vs T3 was 65% and 98% respectively for an experienced reader 
(more than 10 years of prostate MRI experience). For the less experienced readers (2 readers with 
less than 2 years experience) this was 59% (sensitivity) and 96% (specificity). The positive predic­
tive values and negative predictive values ranged (experienced-less experienced) between 92-96% 
and 74-77%. Although the experienced reader demonstrated a larger area under the ROC-curve 
(Az=0.74 for the ER-PPA), the difference between the less experienced readers (Az=0.70 for the ER- 
PPA coil) and the experienced reader was not significant.
Because the results of this study were better than the literature mean estimates from our modeling 
study in chapter 4 (sensitivity/specificity 65%/98% versus 64%/86% respectively), the study 
threshold to perform MR imaging in our institution is lower and consequently a larger spectrum of 
patients undergo MR imaging. Using the results from our local staging study, MR imaging is con­
sidered useful at an a priori chance between 0.08-0.86 (range low-risk- high risk). In our clinical 
practice this means that both patients with a low risk and patients with an intermediate-high risk 
of non-organ confined disease undergo MR imaging. This strategy has been proven to be valid in 
49 patients at low risk who underwent MR imaging; in this group 13 patients proved to have either 
extracapsular extension or seminal vesicle invasion. MR imaging detected stage T3 in 7 out of these
13 (sensitivity: 54%) patients, with 1 false positive case (specificity: 97%).
In chapter 6 the basic principles of dynamic contrast-enhanced MR imaging (DCM RI) are reviewed. 
After intravenous bolus injection in the antecubital vein of the contrast agent (gadolinium-chelates) 
passes through the heart and lungs and enters the arterial circulation as a bolus. The enhancement 
of the prostate can then be displayed by concentration [cGd-DTPA]-time curves. The curve is 
defined by four parameters: onset time of enhancement with respect to the nearest large vessel;
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time (sec.) to peak (this is the fastest slope of enhancement); peak-enhancement, which occurs 
when enhancement of the specific tissue is maximum and the wash-out phase of the contrast medi­
um, when contrast leaves the tissues and returns to the venous system. The enhancement rate and 
onset of enhancement in a given tissue depend on the number of vessels, perfusion (= flow) 
through the vessels, vascular resistance, vessel wall permeability, composition of the extracellular 
interstitial space, and venous outflow. These factors differ from tissue to tissue, and therefore 
enhancement curves differ. Vascular abnormalities seen in malignancies include leaky/porous ves­
sels, tortuous vessels, increased interstitial pressure, altered viscosity of blood inside tumor ves­
sels, uneven distribution of vessels throughout the tumor, increased interstitial pressure causing 
compression of tumor vessels and the development of arteriovenous shunts (10;11). DCMRI uses 
these mentioned differences to discriminate between malignancies and normal tissue.
In chapter 7 a new curve fitting method for estimating dynamic enhancement curves was investi­
gated, using the most probable slope. The commonly used "least-squares optimization” curve fit 
method and the "most probable, steepest slope” curve fit methods were compared. The "most 
probable steepest slope” method was significantly more accurate for all dynamic parameters 
(onset time, time to peak, peak-enhancement and wash-out). Additionally we found a method to 
decrease inter-patient variation in the dynamic parameter peak-enhancement (normalization) by 
subtracting for each patient the mean value of the peak-enhancement in the normal peripheral 
zone or central gland for a region of interest; yielding the relative peak-enhancement. Finally using 
intermediate weighted images we have developed a method to estimate the actual tissue-gadolin- 
ium concentration up to a constant.
In chapter 8 DCMRI enhancement patterns in 58 patients were examined.
After exclusion of 22 patients due to motion artifacts, post-biopsy hemorrhage artifacts and small 
carcinomas (< 0.5 cm3) enhancement patterns in 36 patients were analyzed. Dynamic enhance­
ment in prostate carcinoma differs significantly from normal peripheral zone and central gland tis­
sue. Both in the peripheral zone and central gland the relative peak-enhancement is the optimal 
parameter for prostate carcinoma discrimination. The second best parameter are peak enhance­
ment in the peripheral zone and wash-out in the central gland. The relative peak-enhancement and 
peak-enhancement improved the discrimination of prostate carcinoma from peripheral zone com­
pared to routine T2-weighted images (p<0.001) . In the central gland routine T2-weighted images 
did not demonstrate significant differences between cancer and central gland tissue. However, 
dynamic parameters showed significant differences (p<0.001) between carcinoma and central 
gland tissue, resulting in a discriminatory performance of (ROC-analysis; Az=0.83) for relative 
peak-enhancement and Az=0.82 for wash-out. Dynamic parameters were not found to correlate 
well with Gleason grade, serum PSA, patient age, cancer volume, SVI and ECE.
In chapter 9 the prostate glands of patients (n=13) with a clinical diagnosis of chronic prostatitis 
were studied using DCMRI and 2D 1H proton MR spectroscopy (M RSI). The results were com­
pared (unmatched) with DCMRI and MRSI of prostate carcinoma patients (n=36 and n=14 respec­
tively). Both in chronic prostatitis and in prostatic carcinoma peak-enhancement was significantly 
elevated compared to normal peripheral zone. There was no significant difference between peak-
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enhancement in chronic prostatitis and prostate carcinoma. MRSI in prostatitis showed a similar 
citrate to choline ratio as in normal peripheral zone. By contrast , in prostate carcinoma the cit­
rate/choline ratio was significantly lower than both areas of prostatitis and normal peripheral zone 
(p<0.001). This implies that the strong contrast enhancement associated with chronic prostatitis 
may lead to a false positive diagnosis of carcinoma. In contrast, MRSI can distinguish between pro- 
statitic carcinoma and prostatitis or normal peripheral zone. Thus when DCMRI cannot differenti­
ate between chronic prostatitis and prostate cancer, then an additional MR spectroscopy may help 
to exclude cancer in the PZ.
Conclusions
The following overall conclusions can be made:
1. The most reliable criteria in the literature for the detection of extracapsular extension of 
prostate cancer on MR imaging are asymmetry of the neurovascular bundle, obliteration of the 
rectoprostatic angle, bulge, overall impression and extra capsular tumor.
2. A large heterogeneity in local staging performance of MR imaging is present in the literature, 
which could not be fully explained due to poor reporting in primary studies and because the 
role of reader experience and clinical knowledge could not be evaluated.
3. Factors which improve local staging performance of MR imaging in prostate carcinoma are the 
use of turbo spin echo sequences, the use of the endorectal coil and the use of multiple imag­
ing planes.
4. Based on an average literature sensitivity and specificity for the detection of stage T3 of 64% 
and 72%, local staging of prostate carcinoma should be limited to patients having intermedi­
ate/high risk of non-organ confined disease.
5. The integrated endorectal-pelvic phased array coil increases anatomical detail and local staging 
accuracy in prostate MR imaging, by increasing specificity significantly, yet maintaining similar 
sensitivity.
6. The "most probable steepest slope” method was significantly more accurate than the "least- 
squares error optimization” method for all dynamic parameters.
7. Dynamic contrast-enhanced MR enhancement patterns in prostate carcinoma differ signifi­
cantly compared to normal peripheral zone and central gland tissue.
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8. The most accurate parameters to differentiate prostate cancer from normal peripheral zone tis­
sue or central gland tissue are the relative peak-enhancement, followed by peak-enhancement 
in peripheral zone and wash-out in the central gland tissue.
9. Dynamic Gd-DTPA-enhanced MR imaging is not useful for prediction of tumor stage, tumor 
volume, serum PSA and Gleason grade.
10. When dynamic contrast-enhanced MR imaging cannot differentiate between chronic prostatitis 
and prostate cancer, then an additional MR spectroscopy may help to exclude cancer in the 
peripheral zone, due to its higher specificity.
Suggestions for Further Research
Clearly there is room for improvement for MR imaging in the evaluation of prostate cancer. The 
local staging accuracy of MR imaging still varies widely. Although some factors were demonstrated 
to contribute to heterogeneity, further study on the role of reader experience, the effect of criteria 
for extracapsular extension and clinical knowledge is necessary. The appropriate role of MR imag­
ing in a given group of prostate cancer patients needs to be further elucidated. In chapter 4 risk- 
stratification based on Partin tables was used to define a selected group of prostate cancer patients 
where MR imaging is useful. These results should be validated in a large prospective study in order 
to evaluate in which subgroup of patients MR imaging alters diagnostic thinking and therapeutic 
efficacy. In chapter 5 the integrated endorectal-pelvic-phased array coil was shown to be superior 
to the pelvic phased array alone. Although both the experienced and unexperienced readers showed 
similar results, validation is still needed.
Potential clinical applications of the investigated new MR techniques, like DCMRI include intensi­
ty modulated radiotherapy (IMRT). Welmers et al (12) have shown that fusion of DCMRI and MRSI 
with CT can help radiation oncologists with more accurate planning of IMRT. In order to reach this 
point it is essential that the accuracy of DCMRI for localizing prostate carcinoma is validated. 
Secondly, the susceptibility of DCMRI to motion artifacts remains a field in which further research 
is essential. Furthermore in chapter 8 enhancement patterns in prostate cancer and normal PZ and 
CG were studied. A limitation of using the peak-enhancement was that, due to large interpatient 
variability, there was no absolute cut-off value above which the tissue can be considered cancer. 
Interpatient variability could not be explained by patient and tumor characteristics. Interpatient 
variability was succesfully decreased by normalization using reference tissue like normal PZ. 
However, in clinical practice it is not known whether a tissue is normal and therefore PZ cannot be 
used as reference tissue. A solution could be to use the arterial input function as a manner of cal­
ibration, which was tried in chapter 8, without success. Future research projects may be directed to 
establishing a robust normalization using reference tissue outside the prostate to decrease inter­
patient variation. In this respect the work of Rijpkema et al should be mentioned (13). In this study
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the reproducibility of a new method is described for measurement of the arterial input function was 
tested in 11 cancer patients (among them 3 prostate carcinoma patients). Improved reproducibil­
ity was demonstrated in 10 of the 11 patients. However in 1 of the 3 prostate carcinoma patients 
there was a significant difference in the arterial input function, which may be in accordance with 
the difficulties encountered, measuring the aterial input function encountered in chapter 8 . 
DCMRI may have potential in treatment monitoring as has been recently demonstrated by Padhani 
et al (14). In this study it was shown that DCMRI demonstrates reduction in both prostate cancer 
volume and vascular permeability in response to antiandrogen therapy. This may be of clinical 
importance, as using DCRMI both hormonal therapy as well as adjuvant radiotherapy may be tai­
lored to each specific patient.
Furthermore there may be a role in the localization and local staging of recurrent prostate cancer 
prior to salvage prostatectomy (15). Although this thesis has focussed on local staging, MR imag­
ing has an important role in the detection of metastatic disease. In this respect the study of MR 
imaging in the detection of metastatic lymphnodes using Ultra small Super Paramagnetic Iron 
Oxide particles (USPIO ) by Deserno et al. should be mentioned (16).
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Het doel van dit proefschrift was drieledig. Ten eerste het beschrijven en verklaren van de variabi­
liteit van studie resultaten in de literatuur over de nauwkeurigheid van de locale stagering van pro- 
staatcarcinoom middels MRI. Ten tweede te onderzoeken voor welke groep patienten met pro- 
staatcarcinoom locale stagering middels MRI van waarde is. Tenslotte het onderzoeken hoe met 
nieuwe MR technieken zoals de geintegreerde pelvic-phased array-endorectale spoel, dynamische 
MRI en MR spectroscopie de locale stagering en lokalisatie van prostaat carcinoom verbeterd kan 
worden. In hoofdstuk 2 wordt besproken met welk doel en hoe met behulp van klinische metho­
den, transrectaal ultrageluid en MRI prostaatcarcinoom gestadieërd wordt. De belangrijkste cura­
tieve behandeling van prostaat carcinoom is de radicale retropubische prostatectomie (RRP). Een 
RRP is alleen curatief indien het carcinoom zich beperkt tot de prostaat. Als er doorbraak is buiten 
het prostaatkapsel, naar de zaadblaasjes, lymfeklieren of naar elders in het lichaam dan is een RRP 
niet meer zinvol. Het doel van stadieëring met behulp van MRI is om deze doorgroei buiten de pro­
staat te detecteren, zodat een niet curatieve RRP voorkomen kan worden en een passende behan­
deling zoals radiotherapie kan worden aangeboden. Prostaat carcinoom kan worden herkend op 
T2-gewogen beelden door een lagere signaal intensiteit in vergelijking met de omringende perifere 
zone. De differentiaal diagnose van een lage signaal intensiteit op T2 is uitgebreid en omvat onder 
andere bloedingen (zoals na biopsie), prostatitis, benigne prostaat hypertrofie, effecten van hor­
monale behandeling en radiotherapie, littekens, calcificatie’s, glad spierweefsel hyperplasie en 
fibromusculaire hyperplasie. Meer centraal in de prostaat (de zgn central gland) is carcinoom nog 
moeilijker te herkennen, doordat dit gebied in de populatie met prostaat carcinoom bijna altijd is 
aangedaan door benigne prostaat (hyperplasie).
Betrouwbare criteria uit de literatuur voor locale tumor doorgroei door het prostaat kapsel zijn; 
asymmetrie van de neurovasculaire bundel, het verdwijnen van de hoek tussen het rectum en de 
prostaat, een locale verheffing (eng. bulge) van het prostaatkapsel, de algemene indruk en de aan­
wezigheid van tumor buiten het kapsel. Tumor doorgroei richting de zaadblaasjes kan worden 
gedetecteerd door een asymetrisch lage signaal intensiteit van de zaadblaasjes op T2-gewogen 
beelden. Het bleek niet goed mogelijk om uit de literatuur een algemeen beeld te verkijgen van de 
waarde van MRI bij het locaal stadieëren van prostaatcarcinoom, doordat de meeste studies ver­
schillende afbeeldingsprotocollen en patient populaties gebruikten. Hierom werd besloten een sys­
tematische meta-analyse te verichten waarvan de resultaten in hoofdstuk 3 beschreven staan. Met 
behulp van literatuur data-bases (Medline, Embase) en Abstract boeken werden in totaal 134 arti­
kelen en 35 abstracts gevonden. Na exclusie van reviews, dubbel publicatie’s en artikelen waar geen 
vergelijking met histopathologie aanwezig was bleven er 71 artikelen en 5 abstracts over voor ver­
dere analyse. Er bleek een grote variatie (= heterogeniteit) in studie resultaten te zijn, met een maxi­
male gemeenschappelijke sensitiviteit en specificiteit (maat voor de gemiddelde nauwkeurigheid in 
de literatuur) van 71%. Een beperking van deze schatting is dat door de grote variabiliteit in studie 
resultaten dit getal moelijk is te extrapoleren naar de lokale kliniek. Daarom blijft het belangrijk om 
voordat met locale stagering wordt begonnen er eerst onderzocht wordt wat de nauwkeurigheid
Samenvatting
151
10
van MRI in de eigen kliniek is. Deze meta-analyse bleek onvoldoende in staat om de heterogenei- 
teit in de literatuur te verklaren, door de vaak onvolledige informatie in artikelen over de studie pop­
ulatie , het gebrek aan informatie over de ervaring van de beoordelaars en de aanwezige klinische 
kennis. Factoren die wel bijdragen aan een hogere locale stagerings nauwkeurigheid van MRI waren 
het gebruik van Turbo spin echo sequentie’s, het gebruik van de endorectale spoel en ook het 
gebruik van meer dan een afbeeldingsrichting. Tevens lijkt er sprake te zijn van publicatie bias in 
de literatuur; studies met kleine hoeveelheden patienten en slechte resultaten worden minder waar­
schijnlijk gepubliceerd. Met behulp van de gegevens uit hoofdstuk 3 werd een subgroup patienten 
gedefiniëerd in hoofdstuk 4 waarbij een MRI nuttig kan zijn. In een model werden 3 patient groe­
pen gedefinieerd; een groep waarbij een RRP zonder gebruik van MRI kan plaatsvinden. Een groep 
patiëten waarbij eerst een MRI plaatsvindt en aan de hand van de resultaten er een verder beleid 
wordt bepaald; in dit model RRP of radiotherapie. Tenslotte de groep waar er zonder MRI besloten 
wordt af te zien van een RRP en er direkt wordt overgegaan tot radiotherapie. Bij aanname van een 
sensitiviteit/specificiteit van MRI van respectievelijk 64% en 72% bleek dat bij een a priori kans van 
0-0.45 op tumor doorgroei patiënten het beste geen MRI konden ondergaan en direct een RRP 
moesten ondergaan. Met een a priori kans tussen de 0.45 en de 0.81 was patiënt het meest gebaat 
bij een MRI scan, waarbij aan de hand van de uitkomst verder beleid bepaald werd. Tenslotte de 
groep waarbij de a priori kans op tumor doorgroei groter dan 0.81 was bleek het meest gebaat bij 
directe radiotherapie zonder MRI scan. Aan de hand van de bekende klinische gegevens (PSA, 
Gleason score, transrectaal onderzoek en rectaal toucher) kan met behulp van de Partin tabellen 
de a priori kans berekend worden. In hoofdstuk 5 werd onderzocht wat de meerwaarde is van de 
geintegreerde-pelvic-phased array-endorectale (ERC-PPA) spoel ten opzichte van het gebruik van 
de pelvic-phased array coil (PPA) bij de afbeelding van anatomische details en locale stagering. Het 
gebruik van de ERC-PPA resulteerde in een significante verbetering van anatomische details in de 
prostaat en dus ook in een verbetering van de locale stagering. Deze verbetering gold voor zowel 
de ervaren als de minder ervaren beoordeelaars. De voornaamste winst bij het gebruik van een 
ERC-PPA ligt in de toegenomen specificiteit bij een gelijkblijvende sensitiviteit bij de locale stage­
ring. Hoofdstuk 6 beschrijft de basis principes van dynamische MRI . Na een intraveneuze bolus 
toediening komt het contrast in de arterieële circulatie, waarna de prostaat aankleurt. De aankleu- 
ring van de prostaat kan beschreven worden aan de hand van 4 parameters namelijk het begin van 
de aankleuring ten opzichte van een nabijgelegen vat (onset time), de tijd nodig om de piek con­
centratie gadolinium in de weefsels te verkrijgen (time to peak), de maximale concentratie gadoli­
nium in het weefsel (peak-enhancement) en tenslotte de snelheid waarmee het contrast middel 
weer het weefsel verlaat aan de veneuze zijde (wash-out). Deze aankleurings parameters varieëren 
aan de hand van verschillen in aantal en soort vaten. Omdat bij carcinomen de vascularisatie ver­
schilt (tumor angiogenese) in vergelijking met gezond weefsel kan met behulp van dynamische 
MRI maligniteiten herkend en gelocaliseerd worden. Hoofdstuk 7 beschrijft een nieuwe methode 
"most probable steepest slope” (M SS) om dynamische contrast curves the schatten aan de hand 
van de oorspronkelijke data. M SS wordt vergeleken met de vaak gebruikte "least squares optimi­
zation method” . De meest waarschijnlijke helling methode bleek voor alle onderzochte dynamische
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parameters nauwkeuriger te zijn. Tevens werd een methode gevonden waarbij de interpatient varia­
tie - door middel van normalisatie met behulp van normaal prostaat weefsel - verminderd werd (de 
zgn relative peak-enhancement). Tenslotte bleek het mogelijk om met behulp van proton density 
opnames de concentratie GdDTPA in weefsel te benaderen tot op een constante.
In hoofdstuk 8 zijn dynamische aankleurings karakteristieken bestudeerd in 58 patiënten. Na exclu­
sie van 22 patiënten vanwege bewegingsartefacten, biopsie artefacten en carcinomen kleiner dan
0.5 cm3 werden 36 patiënten geanalyseerd. Dynamische aankleuring van prostaat carcinoom bleek 
significant te verschillen van gezonde perifere zone en de meer centraal gelegen prostaat (central 
gland). Zowel in de perifere zone als in de central gland bleek de "relative peak-enhancement” de 
beste parameter te zijn om prostaat carcinoom mee te herkennen. Na de "relative peak-enhance­
ment” bleek de peak-enhancement voor de perifere zone en wash-out voor de central gland de 
beste parameters te zijn voor carcinoom detectie. Zowel in de perifere zone als in de central gland 
was carcinoom discriminatie met dynamische parameters significant beter in vergelijking met con­
ventionele T2-gewogen opnamen. De dynamische parameters bleken niet goed te correleren met 
de leeftijd van patiënt, Gleason grade, serum PSA, tumor volume, kapseldoorbraak en invasie van 
de zaadblaasjes. In hoodstuk 9 zijn de prostaten van prostatitis patiënten bestudeerd (n=13) met 
behulp van dynamische MRI en 2D 1H spectroscopie en vergeleken met dynamische MRI en 2D 1H 
spectroscopie van prostaat carcinoom (n=36 en n=14 patiënten respectievelijk). Zowel in chroni­
sche prostatitis als in prostaat carcinoom bleek de peak-enhancement significant verhoogd te zijn 
ten opzichte van normale perifere zone. Er bleek geen vershil te zijn tussen de peak-enhancement 
in prostatitis en prostaat carcinoom. Bij spectroscopie van prostatitis werd er echter eenzelfde 
citraat/choline ratio aan getroffen als in de normale perifere zone. Echter bij prostaat carcinoom 
werd een citraat/choline ratio gevonden, welke lager was dan prostatitis en normale perifere zone 
(p<0.001). Dit betekent dat de sterke aankleuring passend bij chronische prostatitis kan leiden tot 
een fout positieve diagnose van prostaat carcinoom. MR Spectroscopie daarentegen bleek wel 
onderscheid te kunnen maken tussen prostaat carcinoom, prostatitis en normale perifere zone. 
Dus als dynamische MRI niet kan differentieëren tussen chronische prostatitis en prostaat carci­
noom, dan kan spectroscopie een carcinoom in de perifere zone uitsluiten.
Conclusies
De volgende algemene conclusies worden in dit proefschrift getrokken:
1. De meest betrouwbare criteria uit de literatuur voor de detectie van kapselpenetratie op MRI 
zijn; asymmetrie van de neurovasculaire bundel, het verdwijnen van de hoek tussen het rectum 
en de prostaat, een locale verheffing (eng. bulge) van het prostaatkapsel, de algemene indruk 
en de aanwezigheid van tumor buiten het kapsel.
153
10
2. Er is een grote heterogeniteit in lokale stagerings resultaten aanwezig in de literatuur, welke 
niet verklaard kon worden door de beperkte informatie in primaire studies en omdat de rol van 
ervaring van radioloog en klinische informatie niet geëvalueerd konden worden.
3. Factoren die de locale stagering van prostaat carcinoom middels MRI verbeteren zijn het 
gebruik van turbo spin echo sequenties, het gebruik van een endorectale spoel en het gebruik 
van meerdere afbeeldingrichtingen.
4. Gebaseerd op een gemiddelde literatuur sensitiviteit en specificiteit bij de detectie van stadium 
T3 prostaat carcinoom van 64% en 72% respectievelijk, zou locale stagering middels MRI 
beperkt moeten worden tot patiënten met een middelmatig tot hoog risico van doorbraak bui­
ten de prostaat.
5. De geïntegreerde endorectale-pelvic phased array-coil verbetert de visualisatie van anatomi­
sche prostaat details en nauwkeurigheid van de lokale stagering, door significante toename in 
specificiteit, bij gelijkblijvende sensitiviteit.
6. De "most probable steepest slope method” was significant nauwkeuriger dan de "least-squares 
error optimization method” voor alle dynamische parameters.
7. De aankleuringspatronen van dynamische MRI in prostaat carcinoom verschillen significant 
van normale perifere zone en centraal klier weefsel.
8. De nauwkeurigste dynamische MRI parameters voor differentiatie van prostaat carcinoom van 
normale perifere zone en centraal klier weefsel zijn de relatieve piek-aankleuring, gevolgd door 
piek-aankleuring in de perifere zone en wash-out in de centrale klier.
9. Dynamische MRI met behulp van Gd-DTPA is niet bruikbaar voor de voorspelling van tumor 
stadium, tumor volume, serum PSA en Gleason graad.
10. Als dynamische MRI niet kan differentiëren tussen chronische prostatitis en prostaat carci­
noom, dan kan een 1H MR spectroscopie onderzoek door hogere specificiteit carcinoom exclu- 
deren in de perifere zone.
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Dr. Ir. Henk Jan Huisman, beste Henk Jan. Tijdens ons onderzoek heb ik veel gehad aan je kritisch 
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schrift.
Dr. Robert Laheij en Leo van Rossum; het team van de medische statistiek. Dank voor jullie gewel­
dige statistische ondersteuning. Beste Robert dank voor je eindeloze SAS analyses. Alhoewel de 
gezamenlijke meta-analyse toch ietsje meer werk was dan verwacht, vond ik het een erg interessant 
en leerzaam onderdeel van mijn proefschrift.
Dr. Michiel Sedelaar; beste Michiel, dankzij jouw organsiatiekunst was het mogelijk 3 jaar lang alle 
RRP kandidaten zowel een MRI, TRUS en MR spectroscopie te laten ondergaan. Het was altijd weer 
een genoegen om een MR-aanvraag van jou liefst deze week, maar zeker binnen 2 weken te regelen. 
Dr. Arno van Leenders en Dr. Christina Hulsbergen-Van De Kaa; dank voor jullie bereidwilligheid de 
coupes in te tekenen en de voor mij waardevolle discussies over de pathologische benadering van 
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ieder bij naam kan noemen. Toch zou ik in het bijzonder Mevrouw Denise Jansen en Mevrouw 
Yvonne van der Meulen willen noemen. Dank voor jullie flexibele opstelling bij het inplannen en 
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Dr. A. Smeets, dank voor al uw raad.
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De heer en mevrouw Nève, beste Paul en Regina. Strijders van het eerste uur! Dankzij jullie is mijn 
aankomst in Nijmegen vanuit het westen een zachte landing geweest. Fijn dat ik bij jullie (gevraagd 
en ongevraagd) de nodige relativering van mijn ziekenhuis'leventje' kreeg.
Mijn collega-wetenschappers en lunchgenoten; Drs Ir. Mark Stoutjesdijk, Dr. Wouter Veldkamp, Dr. 
Guido te Brake, Dr. Ir. Nico Karssemeijer en Dr. Ir. Henk Jan Huisman bedankt voor de gezellige 
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Ook mijn vrienden zowel in Nijmegen als elders in het land wil ik noemen. Vaak zocht ik hen in de 
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Tenslotte mijn moeder, die altijd door dik en dun 100% achter me stond. Promoveren kan af en toe 
ietsje minder succesvol zijn. In zulke tijden heb jij me de inspiratie gegeven niet op te geven. 
Woorden schieten tekort om jou te bedanken voor je hulp, steun en raad. Ik ben er trots dat ik een 
moeder heb die nog zo betrokken is bij de ontwikkeling van jonge mensen.
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die niet altijd de jouwe waren ondersteund hebt.
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